Functional and Structural Analysis of the
Yersinia enterocolitica Type III Secretion
Translocon

Inauguraldissertation

zur
Erlangung der Würde eines Doktors der Philosophie
vorgelegt der
Philosophisch-Naturwissenschaftlichen Fakultät
Der Universität Basel

von

Petr Broz

aus
Rheinfelden, Schweiz

Basel, 2006
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von
- Prof. Dr. Guy Cornelis
- Prof. Dr. Urs Jenal
- Prof. Dr. Andreas Engel

Basel, den 19.9.2006

Prof. Dr. Hans-Jakob Wirz
Abstract

Many pathogenic bacteria use type III secretion systems (TTSS) to deliver effector proteins into the cytosol of target cells to subvert host cell functions. The actual secretion apparatus, called injectisome, consist of a basal body embedded in the bacterial membranes and a needle. The needle is thought to serve as a conduit for protein secretion. However, to cross the target cell membrane an additional translocation step is necessary. This translocation involves the formation of a pore in the target cell membrane, which is presumably connected to the needle. Three proteins are required for the assembly of this pore. In *Yersinia*, the three “translocators” are YopB and YopD, two putative membrane proteins, and LcrV a hydrophilic protein. LcrV is also known, since the mid-fifties, to represent the major protective antigen against plague infections. The aim of my thesis was to characterize the structure and function of the translocators.

Infection of erythrocytes with wildtype *Yersinia* causes hemolysis due to the formation of the translocation pore in the red blood cell membrane. We showed that the isolated membranes of these erythrocytes contain the hydrophobic translocators YopB and YopD, but not LcrV. Bacteria deprived of LcrV did not assemble a functional pore, but were still able to insert reduced amounts of YopB and YopD into the target cell membrane. This is in agreement with reports showing that purified YopB and YopD can oligomerize and insert into artificial membranes independently of LcrV. We showed further that polyclonal antibodies directed against LcrV interfere with the formation of a functional translocation pore by live bacteria. Based on these results, we hypothesized that LcrV acts as a platform or scaffold onto which the YopBD translocation pore assembles (Goure, Broz et al. 2005, *Journal of Infectious Diseases* 192:218-25).

We purified needles and detected LcrV as well as YscF, the needle subunit, in these preparations. In parallel we analyzed these purified needles by STEM (scanning transmission electron microscopy) and found that the needle ends with a defined tip complex, that comprises a head, a neck and a base. We then showed that the tip complex is missing in *lcrV* mutant bacteria and can be restored after the mutation is complemented in *trans*. These results indicated that LcrV is involved in the formation of the tip complex. In addition, crosslinking of purified needles indicated that LcrV and YscF interact and thus the V-antigen might form the tip complex. Immunolabelling of wildtype needles with anti-LcrV antibodies showed a strong binding to the tip complex, anti-YscF antibodies bound to the bottom of the needle. Together these results demonstrate that LcrV forms the observed tip complex and explain why anti-LcrV antibodies can inhibit pore formation. In addition, these data reinforce the assembly platform hypothesis (Mueller, Broz et al. 2005, *Science* 310: 674-676).

*P. aeruginosa* and *A. salmonicida* possess an injectisome closely related to that of *Yersinia*. Their respective LcrV orthologs, PcrV (32.3 kDa) and AcrV (40.2 kDa) are slightly different in size to LcrV (37.6 kDa). We demonstrated that PcrV as well as AcrV can functionally complement a *lcrV* deletion in *Y. enterocolitica*. The needles exhibited distinct tip complexes similar to those of wildtype needles but they were smaller in the case of PcrV and larger with AcrV (Mueller, Broz et al. 2005, *Science* 310: 674-676). Hybrids between the three proteins LcrV, PcrV and AcrV could complement an *lcrV* deletion in *Y. enterocolitica* in the hemolysis assay, but the level of complementation varied. The amino-terminus seemed to play an important role in the function of the protein. STEM analysis of tip complexes formed by different hybrid proteins allowed us to show that the aminoterminal domain of LcrV forms the base while the second globular domain forms the head of the tip complex. In addition we determined the stoichiometry of YscF and LcrV in purified needles and found that between three to six molecules of LcrV form the tip complex. Together, these results allowed us to propose an atomic modeling of the LcrV tip complex on top of the injectisome needle.
Table of contents

1 Introduction .................................................................................................................. 2
  1.1 Type III secretion systems .................................................................................... 3
  1.2 The concept of translocation ............................................................................... 6
  1.3 The triplet of translocators ................................................................................... 6
  1.4 The role of the translocators during infection ...................................................... 9
  1.5 Evidence for a pore formed by the translocators ................................................ 10
  1.6 Structure of the translocation pore ...................................................................... 11
  1.7 The role of the needle in the translocation process ............................................ 14
  1.8 How is the injectisome coupled to the translocation pore? ............................... 15

Accessory ......................................................................................................................... 18
  1.9 The chaperone of the hydrophobic translocators ............................................... 18
    1.9.1 Role as chaperone ......................................................................................... 18
    1.9.2 Role in regulation ......................................................................................... 20
  1.10 The LcrG-LcrV complex regulates the secretion of effector Yops .................... 22
  1.11 Requirements on the membrane side ............................................................... 25
  1.12 Other needle extensions ..................................................................................... 27
  1.13 Double function as translocator and effector ................................................... 31

2 Aim of the thesis .......................................................................................................... 32

3 Results .......................................................................................................................... 34
  3.1 The Needle Length of Bacterial Injectisomes
      is Determined by a Molecular Ruler ........................................................................ 34
  3.2 Protective Anti-V Antibodies Inhibit Pseudomonas and Yersinia Translocon
      Assembly within Host Membranes ........................................................................ 36
  3.3 The V-antigen of Yersinia Forms a Distinct Structure at the Tip of Injectisome
      Needles .................................................................................................................... 38
  3.4 Unpublished results .............................................................................................. 41
    3.4.1 The orientation of the LcrV molecule in the tip complex .............................. 42
    3.4.2 Production of antibodies directed against PcrV and AcrV ............................ 53
    3.4.3 Determination of the Stoichiometry of needle components ....................... 54
    3.4.4 Estimation of the size of pores made by LcrV and its orthologs ................. 56
    3.4.5 The translocators YopB and YopD interact with liposomes in vitro ............. 58
    3.4.6 Purification of the TTS translocation pore using tagged translocators .......... 66

4 Discussion ..................................................................................................................... 71

5 Outlooks ....................................................................................................................... 81

Appendix .......................................................................................................................... 83
  A List of constructs ....................................................................................................... 84
  B References ............................................................................................................... 86
  C Acknowledgments ..................................................................................................... 91
  D Curriculum vitae ..................................................................................................... 92
1 Introduction
1 Introduction

1.1 Type III secretion systems

Interaction of bacterial pathogens or symbionts with host cells is mediated by factors that are located on the bacterial surface or are secreted into the extracellular space. Although these proteins are numerous and diverse, exhibiting a wide variety of functions that include proteolysis, hemolysis, cytotoxicity, protein phosphorylation and dephosphorylation, only a few pathways exist by which these proteins are transported from the bacterial cytoplasm to the extracellular space. Such secretion systems are classified into four major types: I-IV.

Type III secretion, the subject of this work, is probably the most sophisticated export apparatus described so far and is found in many gram-negative bacteria, pathogenic for animals and plants, as well as in endosymbionts. The discovery of type III secretion (TTS) was made in the early 1990s, when a few groups, studying Yersinia, were trying to understand the mysterious phenomenon of Calcium-dependency: When incubated at 37°C in the absence of Ca^{2+}-ions, Yersinia bacteria stop growing and start to release large amounts of proteins, called Yops, into the culture medium (Michiels et al., 1990). Amino-terminal sequence analysis revealed that these Yop proteins must be secreted in a sec-independent manner and hence by a new pathway.

This release, generally referred to as Yop secretion, is rather a massive leakage resulting from an artificial opening of an otherwise tightly controlled secretion apparatus. Despite the fact that this leakage is presumably artefactual, this observation turned out to be of great importance because it allowed to carry out genetic analysis that lead to the identification of more than 25 genes involved in the process of Yop secretion. These genes, encoded together with the yop genes on the 70 kb Yersinia virulence plasmid (pYV), were called ysc for Yop secretion (Fig. 1). Interestingly most of the inner membrane Ysc proteins are homologous to components of the flagellar biosynthesis apparatus, suggesting a common evolutionary origin with the flagellum. These similarities prompted the research groups led by J. Galan and S.I. Aizawa to apply extraction and visualization techniques of the flagellum basal body to the Salmonella enterica serovar Typhimurium TTS system, which allowed them to visualize the secretion apparatus (Fig. 2A, Kubori et al., 1998). This structure, called needle-complex (NC) or injectisome, is composed of a needle like portion that projects outward from the surface of the bacterial cell and a cylindrical basal body that anchors the structure to the inner and outer membranes. Since then electron micrographs of NCs from Shigella flexneri and enteropathogenic Escherichia coli (EPEC) have been produced (Fig. 2B-D; Blocker et al., 1999; Sekiya et al., 2001; Tamano et al., 2000; Kimbrough and Miller, 2000; Daniell et al., 2001; Blocker et al., 2001; Ogino et al., 2006; Morita-Ishihara et al., 2006).
Lately a model of the NC from \textit{S. Typhimurium} has been presented at a resolution of 1.7 nm (Fig. 2F; Marlovits \textit{et al.}, 2004).

Little is known about the actual mechanism of export, but the structure of the injectisome implies that it serves as a hollow conduit across both bacterial membranes for the exported proteins.

\textbf{Fig. 1. The \textit{Y. enterocolitica} pYV plasmid.} Taken from “The 70-Kilobase Virulence Plasmid of \textit{Yersiniae},” Iriarte M. and Guy R. Cornelis, in “Pathogenicity Islands and Other Mobile Virulence Elements”, ASM press 1999.
Fig. 2. Electron micrographs of the flagellum and the needle complexes from different bacteria. (A) Purified needle complexes from *S. Typhimurium* (Kubori *et al.*, 1998). (B) Purified needle complexes from *S. flexneri* (Tamano *et al.*, 2000). (C) Purified needle complexes from EPEC (Sekiya *et al.*, 2001). (D) Isolated flagella from EPEC (Sekiya *et al.*, 2001). (E) Surface rendering of the needle complex from *S. flexneri* assuming cylindrical symmetry (Blocker *et al.*, 2001) (F) Surface rendering of the needle complex from *S. Typhimurium* (Marlovits *et al.*, 2004). Scale bar represent 100 nm in (A, B, D) and 50 nm in (C).
1.2 The concept of translocation

The actual destination of effector proteins secreted by type III secretion systems is not the extracellular medium but the cytosol of eukaryotic cells, where they affect signaling or control pathways. Surprisingly the secreted Yop proteins have no cytotoxic effects on cultured cells, although live Yersiniae have such an activity. Cytotoxicity was found to depend on the capacity of the bacterium to secrete both YopE and YopD (Rosqvist et al., 1991). Moreover YopE alone was shown to be cytotoxic when microinjected into the cells. This suggested that YopD somehow helps the injection of the cytotoxic YopE into the target cell. In 1994, this hypothesis was demonstrated by two different methods, immunofluorescence and a reporter enzyme based strategy (Rosqvist et al., 1994; Sory and Cornelis, 1994) that allowed the detection of Yop-proteins in target cells. Thus, extracellular Yersinia bacteria do not only secrete YopE, but they also inject YopE into the cytosol of eukaryotic cells by a mechanism that involves at least one other protein, YopD. Later, YopB was shown to be required for the delivery of YopE and YopH (Boland et al., 1996; Hakansson et al., 1996). Finally, LcrV was shown to be also involved (Fields et al., 1999; Marenne et al., 2003; Pettersson et al., 1999).

These observations and others lead to the present concept that the secreted Yop proteins consist of two groups, a collection of intracellular effectors and proteins that are required for the translocation of these effectors across the plasma membrane of the target cells. This general principle: secretion machinery, “effectors” and “translocators” (Fig. 1), applies to all type III secretion systems studied so far. While the secretion machinery is more or less conserved, the effectors vary considerably, depending on the particular needs of the bacteria. Among the animal pathogens, type III secretion systems have been most intensely studied in Yersinia spp., Shigella spp., Salmonella spp., Pseudomonas aeruginosa, EPEC and enterohemorrhagic E. coli. The best-studied system of a plant pathogen is the one of Pseudomonas syringae (for a review see, Mota et al., 2005b).

1.3 The triplet of translocators

As the concept of type III secretion evolved and more proteins were studied, it became evident that the group of the translocators generally consists of three proteins (YopB, YopD and LcrV in Yersinia). They have in common that knockout mutants in these proteins completely lose the ability to translocate effector proteins into target cells, while the secretion process itself is not affected (for a review see, Buttner and Bonas, 2002). Another general feature of the three translocators is that two have hydrophobic domains (YopB and YopD) while the third is clearly hydrophilic (LcrV) (Fig. 3). This applies to the type III secretion
translocators from *P. aeruginosa* (PopB, PopD and PcrV), *Aeromonas salmonicida* (AopB, AopD and AcrV), *S. flexneri* (IpaB, IpaC and IpaD), *S. Typhimurium* SPI-1 (SipB, SipC and SipD), EPEC (EspB, EspD and EspA) and *S. Typhimurium* SPI-2 (SseD, SseC and SseB). In several systems, the three translocators were reported to interact with each other (Chiu and Syu, 2005; Menard *et al.*, 1994; Sarker *et al.*, 1998a; Schoehn *et al.*, 2003; Tucker and Galan, 2000) and most translocators even contain coiled-coil domains, known to be involved in protein-protein interactions (Fig. 3).

![Fig. 3. Structural organization of the three type III secretion translocators found in different pathogenic bacteria.](image)

In all type III secretion systems studied so far the three translocators were found to be encoded together in one large operon (Fig. 4). In addition to the translocators, this operon contains genes coding for proteins involved in the regulation of type III secretion and for small proteins that serve as chaperones for the hydrophobic translocators (see chapters 1.9 and 1.10).

The similarities between the translocators are not restricted to their function and genetic localization, but also extend to their sequence (Buttner and Bonas, 2002). The most closely
related homologs of YopB/YopD are PopB/PopD of \textit{P. aeruginosa} and AopB/AopD of \textit{A. salmonicida}. The homology goes so far that popB/popD can complement a mutation of the yopB/yopD genes in \textit{Yersinia} when expressed from its native operon (Broms et al., 2003; Frithz-Lindsten et al., 1998). IpaB/IpaC from \textit{Shigella} and SipB/SipC from \textit{Salmonella} SPI-1 also share homologies to YopB/YopB, especially in the hydrophobic domains (Hakansson et al., 1993).

The hydrophilic translocators seem to be more diverse. The only sequence homologs of LcrV are PcrV of \textit{P. aeruginosa} and AcrV of \textit{A. salmonicida}. These proteins are so closely related that PcrV and AcrV complement a \textit{Yersinia} lcrV mutation (Holmstrom et al., 2001; Mueller, Broz et al., 2005). Others, like IpaD, SipD, EspA and SseB, exhibit only low sequence homology to LcrV and should be rather considered as functional homologs.

\begin{figure}
\centering
\includegraphics[width=\textwidth]{translocator_operons.png}
\caption{Organization of the translocator operons from different TTS systems.}
\end{figure}
1.4 The role of the translocators during infection

As mentioned above two of the translocators have hydrophobic domains. It was hypothesized that they could act as some kind of transmembrane proteins (Hakansson et al., 1993). Early reports mentioned that YopB has a membrane disturbing activity (Hakansson et al., 1996) suggesting that the translocators may destabilize the membranes and thus allow translocation. Consistent with this YopB/YopD, PopB/PopD, IpaB/IpaC and EspB/EspD were found to be inserted in the membranes of erythrocytes after infection (Blocker et al., 1999; Goure et al., 2004; Goure, Broz et al., 2005; Ide et al., 2001). In addition YopB and YopD were reported to bind to artificial liposomes that were incubated with secreting Yersinia spp. (Tardy et al., 1999). Several in vitro studies were done with purified translocators to analyze their properties. It was shown that purified IpaB and SipB are able bind membranes, lead to release of Calcein from liposomes and have membrane fusion activity (De Geyter et al., 2000; Hayward et al., 2000; Hume et al., 2003). Other translocators, PopB/PopD and YopB/YopD, were also shown to bind to liposomes and insert into liposome membranes in vitro (Faudry et al., 2006; Schoehn et al., 2003), P. Broz unpublished data). On the basis of these results it was hypothesized that the hydrophobic translocators form the transmembrane part of the type III secretion translocon.

To understand the role of the hydrophilic translocator was more difficult. The best-studied example is LcrV. This protein was described already in the nineteen fifties as a soluble antigen involved in the virulence of Yersinia spp. (hence named V antigen) long before the concept of type III secretion was shaped (Burrows, 1956). Early studies reported that it was a protective antigen against plague infections (Lawton et al., 1963) and antibodies directed against LcrV protect cultured cells from Yersinia infections (Pettersson et al., 1999). In 1999 it was shown by immunogold electron microscopy that LcrV is exposed on the surface of Yersinia spp. before contact to target cells (Pettersson et al., 1999). Its functional counterparts IpaD and SipD are probably surface exposed as well (Turbyfill et al., 1998), but this was not formally demonstrated so far. These results suggested that the hydrophilic translocator is part of a structure that is preassembled on the bacterial surface.
1.5 Evidence for a pore formed by the translocators

A feature, observed for most bacteria employing type III secretion systems is a contact-dependent lytic activity on red blood cells. Erythrocyte lysis was reported for *Yersinia* spp., *P. aeruginosa*, *S. flexneri*, *Salmonella* spp. and EPEC and was dependent on the presence of the translocators (Blocker et al., 1999; Dacheux et al., 2001; Hakansson et al., 1996; Holmstrom et al., 2001; Ide et al., 2001; Miki et al., 2004; Neyt and Cornelis, 1999a; Shaw et al., 2001). This suggests that the translocation apparatus involves some kind of a pore in the eukaryotic cell membrane by which the effectors are injected into the target cell. For *Yersinia*, the hemolytic activity is higher when the effectors are deleted suggesting that the pore is normally filled with trafficking effectors (Hakansson et al., 1996). Osmoprotection experiments allowed the estimation of the size of this translocation pore, which is around 2-3 nm in diameter (Table 1; Blocker et al., 1999; Dacheux et al., 2001; Holmstrom et al., 2001; Ide et al., 2001; Miki et al., 2004; Shaw et al., 2001). The idea of a translocation pore is further supported by the observation that the membrane of macrophage-like cells infected with an effector polymutant *Y. enterocolitica* becomes permeable to small dyes (Neyt and Cornelis, 1999a). If the macrophages are preloaded with a low-molecular-weight fluorescent marker, they release the marker but no cytosolic proteins, indicating that there is no membrane lysis but rather the insertion of a small pore into the macrophage plasma membrane (Neyt and Cornelis, 1999a). Finally the hypothesis of a channel was reinforced by the observation that artificial liposomes that have been incubated with *Yersinia* spp. contained channels, detectable by electrophysiology (Tardy et al., 1999).

The formation of the translocation pore and the translocation of effector proteins are in all cases dependent on the presence of the three translocators. This suggests that the translocators form a pore in the target cell membrane. But, it could not be formally proved so far that the two events, translocation of effectors and formation of a channel, are linked.

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Pore size</th>
<th>System</th>
<th>Method</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Yersinia</em></td>
<td>1.2-3.5 nm</td>
<td>erythrocytes</td>
<td>osmoprotection</td>
<td>(Hakansson et al., 1996)</td>
</tr>
<tr>
<td></td>
<td>2.2-3.5 nm</td>
<td>erythrocytes</td>
<td>osmoprotection</td>
<td>(Holmstrom et al., 2001)</td>
</tr>
<tr>
<td></td>
<td>2.4-3.2 nm</td>
<td>erythrocytes</td>
<td>osmoprotection</td>
<td>P. Broz, unpublished data</td>
</tr>
<tr>
<td></td>
<td>1.6-2.3 nm</td>
<td>macrophages</td>
<td>dye release</td>
<td>(Neyt and Cornelis, 1999a)</td>
</tr>
<tr>
<td><em>P. aeruginosa</em></td>
<td>2.8-3.5 nm</td>
<td>erythrocytes</td>
<td>osmoprotection</td>
<td>(Dacheux et al., 2001)</td>
</tr>
<tr>
<td><em>S. flexneri</em></td>
<td>~2.5 nm</td>
<td>erythrocytes</td>
<td>osmoprotection</td>
<td>(Blocker et al., 1999)</td>
</tr>
<tr>
<td><em>S. Typhimurium</em> SPI-1</td>
<td>~3.5 nm</td>
<td>erythrocytes</td>
<td>osmoprotection</td>
<td>(Miki et al., 2004)</td>
</tr>
<tr>
<td>EPEC</td>
<td>2.2-5 nm</td>
<td>erythrocytes</td>
<td>osmoprotection</td>
<td>(Ide et al., 2001)</td>
</tr>
<tr>
<td></td>
<td>2-3.2 nm</td>
<td>erythrocytes</td>
<td>osmoprotection</td>
<td>(Shaw et al., 2001)</td>
</tr>
</tbody>
</table>

Table 1. Estimated sizes of the translocation pore from different type III secretion systems
1.6 Structure of the translocation pore

As mentioned above it was hypothesized that the three translocators constitute a pore that mediates translocation. In agreement with their hydrophobic nature, two of the translocators would form the transmembrane part of the pore. How the third, hydrophilic translocator is involved, remained unclear. It was proposed that it could form the core of a membrane channel, stabilized by YopB and YopD (Holmstrom et al., 2001).

The first study trying to visualize the translocation pore and analyze its components was published in 2001 (Ide et al., 2001). The authors incubated erythrocytes with concentrated culture supernatant from wildtype DA-EPEC bacteria and from a mutant deficient for type III secretion. They examined the membranes of these erythrocytes by negative stain TEM and observed segmented, pore-like structures in the sample incubated with SN from wildtype bacteria (Fig. 5). These big rings had an outer diameter of 55-65 nm and rose up to 20 nm from the membrane plane. The inner diameter was estimated to be at least 8 nm, which is considerably bigger than the diameter of the translocation pore determined by osmoprotection. In addition, the authors demonstrated that EspD and EspB are associated to the membranes of the erythrocytes after incubation with SN from wildtype bacteria. They concluded that the observed structures might be the type III secretion translocon of EPEC, formed by EspD and EspB. The major drawback of this study was that it could not be shown that the observed rings are composed of the translocators EspD and EspB. Furthermore the inner diameter of the observed rings was far too big to be the translocation pore and the overall dimensions of these rings suggest that the authors had rather purified some porin-like structures.
Fig. 5. Electron micrographs of red blood cell membranes incubated with concentrated supernatant from wildtype EPEC bacteria (Ide et al., 2001). Transmission electron micrographs (A) and etched replicas (B) viewed by electron microscopy. Ring-like structures are indicated (black arrowheads). Scale bar is 100 nm in (A) and 200 nm in (B). Three-dimensional image of a representative single pore-like structure (C) after Atomic Force Microscopy (AFM) analysis.

The next study, using an in vitro approach to analyze the structure of the translocon, was published two years later (Schoehn et al., 2003). The authors expressed and purified the translocators PopB and PopD of P. aeruginosa together with their native chaperone PcrH. They found that at acidic pH the translocators could bind and disrupt artificial liposomes. Electron microscopy revealed ring-like structure on and next to these liposomes with an internal diameter of 4 nm and an external diameter of 8 nm (Fig. 6). What was puzzling was the observation that the incubation with PopB alone, PopD alone and an equimolar mix of PopB and PopD lead to the formation of comparable ring-like structures. The authors concluded that upon secretion the translocators PopB and PopD oligomerise, form ring-like structures and insert into the target cell membranes (Fig. 7). Even though the approach was new and ingenious, this study was incomplete and opened more new questions than it could answer. First, it was reported that purified PcrV had no influence on the ring-formation, even though PcrV is absolutely required for pore formation in vivo. Second, PopB alone, PopD alone and a mix of both formed similar ring-like structures. Third, the authors did not show that the rings represented functional pores. And finally, there is no evidence that the translocation pores formed by bacteria in vivo are the same as those formed by the translocators in vitro.

A recent follow-up paper from the same group (Faudry et al., 2006) showed that liposomes incubated with purified PopB and PopD are permeabilized due to the formation of
pores. These pores were estimated to have a rather wide range of diameter from 3.4 to 6.1 nm, which is in contrast to native pores formed by *P. aeruginosa* that have a defined size from 2.8-3.4 nm (Dacheux *et al.*, 2001). This suggests that the pores formed *in vitro* are a heterogeneous mix of pore-like structures with different diameters as observed for *Yersinia* (P. Broz, unpublished data), possibly due to the lack of LcrV/PcrV.

Even though it is by now generally accepted that the hydrophobic translocators form the translocation pore, it could not be convincingly visualized so far. Therefore the structure and composition of the translocation pore remains one of the big mysteries of type III secretion.

Fig. 6. Negative staining electron micrographs showing ring-like structures formed by the *P. aeruginosa* translocators upon interaction with liposomes at acidic pH (Schoehn *et al.*, 2003). (A) PopB incubated with liposomes at pH 5.3, stained with uranyl acetate. (B) PopD incubated with liposomes at pH 5.3, stained with uranyl acetate. (C) Equimolar mixture of PopB and PopD incubated with liposomes at pH 5.3, stained with uranyl acetate. Scale bars are 50 nm.

Fig. 7. Model of translocon formation by PopB and PopD in *P. aeruginosa* (Schoehn *et al.*, 2003). (A) PcrH associates to both PopB and PopD while they remain in the bacterial cytosol preventing aggregation and/or activation. (B) The “in vivo switch”, which *in vitro* is mimicked by a decrease in pH leads to the formation of metastable oligomers. (C) PopB and PopD may associate into a homomeric and/or heteromeric ring-like structures that bind to membranes. (D) The rings insert into the membranes.
1.7 The role of the needle in the translocation process

As mentioned above the secretion apparatus consists of a basal body, embedded in the bacterial membranes, topped by a needle-like structure. Electron micrographs of purified needle-complexes show that a central channel of 2-3 nm extends from the bottom set of rings all the way to the tip of the needle. This suggests that the secreted proteins have to travel in a partially unfolded way through this channel and emerge at the tip of the needle. Hoiczyk and Blobel proposed that the needle itself, powered by the oligomerization of the needle subunit YscF, would punch a hole in the target cell membrane thus placing its tip inside the host cell and thereby deliver the effector proteins (Hoiczyk and Blobel, 2001). Attractive as this model is, it neglected the fact that the translocators are essential for the delivery of the effector proteins. Still one could imagine that the hydrophobic translocators interact with the host cell membrane, destabilize it and hereby allow the needle to pierce into the target cell. The observed “translocation pores” might in fact just be needles that have been broken off, stay inserted in the membranes and thus allow the passage of molecules through a 2-3 nm wide channel.

The Yersinia injectisome needle has a remarkably constant length of around 60 nm (± 10 %) suggesting that it is genetically controlled. Journet et al. proposed that YscP acts as a molecular ruler, the length of the protein determining the length of the needle (Journet et al., 2003). This opened the question, why it has to be controlled. Structures like the adhesin YadA and/or the LPS, found on the bacterial surface, determine the distance between the bacterium and the target cell, which have to be bridged by the needle. Indeed, it seems that the precise length of the needle has been evolutionarily adjusted relative to the dimensions of the adhesin YadA (Mota et al., 2005a) and the LPS (West et al., 2005). If the needle is too short to bridge the distance between the bacterium and the target cell, the effector proteins cannot be translocated.

Surprisingly, when the needle is too short the effectors are not lost in the extracellular space. Rather, they are not exported, meaning that the needle itself acts as a sensor to trigger export (Mota et al., 2005a). This suggests that the secretion and translocation of effectors is only triggered when the needle is long enough to reach the target cell membrane and the translocation pore is assembled. Furthermore it can be assumed that the pore is somehow connected to the needle, as no leakage of effectors can be observed during the infection.
1.8 How is the injectisome coupled to the translocation pore?

One central question is how the pore, presumably consisting of the hydrophobic translocators, is connected to the needle of the injectisome. First clues to answer this question were provided, when the membranes of erythrocytes, infected with *Yersinia*, were analyzed. Wild type bacteria (*lcrV*) formed functional pores and inserted YopB and YopD, but no LcrV into the erythrocyte membranes. On the other hand, Δ*lcrV* bacteria did not form pores, but still inserted YopB and YopD into the erythrocyte membranes. This suggested that LcrV mediates the assembly of the YopB/YopD translocation pore (Goure, Broz *et al.*, 2005). In addition, protective antibodies directed against LcrV inhibited pore formation in infected erythrocytes, but not the insertion of the hydrophobic translocators YopB and YopD into the erythrocyte membranes (Goure, Broz *et al.*, 2005). Similar observations were made with the LcrV orthologs, IpaD from *S. flexneri* (Picking *et al.*, 2005) and PcrV from *P. aeruginosa* (Goure *et al.*, 2004). These data support a model in which the hydrophilic translocator, acting as an extracellular chaperone or assembly scaffold, helps the hydrophobic translocators to integrate into the eukaryotic cell membrane and to form a functional pore (Goure, Broz *et al.*, 2005). Protective antibodies inhibit the translocation by blocking the function of LcrV and thus prevent the assembly of the translocation pore.

According to this model, the obvious localization of LcrV would be at the tip of the injectisome needle, where the secreted proteins are thought to exit the secretion machinery. This prompted Mueller, Broz and coworkers to closely analyze the needles of *Y. enterocolitica* (Mueller, Broz *et al.*, 2005). They reported a novel structure, called the tip complex, at the distal end of wildtype needles (Fig. 8). Needles of *lcrV* mutant bacteria lacked this tip structure and it was restored when the mutation was complemented in *trans*. When the mutation was complemented with the LcrV orthologs, PcrV from *P. aeruginosa* or AcrV from *A. salmonicida*, the tip complex was brought back, resembling that formed by LcrV. As a final proof that the tip complex is composed of LcrV the authors showed that anti-LcrV antibodies bound specifically to the tip complex. This lead to the present model, in which the LcrV tip complex, localized at the tip of the needle, assists the assembly of the translocation pore, formed by the secreted translocators YopB and YopD (Fig. 9). At a later stage LcrV presumably connects the pore to the needle, forming a continuous channel from the bacterium to the cytoplasm of the eukaryotic cell.
Fig. 8. LcrV forms a structure at the tip of the injectisome needle (Mueller, Broz et al., 2005). (A) Transmission electron micrograph of Y. enterocolitica negatively stained with 2 % uranyl acetate. Needles protrude from the cell surface and have a distinct structure at their distal end. Scale bar is 40 nm. (B) Scanning Transmission Electron Microscopy (STEM) images of negatively stained wt needles. The characteristic tip complex (white arrow) comprises a head, a neck and a base. Scale bar is 20 nm. (C) STEM images of wt needles incubated with anti-LcrV antibodies and negatively stained. The antibodies generally attached to the “head” domain of the tip complex. Scale bar is 20 nm. (D) Projection averages of the complexes formed by LcrV, PcrV and AcrV at the tip of the injectisome needle of Y. enterocolitica E40 (resolution 1.5 nm). A central channel permeates both the needle and the tip complex. Scale bar is 5 nm.
Fig. 9. Hypothetical model for the function of the LcrV tip structure in the assembly of the translocation pore formed by the translocators YopB and YopD (Mueller, Broz et al., 2005). (A) Before contact to a target cell. The injectisome is assembled and LcrV forms the tip complex on the distal end of the needle. (B) Contact to target cell. The translocation pore is assembled, forming a continuous channel from the bacterium to the host cell cytosol and allowing translocation of effector proteins. The LcrV tip complex serves as an assembly platform. (C) Situation in lcrV deletion mutant. The translocators YopB and YopD are secreted and insert into the target cell membrane. No translocation pore is formed due to the lack of the tip complex. (D) Presence of protective antibodies. The translocators are secreted and insert into the target cell membrane. No functional pore can be assembled, because anti-LcrV antibodies bind to the tip complex and block its function.
1 Introduction

1.9 The chaperone of the hydrophobic translocators

A hallmark of type III secretion is that efficient secretion or translocation of some substrate proteins requires the presence of small cytosolic chaperones. They are divided into three distinct classes: I, II and III. Chaperones of the hydrophobic translocators constitute the class II. The archetype of this chaperone class is SycD, the specific chaperone of both YopB and YopD from *Yersinia* (Neyt and Cornelis, 1999b; Wattiau *et al.*, 1994). Homologs of SycD in other type III secretion systems usually serve as chaperone for two hydrophobic translocators as well (Fig. 4): PcrH for PopB and PopD (Allmond *et al.*, 2003; Schoehn *et al.*, 2003), SicA for SipB and SipC (Kaniga *et al.*, 1995; Tucker and Galan, 2000) and IpgC for IpaB and IpaC (Menard *et al.*, 1994). In EPEC the situation seems to be more complex: Initially, CesD was reported to be the chaperone for the translocators EspB and EspD (Wainwright and Kaper, 1998). Meanwhile, a second chaperone for EspD, called CesD2, was discovered (Neves *et al.*, 2003). In the SPI-2 system of *S. Typhimurium*, the *sscA* gene shares homology to *sycD* of *Yersinia*, but the protein has not been analyzed so far.

1.9.1 Role as chaperone

Immunoprecipitation experiments have shown that, in the cytoplasm of *S. flexneri*, IpgC is associated either with IpaB or IpaC (Menard *et al.*, 1994). As IpaB and IpaC have been shown to form a complex after secretion it was proposed that the chaperone prevents the premature association of the two translocators (Menard *et al.*, 1994). The same role has been attributed to SicA, the homolog of IpgC, in *S. Typhimurium* (Tucker and Galan, 2000). Consistent with this it could be shown that in *Yersinia* and *P. aeruginosa*, SycD/PcrH also associates independently with YopB or YopD, PopB or PopD respectively (Anderson *et al.*, 2002; Schoehn *et al.*, 2003). In contrast to chaperones of the effectors (class I), chaperones of the translocators might not bind to a unique region on their substrates. YopD possesses two distinct SycD binding domains, one spanning the N-terminus and one encompassing the C-terminal amphipathic domain (Francis *et al.*, 2000), while several binding sites were identified in YopB (Neyt and Cornelis, 1999b). In *S. flexneri*, however, a unique binding site for IpgC has been identified in the N-terminal part of both IpaB and IpaC (Page *et al.*, 2001). So far no similarities between these regions could be identified. Only the crystallization of the chaperones together with their substrates will determine the nature of this interaction.

When expressed in *E. coli*, IpaB is degraded in the absence of the chaperone IpgC, while IpaC is stable (Menard *et al.*, 1994). When IpaB and IpaC are co-expressed both proteins are degraded but this can be prevented by the expression of IpgC. Thus in the
absence of IpgC the unstable IpaB associates to IpaC and leads to its degradation. In *Salmonella*, SipB is degraded in a *sicA* mutant, but not in a *sicAsipC* mutant, suggesting that, in the absence of SicA, SipC interacts with SipB and leads to its degradation (Tucker and Galan, 2000). In *Yersinia* also YopB and, to a lesser degree YopD, require SycD for its stability (Edqvist et al., 2006; Francis et al., 2000; Neyt and Cornelis, 1999b). In addition, if YopB is expressed in *E. coli* without the chaperone it leads to lysis of the bacteria, probably due to the interaction with membranes (Neyt and Cornelis, 1999b). Similar observations were reported for PopB and PopD from *P. aeruginosa* (Schoehn et al., 2003). No toxic effects are observed when the translocators are expressed with their chaperone.

Altogether these results suggest that the function of class II chaperones is to prevent premature association of the translocators and also to stabilize their substrates. Because some of the translocators might have a deleterious effect on the bacteria, they are rapidly degraded if they are not bound to the chaperone.

Structurally, class II chaperones are characterized by the possession of three tandem tetratricopeptide repeats (TPR’s), which are otherwise only found in eukaryotic molecular chaperones (Pallen et al., 2003). No class II chaperone has been crystallized so far, but the TPR’s allowed a homology modeling of SycD based on human protein phosphatase 5 (Fig. 10, (Pallen et al., 2003). According to this, class II chaperones would have an all-alpha-helical domain structure in contrast to class I chaperones, which comprise alpha-helical and beta-strand structures (Parsot et al., 2003). The mapping of residues critical for the interaction with the translocators revealed two distinct interaction interfaces in SycD, one for YopD and one for YopB (Fig. 10, (Edqvist et al., 2006).

![Fig. 10. Homology modeling of the hypothetical structure of the translocator chaperone SycD (Edqvist et al., 2006). The modeling is based on the TPR’s of the human protein phosphatase 5. Interaction interfaces with YopB and YopD were determined by mutagenesis and are indicated.](image)
1.9.2 Role in regulation

Initially, SycD was discovered as a negative regulator because a sycD mutation leads to increased yop gene expression and reduced growth in high calcium conditions; hence it is also called LcrH for “low Calcium response H” (Bergman et al., 1991; Price et al., 1989). Overexpression of SycD in Yersinia causes a decrease in Yop synthesis. Deletion of the yopD gene results in a constitutive production of Yops, similar to a sycD mutation. It was shown that the formation of a complex between YopD and SycD is necessary for the regulation of yop gene expression (Anderson et al., 2002; Francis et al., 2000). Mutants that could not form the complex could no longer regulate yop gene expression, even though YopD and SycD were both produced. Therefore it has been proposed that together with YopD, SycD/LcrH establishes a negative regulatory loop for the control of Yop synthesis (Francis et al., 2000).

Homologs of SycD/LcrH from other system have been shown to be involved in regulation as well. In S. Typhimurium the chaperone SicA is necessary for the activation of the sicA, sigDE and sopE operons, which also depends on the presence InvF, a transcriptional activator of the AraC family (Darwin and Miller, 2001; Tucker and Galan, 2000). Co-expression of SicA and InvF is sufficient to activate the promoters of these operons in E. coli (Darwin and Miller, 2001). In addition both proteins were shown to interact in E. coli, suggesting that SicA could act as co-activator of InvF. In S. flexneri, IpgC and MxiE, the homologs of SicA and InvF, are involved in the activation of effector genes, like ipaH (Mavris et al., 2002). Co-expression of both proteins in E. coli is sufficient to activate transcription from regulated promoters. Furthermore, overexpression of IpgC in wildtype S. flexneri leads to the activation of the regulated genes. Similar observations were made for SycB and YsaA from the Yersinia Ysa-Ysp system (Walker and Miller, 2004). The model proposed for this family of TTSSs states that, in non-secreting conditions, the chaperone is associated with the translocators and is not available for the AraC-like activator (Fig. 11). Upon secretion of the translocators the chaperone is released and can act as co-activator for the transcription of regulated promoters. This imposes a level of hierarchy between the translocators and the effectors. One could therefore speculate that the class II chaperones not only serve as chaperones for the hydrophobic translocators but also might ensure the secretion of the translocators at the right time, before the effectors.

According to this model, the translocators have to be secreted before the effectors can be produced. However, it is known that effectors are synthesized and stored in the cytosol already before the system is triggered. Upon activation they are supposed to be secreted post-translationally. This implies that the translocators have to be detached from the chaperone already before the secretion is triggered. This suggest that, during the assembly of the injectisome, the translocators are secreted and/or stored somewhere in the injectisome. It could be possible that the needle is filled with the translocators. Purified needle preparations
from *Yersinia* contain YopD (Mueller, Broz *et al.*, 2005) and recently it was reported for *S. flexneri* that IpaB is present in purified needle preparations (Espina *et al.*, 2006). If these proteins are only contaminants of the needle preparations or indeed the needles were preloaded with translocators remains to be determined.

![Fig. 11. Simplified model of regulation of transcription by TTS apparatus activity in *S. flexneri*, *S. Typhimurium* SPI-1 and *Y. enterocolitica* Ysa-Ysp system.](image)

(A) Inactive secretion apparatus. The translocators (red) are bound to their chaperone (orange). The AraC-like activator (turquoise) cannot activate the transcription of effector genes. (B) Active secretion apparatus. Secretion of the translocators leads to the release of the chaperone. (C) The chaperone interacts with the AraC-like activator. This allows the transcription of effector genes (green). (D) The effectors are secreted.
1.10 The LcrG-LcrV complex regulates the secretion of effector Yops

As mentioned above the operon encoding the translocators and SycD also encodes LcrG, a small cytosolic protein, which is also involved in the low Calcium response (LCR) of Yersinia. A mutant in lcrG exhibits a Calcium-blind phenotype, expressing and secreting Yop proteins independently of the presence of Calcium at 37°C (Perry et al., 1986; Price et al., 1991; Skryzpek and Straley, 1993). LcrV, encoded in the same operon, is also involved in the LCR of Yersinia. But in contrast to lcrG mutants, lcrV mutants express and secrete severely reduced amounts of effectors and translocators and also do not show any growth inhibition when deprived of Calcium at 37°C (Marenne et al., 2003; Skrzypek and Straley, 1995).

LcrG and LcrV form a stable heterodimeric complex in the cytosol (Nilles et al., 1997). This complex-formation prompted the analysis of an lcrGV double mutant (Matson and Nilles, 2001; Nilles et al., 1998) and it appeared that this mutant exhibited the same phenotype as an lcrG mutant, expressing and secreting Yop proteins independently of the presence of Calcium at 37°C. Providing lcrV in trans had no effect on the phenotype. On the other hand, complementation of the double mutant with lcrG completely abolished secretion and decreased expression of Yops at 37°C in the presence and the absence of Calcium. This indicated that LcrG could act as a negative regulator for Yop secretion. If the mutant was complemented with both genes (lcrG and lcrV) the wildtype phenotype was restored. These results lead to the so-called LcrG titration model for the regulation of Yop secretion that was first proposed by Nilles et al. (Fig. 12; Nilles et al., 1998). This model states that, before the machinery is active, LcrG is expressed and directly or indirectly blocks the secretion machinery, acting from within the bacterial cytoplasm. Contact with the target cell or Calcium chelation (in vitro) would lead to increased expression of LCR-regulated genes, including the positive regulator LcrV. Increasing levels of LcrV would lead to complex formation between LcrV and LcrG, thus removing LcrG from its secretion-blocking function. In agreement with this, mutant LcrG proteins that cannot longer interact with LcrV block secretion, mimicking an lcrV phenotype (Matson and Nilles, 2001). Although the titration model is appealing, it is hard to imagine how contact to the target cell increases the expression of LcrV and not of LcrG as both of them are in the same operon. It is also unknown how the LcrG-LcrV plug is connected to the YopN plug, which also controls secretion.

Interestingly, it was shown that LcrG is also necessary for the efficient translocation of effectors into target cells, because when HeLa cell were infected with an lcrG mutant for 2 h, no cytotoxicity was observed (Sarker et al., 1998b). Only after prolonged infection (4 h) cytotoxic effects were observed (Nilles et al., 1998), suggesting that LcrG is not essential for translocation, but has a facilitating effect. This is consistent with the observation that LcrG might be required for maximal or efficient secretion of LcrV (Fields et al., 1999). These results
indicate that LcrG has a facilitating role in Yop targeting by promoting LcrV secretion, which is necessary to form the translocation pore.

Based on these observation it has also been proposed that LcrG could be the chaperone of LcrV (Lee et al., 2000). This idea is in addition supported by the facts that LcrG is small and primarily cytosolic. Purified LcrV forms dimers and to a certain extend also multimers (Lawton et al., 2002). Upon addition of LcrG the LcrV-dimer is dissociated and LcrG-LcrV heterodimers are formed. This suggests that LcrG prevents the polymerization of LcrV. The observation that LcrV forms the tip complex, implies that it has to polymerize (Mueller, Broz et al., 2005). In addition crosslinking of purified needles indicates close interaction between LcrV molecules (Mueller, Broz et al., 2005).

EspA, the ortholog of LcrV in EPEC, requires the chaperone CesA that keeps it in a monomeric form and prevents polymerization in the bacterial cytoplasm (Yip et al., 2005). Both LcrG and CesA have a basic pI, unlike class I chaperones that have an acidic pI. In contrast to EspA, LcrV does not require LcrG for its stability and secretion. The interaction between CesA and EspA is mediated via a coiled-coil motif, made of long alpha helices (Fig. 13). LcrV is much bigger than EspA but also has two long alpha helices that form a coiled-coil, similar to EspA. Comparably, in the S. Typhimurium SPI-2 system the interaction of SseB and its chaperone SseA is mediated by a putative coiled-coil motif (Zurawski and Stein, 2004). Indeed it has been reported that the interaction between LcrG and LcrV is also mediated by coiled-coil domains (Lawton et al., 2002). These coiled-coils are formed by the two long alpha helices that connect the globular domains of LcrV (Fig. 13). It is possible that these hydrophilic translocators need the chaperone to prevent their polymerization by masking their coiled-coil motifs.
Fig. 12. The LcrG titration model (Nilles et al., 1998). (A) Non secreting condition: LcrG is expressed and blocks the secretion apparatus from within the bacterial cytosol. (B) Contact with the target cell membrane or Calcium chelation leads to increased LcrV synthesis. (C) Formation of LcrG-LcrV dimers. Removal of gating. (D) The channel is open and secretion of effectors is possible.

Fig. 13. The coiled-coil motifs in EspA and LcrV. (A) Structure of CesA (blue) in complex with EspA (red) (Yip et al., 2005). The flexible central region of EspA is drawn as a dashed red line. Two extensive alpha helices of EspA (coiled-coil) interact closely with CesA in the protein complex. (B) Structure of LcrV (gray) as reported by Derewenda et al., 2004. The two long alpha helices that connect the globular domains and that are involved in the formation of coiled-coils and the interaction with LcrG are arranged in front (yellow).
1.11 Requirements on the membrane side

Many pathogenic bacteria have been found to interact with specialized domains of the host membrane that are rich in cholesterol and sphingolipids and that are termed rafts. Cholesterol rich microdomains have been found to be necessary for type III secretion mediated uptake of *S. Typhimurium* (Garner et al., 2002) and *S. flexneri* (Lafont et al., 2002) (for a review see, Lafont and van der Goot, 2005). Cellular receptors that partition into microdomains cluster during *Salmonella* and *Shigella* entry and upon initial EPEC-host contact (Garcia-del Portillo et al., 1994; Lafont et al., 2002; Zobiack et al., 2002). As the translocators insert directly into host cell membranes it was speculated that the formation of the translocation pore could depend on the presence of certain lipids in the host cell membrane. Indeed it could be shown recently that cholesterol is required for the translocation of effector proteins into host cells by *Salmonella, Shigella* and EPEC (Hayward et al., 2005). In addition the authors show that purified *Salmonella* SipB and *Shigella* IpaB are cholesterol-binding proteins and that cholesterol is the main binding determinant of purified SipB/IpaB to host cells (Hayward et al., 2005).

In vitro, liposome fusion induced by purified SipB protein is enhanced when target liposomes contain cholesterol (Hayward et al., 2000). Cholesterol-containing liposomes have also been shown to weakly stimulate the *Shigella* TTSS, suggesting that raft-like lipids may trigger effector release (van der Goot et al., 2004).

No cholesterol dependence has been reported for infections with *P. aeruginosa* so far, but the interaction of the *P. aeruginosa* translocators with artificial membranes has been studied (Schoehn et al., 2003). It was reported that purified PopB and PopD only bind to liposomes containing negatively charged phospholipids (phosphatidylycerine) and that PopB and PopD can lyse liposomes containing cholesterol (Schoehn et al., 2003). The latter observation had to be revised in a later study (Faudry et al., 2006), as no lysis could be observed any more, even with liposomes containing cholesterol. Similar experiments with purified translocators from *Yersinia* suggested that negatively charged phospholipids (DOPS) are required for the association of YopB and YopD with liposomes and for their insertion into membranes, while cholesterol is dispensable (P. Broz, unpublished results). *In vivo* studies with *Yersinia* showed that the depletion of cholesterol has no influence on the infection of cells (L. J. Mota, unpublished results).

Taken together, there is strong evidence that the interaction of several pathogens employing type III secretion systems, like *Shigella, Salmonella* and EPEC, is dependent on lipid rafts in the host cell membrane. Although some raft- or cholesterol-dependent events have been identified, the exact mechanisms at the molecular level remain obscure and will require further studies. However, not all type III secretion systems need to be triggered by the
same kind of lipids. Some bacteria have to act in seconds to escape macrophages, while others have more time to find the right spot to enter a target cell.
1.12 Other needle extensions

As mentioned before the LcrV tip complex forms an extension of the needle structure and possibly connects the translocation pore to the needle. Another type of extension is the EspA filament found in EPEC (Fig. 14; Knutton et al., 1998). This filament is a polymer made of multiple copies of a single hydrophilic protein, EspA. This protein, together with the hydrophobic proteins EspD and EspB is necessary for translocation of effectors and the formation of the translocation pore. EM analysis of purified injectisomes of EPEC show that the EspA filament is firmly attached to a very short needle made by EscF (Fig. 14; Daniell et al., 2001; Sekiya et al., 2001), which is similar to needles observed in other type III secretion systems. So far it was not defined whether EspA polymerizes around or on top of the EscF needle. The length of the EspA filament varies considerably and can reach up to 600 nm. The 3D structure of EspA filaments at a resolution of 26 Å revealed that the structure comprises a helical tube with a diameter of 120 Å enclosing a central channel of 25 Å diameter (Daniell et al., 2003), which is similar to the diameter of the injectisome needle (25 Å). Furthermore the helical parameters of the EspA filament (5.6 subunits per turn, 4.6 Å axial rise per subunit, Daniell et al., 2003) resemble that of the needle (5.6 subunits per turn, 4.3 Å axial rise per subunit, Cordes et al., 2003) and the R-type straight flagellar filament of Salmonella (5.47 subunits per turn, 4.69 Å axial rise per subunit, Mimori et al., 1995). In addition all three structures have five-fold symmetry.

The EspA filament is thought to be a necessary adaptation to enable the pathogen to penetrate the thick glycocalyx layer and to reach the cells of the intestinal. The EspA filament would serve as a hollow conduit connecting the injectisome of EPEC with the translocation pore, formed by EspD and EspB.
Fig. 14. EspA forms a long filament, attached to the needle of the injectisome from EPEC. (A) Electron micrographs of osmotically shocked EPEC stained with 1 % PTA (Daniell et al., 2001). (B) Electron micrographs of negatively stained purified NCs from EPEC. The white arrow indicates NCs and black arrow indicates pilus-like structures (Sekiya et al., 2001). (C) Electron micrographs of negatively stained purified NCs from *S. flexneri*. The white arrows indicate NCs (Sekiya et al., 2001). (D) Alignment of EPEC NCs and comparisons to *S. flexneri* NCs. N and B indicate the needle and basal body of EPEC NCs (Sekiya et al., 2001). (E) Immunogold labeling of purified NCs from EPEC with anti-EspA antibodies. Only the filament is decorated with gold particles while the basal body and the thinner needle part is not labeled. Scale bars are 100 nm (Sekiya et al., 2001).

A similar structure could exist in the SPI-2, the second T3SS of *S. Typhimurium* (Chakravortty et al., 2005). The three translocators of this system are SseB, SseC and SseD (Nikolaus et al., 2001). TEM analysis of *S. Typhimurium* grown *in vitro* revealed novel surface appendages (Fig. 15). These appendages are composed of a needle, 150 nm long, sheathed with an irregular proteinaceous structure. Immunogold analysis revealed that this sheath contains the translocators SseB and SseC. It is likely that these sheath structures, observed *in vitro*, are the result of prolonged secretion in the absence of contact to a target cell membrane. But, ultrathin section analysis of intracellular *S. Typhimurium* in macrophages revealed that *in vivo* similar needles are formed and have also a sheath-like structure but only at their distal end. This sheath contains SseB, the hydrophilic translocator of the SPI-2 type III secretion system. It still remains to be elucidated, how the sheath structure looks in detail, what is its function and whether the sheaths, formed *in vivo*, are not also just an artifact resulting from prolonged secretion.
Fig. 15. Electron micrographs of surface structures encoded by the S. Typhimurium SPI-2 system (Chakravortty et al., 2005). (A, B) High magnification electron micrographs of surface appendages present on wildtype S. Typhimurium, grown in secreting conditions. The appendages consist of an inner cylindrical needle (black arrowhead) and different extends of a proteinaceous structure. (C, D) Double immunogold labeling with antibodies directed against the translocators SseB (arrowheads) and SseC (arrows) of the surface appendages on S. Typhimurium grown in vitro. The antibodies were detected with protein A coated gold-particles of 10 nm for SseB and 15 nm for SseC. Both translocators are part of the sheath-like structure. (E, F) Ultrathin section analysis of intracellular S. Typhimurium bacteria. Structures consisting of needle-like stem and a sheathed distal end can be seen (E). Immunogold labeling for SseB (F) of surface appendages formed in vivo stains the sheath structure. Scale bars are 25 nm in (A, B, E), 100 nm in (C, D) and 50 nm in (F).

Recently, IpaD the functional ortholog of LcrV in S. flexneri, has been shown to be localized at the tip of the S. flexneri needle by immunogold electron microscopy (Espina et al., 2006). What kind of structure it forms there could not be defined yet.

The EspA filament and the putative SPI-2 needle sheath resemble, at a functional level, the LcrV tip structure of Yersinia. It can be hypothesized that the tip protein would have evolved to polymerize as a filament rather than a simple ring structure, but that it has probably kept its scaffolding property for the hydrophobic translocators (Fig. 16).
Fig. 16. Schematic representations of the flagellum (A) and different kinds of injectisomes (B, C, D). The flagellar hook, counterpart of the injectisome needle, is extended with a long filament made of FliC. The injectisomes of different species vary in the form of their needle extension. The needles of *Yersinia* spp., *P. aeruginosa* and *A. salmonicida* have a distinct tip complex at their distal end formed by LcrV, PcrV, AcrV, IpaD, SipD respectively (B). The same is probably true for *S. Typhimurium* and *S. flexneri* (SipD and IpaD). The needle from EPEC is extended by the long EspA filament (C). The needle from the *S. Typhimurium* SPI-2 TTS system (D) is likely to be topped with an yet undefined sheat-like structure, containing SseB.
1.13 Double function as translocator and effector

Type III secretion effectors are proteins that are injected into the eukaryotic cell, where they act on cellular signaling and control pathways. It appears that, in addition to the known effectors, some of translocators, namely IpaB, SipB, EspB and YopD are delivered into the eukaryotic cell.

A feature of Shigella and Salmonella infections is the induction of the inflammatory response. It has been shown that IpaB as well as SipB activate the ICE cysteine protease, which converts pro-IL-1 to the mature proinflammatory cytokine IL-1 (Hersh et al., 1999; Tran Van Nhieu et al., 1997). In addition, IpaB leads to the activation of NF-kB, which is followed by the release of proinflammatory cytokines, such as IL-8 (Hobbie et al., 1997). Because ICE is also a caspase (casp-1), interaction with IpaB or SipB leads to apoptosis of macrophages. Inhibition of Casp-1 activity by a specific inhibitor blocks macrophage cytotoxicity, and macrophages lacking casp-1 are not susceptible to Salmonella induced apoptosis (Chen et al., 1996; Hersh et al., 1999; Hilbi et al., 1998). Shigella- and Salmonella-induced apoptosis is thus distinct from other forms of apoptosis, including that induced by Yersinia, in that it is uniquely dependant on Casp-1.

The host cell cytoskeleton is a major target of effector proteins injected by pathogenic bacteria. The translocators IpaC from Shigella and SipC from Salmonella were shown to act on cytoskeletal dynamics and promote the entry of the bacteria into nonphagocytic cells. IpaC induces rearrangements of the subcortical cytoskeleton via small GTPases of the Rho family, leading to the formation of protrusions and membrane ruffling at the bacterial entry site (Tran Van Nhieu et al., 1999). Purified SipC nucleates actin polymerization and bundles actin into cables (Hayward and Koronakis, 1999).

EspB, one of the translocators from EPEC, is as well targeted to the host cell cytosol (Taylor et al., 1998; Wolff et al., 1998), where it modulates the cell actin cytoskeleton (Taylor et al., 1999). Also YopD from Yersinia was shown to be localized in eukaryotic cells after infection (Francis and Wolf-Watz, 1998), but no function as effector could be attributed yet. As the translocators are probably internalized during the recycling of membranes, this may explain why YopD is found in the eukaryotic cell, even though it is no effector.

Taken together, these observations indicate that depending on the system, the translocators are not necessarily restricted to the contact area between the bacteria and eukaryotic cells, but that they may traffic inside the target cell and act themselves as effectors, possibly in association with membranes.
2 Aim of the thesis
2 Aim of the thesis

The three proteins YopB, YopD and LcrV have been shown to be necessary for the translocation of effectors into target cells by the TTSS of *Yersinia*. It has been hypothesized that the translocators form a pore in the target cell membrane, but this pore has not been visualized so far. The role of the different translocators YopB, YopD and LcrV in the assembly of the translocon was unknown. The hydrophobic domains found in YopB and YopD suggested that they might be transmembrane proteins, facilitating the translocation. In addition, the role of LcrV, the major protective antigen, remained mysterious. The aim of my thesis was to characterize the type III secretion translocon of *Y. enterocolitica* in different aspects.

First the role of the hydrophilic LcrV had to be clarified. Second we wanted to find a way to isolate the translocation pore formed by the translocators, analyze its composition and visualize it by electron microscopy. And third we wanted to determine if certain lipids of the target cell membrane, in particular those found in lipid rafts, play a role during the formation of the translocation pore from *Y. enterocolitica*. 
3 Results

3.1 The Needle Length of Bacterial Injectisomes is Determined by a Molecular Ruler

Journet L., Agrain C., Broz P., and Cornelis G.R.

Summary

The *Yersinia* injectisome needle has a remarkably constant length of around 60 nm suggesting that it is genetically controlled. Mutants affected in the *yescP* gene display abnormally long needles, indicating that the needle length is indeed regulated and that YscP is involved in this process, as it is the case for its counterparts in other TTSS. To determine how YscP is exerting its length control function, we engineered a set of deletions and insertions in the protein. Deletions affecting either the extreme N- or C-term lead to needles of deregulated lengths suggesting that they are required for the length-control of the needles. In contrast, the central part can be shortened or lengthened without the loss of function. Moreover, deletions or insertions in this central part give rise to shorter or longer needles, respectively and a strict linear relationship between the number of residues of YscP and the needle length can be observed. Analysis of purified needles indicated that YscP is found in the purified needle fraction in non-secreting conditions but not any more in secreting conditions. Altogether these results demonstrate that YscP is acting during the assembly of the injectisome as a molecular ruler to determine needle length.

Statement of my work

I contributed to this paper by providing the electron micrographs of the *yescP* mutant strain, the needle purification protocol and the analysis of purified needles. I also contributed by preparing figures (Fig. 1, 3 and 4) and I was involved in the writing of the manuscript.
lines was 1.23 and 1.26 mm, whereas it was 1.23 mm for the ds2M line (Wilcoxon rank-sum test P > 0.1 for all comparisons, sample sizes N = 18). If anything, one of the ds2M lines shows an effect in the wrong direction.

Lack of sex specificity of the influence of ds2 on both starvation and cold tolerance suggests that this effect is not due to differences in cuticular hydrocarbons per se. Perhaps it has an influence of ds2 on phospholipid composition, as in many other organisms (22). Whatever the exact mechanism of ds2 action, our results strongly suggest that it is involved in stress resistance. Note, however, that the ds2M allele appears to be the derived one (6). Consequently, we have restored the ancestral state at the ds2 locus of the Cosmopolitan line, whereas the actual adaptation involved the loss of the ds2M allele from the African population.

The possibility that ecologically driven adaptation to the ds2 locus results in sexual isolation as a pleiotropic by-product is certainly intriguing. The role ds2 may play in Z-M sexual isolation is being debated. The genetic basis of Z behavior is complex (12, 39). Thus, ds2 cannot be the only gene involved and, because the Caribbean flies carry the African ds2M allele but exhibit M-type behavior, the locus has initially been excluded as a candidate sexual isolation gene (4). However, this lack of association across genetic backgrounds is inconclusive. A comparison within populations, in which the genetic background is randomized, is more informative. Indeed, when three African populations polymorphic for both Z behavior and ds2 were tested, a positive correlation between the presence of ds2 and the strength of female Z behavior was found in all three (11). Thus, loss of ds2 from the average African background may reduce Z-M sexual isolation.

Although the role of ds2 in premating isolation remains to be firmly established, we have identified a potential ecological basis for the maintenance of phenome polymorphism as a result of strong geographical differentiation at the ds2 locus. Our ability to detect the role of ds2 in differential adaptation depended crucially on manipulating the gene at its locus while leaving the rest of the genome intact. The phenotypic differences associated with ds2 allele replacement are small enough to be drowned out by the noise introduced by the genetic background in conventional genetic analyses. Precise allele substitution thus promises to lead to insights into the molecular and evolutionary mechanism of adaptation and speciation.

References and Notes
19. Y. Rong et al., Genes Dev. 16, 1568 (2002).
20. A detailed description of allele substitution line construction can be found in the "Gene Targeting" section of Materials and Methods on Science Online.
32. A detailed description of fly rearing and stress tolerance experimental conditions can be found in the "Fly Rearing and Stress Tolerance Assays" section of Materials and Methods on Science Online.
40. Statistical tests were performed with the R package, version 1.6.1. To assess significance levels, survival curves were treated as cumulative distributions and compared with the two-sample Kolmogorov-Smirnov test.
41. Funding for this work was provided by NIH grants for C.-W. and J.A.C. and an NIH Ruth L. Kirschstein National Research Service Award fellowship to A.J.G. We thank K. Galic and Y. Rong for advice and materials, S. Fang and A. Takahashi for information on desaturase2 sequence and primers, J. Huie and J. Fay for comments on the manuscript, J. Shapiro for help with the production and injection of some of the constructs, and M.-L. Wu, V. I., and E. Chang for help with fly work.
42. Supporting Online Material www.sciencemag.org/cgi/content/full/302/5651/1754/DC1
43. Materials and Methods
14 August 2003; accepted 16 October 2003

The Needle Length of Bacterial Injectisomes Is Determined by a Molecular Ruler
Laure Journet, Céline Agrain, Petz Broz, Guy R. Cornelius*

Size determination represents a fundamental requirement for multicomponent biological structures. Some pathogenic bacteria possess a weapon derived from the flagellum. Like the flagellum, this type-III secretion apparatus, called the injectisome, has a transmembrane basal body, but the external component is a needle-like structure instead of a hook and a filament. Here, we provide evidence that the length of this needle is determined by the size of a protein, YscP, acting as a molecular ruler.

Yersinia pestis and Y. enterocolitica, the infectious agents of bubonic plague and gastroenteritis, respectively, share a common plasmid-encoded type-III secretion system consisting of the Ysc (Yop secretion) injectisome and the Yops (Yersinia outer proteins) that are secreted by this apparatus (1). The injectisome, made of 27 Ysc proteins, is thought to resemble those of Salmonella enterica and Shigella flexneri. These injectisomes, or “needle complexes,” appear as two pairs of rings that are anchored to the inner and outer membranes of the bacterial envelope, joined by a central rod and supporting a hollow needle about 10 nm thick and 60 nm long (2–4). It is thought that the injectisome serves as a hollow conduit through which the secreted proteins travel across the two bacterial membranes and the peptidoglycan in one step.

Several Ysc proteins that are anchored in the inner membrane and form the core of the secretion apparatus are similar to proteins from the basal body of the flagellum, suggesting a common evolutionary origin (5). Not surprisingly, the Salmonella and Shigella injectisomes resemble the flagellar basal body (6) except that they are topped by a
needle instead of a hook and a flexible filament. The length of the flagellar hook (55 nm) is genetically controlled. Mutations in the gene fliK give rise to hooks of indefinite length (7), but it is unclear how FliK exerts its control. The fact that all truncated FliK proteins engineered so far lead to longer hooks rather than shorter hooks is presented as an argument that FliK cannot act as a simple molecular ruler (8). In addition, certain mutations in genes that encode the cytoplasmic ring lead to shorter hooks (8), supporting an elegant model in which this structure controls the hook length by acting as “a quantized measuring cup,” storing the subunits before their export (8). In this model, the role of FliK would be to terminate hook elongation by changing the secretion mode from hook-monomer to flagellin-monomer secretion (8). As for the injectosome of Salmonella and Shigella, mutants affected in a gene called invJ or spa32, respectively, display needles of various lengths, ranging from normal (60 nm) to as long as 1 μm (2, 9, 10). Thus, InvJ and Spa32 behave as FliK homologs, although they do not share any substantial sequence homology with FliK.

Here, we address the question of what controls the injectosome needle length in Yersinia. We first examined by electron microscopy Y. enterocolitica E40 bacteria incubated under conditions that artificially induce secretion of the Yops (11). We observed many needle-like structures that were about 6 to 7 nm thick and 60 nm long (12). Many of these needles were detached from the bacterial body (Fig. 1). We purified these detached needles and confirmed that they were made of the 6-kD YscP protein (12). Because it is difficult to define the exact insertion point of needles on bacteria, we measured only the detached needles. The length was distributed with an average of 58 ± 10 nm (Fig. 1), suggesting that the needles either detached or broke at a precise point close to the bacterial surface. Next, we examined Y. enterocolitica with a large deletion (codons 97 to 465 out of 515) in yscP (yscP_{Δ97–465}) (13). This gene is synthetic to spa32 and invJ, but its product has no substantial sequence identity with Spa32, InvJ, or FliK. The yscP_{Δ97–465} mutant bacteria produced needle-like structures with an indefinite length ranging from 45 nm up to 1570 nm (Fig. 1). When the yscP_{Δ97–465} mutation was complemented with the yscP\textsuperscript{+} allele, control of the length was restored (55 ± 8 nm), indicating that YscP played an essential role in length control.

YscP from Y. enterocolitica E40 (YscP\textsubscript{entero}) carries a duplication of 60 central residues (13) (Fig. 2). YscP from Y. pestis KIM5 (YscP\textsubscript{pesiKim5}) is 90% identical in sequence to YscP\textsubscript{entero} but it is shorter (455 residues) because of the lack of such repetition (14). To explore whether the two proteins lead to needles of the same length, we complemented the Y. enterocolitica yscP_{Δ97–465} mutation with the yscP_{pesiKim5}\textsuperscript{+} gene (15). The shorter Y. pestis gene restored length control but programmed shorter needles (41 ± 8 nm) (Fig. 2).

To investigate whether the needle length reduction was a result of the shortening of YscP and not subtle residue changes, we complemented the yscP_{Δ97–465} mutation with...
the allele yscPentero_{222–306} encoding YscPentero without its repeat. The truncated YscPentero_{222–306} programmed short needles (42.5 ± 8 nm) (Fig. 2), suggesting that the needle length indeed correlated with the size of YscP. To further investigate this hypothesis, we engineered a set of deletions within the cloned yscPentero gene and used them to complement the yscPΔ_{307-465} mutation (Fig. 3). Proteins truncated within the first 35 or the last 130 residues were unable to control the length, even though their expression levels were comparable to that of the wild type (Fig. 3). In contrast, YscP with deletions up to 126 amino acids between residues 36 and 306 retained length control but programmed shorter needles. Moreover, the length of the needles was proportional to the size of the YscP protein (Fig. 3). We then inserted a second copy of residues 307 to 381 or 222 to 381 after residue 49, thus generating YscP proteins containing the same 60-residue sequence three or four times (Fig. 3). These mutants programmed longer needles with lengths of 72 ± 10 nm and 88 ± 12 nm, respectively. Insertion of residues 147 to 265 from FltK at the same position also resulted in a functional protein but longer needles (75 ± 14.5 nm). Thus, a strict linear relationship existed between needle length and the number of amino acids in YscP, with 1.9 Å per YscP residue (Fig. 3). To rule out bias as a result of an inadequate gene dosage or gene expression of the complementation plasmids, we replaced the wild-type yscP allele on the virulence plasmid by two truncated alleles (yscPΔ_{46–98} and yscPΔ_{222–306}). In this native genetic environment, the two alleles again programmed shorter needles than those of the wild type (47.5 ± 10 nm and 44 ± 8.5 nm, respectively). Thus, YscP appeared to serve as a ruler determining the length of the needle. This is unprecedented in bacteria but it evokes the molecular rulers controlling the length of bacteriophage tails (16–18), which are structures resembling the needle in morphology, size, and even function. A difference between the two systems is that tails do not assemble in the absence of the ruler whereas needles are of undetermined length in the absence of YscP. The length per residue is also slightly different for tail rulers (1.5 Å per ruler residue).

If YscP acts as a ruler measuring the growing needle, one might expect it to be associated...
with the needle, at least during the needle elongation stage. To test this, we purified needles from *Y. enterocolitica* incubated in conditions that are either nonpermissive or permissive for secretion (11). Under nonpermissive conditions, some YscP was found in the needle fraction as well as in the culture supernatant, whereas under secretion-permissive conditions YscP was found only in the culture supernatant and not in the needle fraction any more (Fig. 4). These data, fitting with previous reports on the localization of YscP (13, 14), show that YscP is associated with newly synthesized needles that are not secreting Yops but not with needles that are secreting Yops.

We propose that YscP controls the length of the needle by acting as a molecular ruler during the stepwise assembly of the injectosome. Because deletions affecting both N- and C-termini of YscP lead to a loss of length control, we hypothesize that the two ends of YscP act as anchors. One end would be attached to the basal body, whereas the other would be connected to the growing tip of the needle. Whatever the anchor mechanism may be, when the needle reaches its mature length, YscP would be fully stretched and signal via its internal anchor, to the secretion apparatus, which would stop exporting YscP and switch to other substrates. This model (Fig. S1) does not contradict the switch function of YscP (8, 19, 20) but rather includes it in a more complex dual function, which may also exist in some phage tail rulers (21). Taking into account the length of 1.9 Å per residue, the ruler domain of YscP would consist of about 300 to 350 residues, leaving more than 150 residues for anchoring and signaling. The fact that the needle is only secreted also fits the model because an internal ruler would be expected to obstruct the 2- to 3-nm-wide secretion channel (22). This evokes again the phage tail rulers, which are thought to exit the tail before the tail exerts its function (21, 23). Given the similarity between all the type-III secretion systems (5) and the fact that Spa32 (9, 10) InvJ (24), and FliK (25) are also secreted proteins, it is likely that the mechanism demonstrated here for YscP may apply to the control of the needle length in the other bacteria as well as the length of the flagellar hook. The proposed organization of FliK in three regions—export, hinge, and switch (25)—is also compatible with this view. Finally, the fact that YscP, InvJ, Spa32, and FliK diverged more during evolution than other proteins from type-III secretion suggests that rulers are subjected to fewer constraints. They nevertheless have to share intrinsic properties still to be discovered.

### Inflammatory Blockade Restores Adult Hippocampal Neurogenesis

**Michelle L. Monje, Hirotki Toda, Theo D. Palmer***

Cranial radiation therapy causes a progressive decline in cognitive function that is linked to impaired neurogenesis. Chronic inflammation accompanies radiation injury, suggesting that inflammatory processes may contribute to neural stem cell dysfunction. Here, we show that neuroinflammation alone inhibits neurogenesis and that inflammatory blockade with indomethacin, a common nonsteroidal anti-inflammatory drug, restores neurogenesis after endotoxin-induced inflammation and augments neurogenesis after cranial irradiation.

The birth of new neurons within the hippocampal region of the central nervous system continues throughout life, and the amount of neurogenesis correlates closely with the hippocampal functions of learning and memory (1, 2). The generation of new neurons within the hippocampus is mediated by proliferating neural stem or progenitor cells (NPCs) (3-5) that are widespread within the adult brain but insulated by local signaling to produce neurons only in discrete areas (6, 7). Alterations in the microenvironment of the stem cell may allow ectopic neurogenesis to occur (6, 8) or even block essential neurogenesis, leading to deficits in learning and memory (10-12) such as that observed in patients who receive therapeutic cranial radiation therapy (13). In animal models, cranial irradiation ablates hippocampal neurogenesis, in part by damaging the neurogenic microenvironment, leading to a blockade of endogenous neurogenesis (12, 13). Injury induces pro-inflammatory cytokine expression both peripherally and within the central nervous system and induces stress hormones, such as glucocorticoids, that inhibit hippocampal neurogenesis (10). The extensive microglial inflammation and release of pro-inflammatory cytokines that accompanies this irradiation-induced failure suggests that inflammatory processes may influence neural progenitor cell activity (12, 14, 15).

To determine the effects of inflammation on adult hippocampal neurogenesis, we injected bacterial lipopolysaccharide (LPS) into adult female rats to induce systemic inflammation (16-19). The intraperitoneal (i.p.) administration of LPS causes a peripheral in

**References and Notes**

11. Yersinia builds injectosomes when temperature reaches 37°C, the host temperature. However, Yop secretion is only triggered upon contact with a target cell or artificially by chelating Ca²⁺ ions. The usual protocol consists of growing bacteria at 28°C in oxalated rich medium and then switching the culture to 37°C. In these secretion-permissive conditions, the production of injectosomes is also stimulated. When bacteria are grown at 37°C in the presence of 5 mM Ca²⁺, they make injectosomes but they do not secrete Yops (nonpermissive conditions). Materials and methods are available as supporting material on Science Online.
15. For complementation, yscP DNA was amplified by polymerase chain reaction and cloned in the pBAD expression vector. Expression was induced with arabinose.
26. We thank M. Duerrrenberger for the electron microscopy copy facility; V. Huchsau for contributing to the needle purification protocol; S. I. Aizawa for advice; M. Kuhn for technical assistance; S. Straley and K. Hughes for supplying yscP mutants and *Salmonella* LT2; and C. Thompson, U. Jeruf, H. Shin, and J. Mota for suggestions. This work was supported by the Swiss National Science Foundation (grant 32-53930.1). I. G. Galan holds a postdoctoral fellowship of l’Education et de la Science (European Union Human Potential-Research Training Network CT-2000-00075).

**Supporting Online Material**

www.sciencemag.org/cgi/content/full/302/5651/1175/DC1

Materials and Methods

Fig. S1

References

11 September 2003; accepted 16 October 2003
Supporting Online Material

Materials and Methods

*Yersinia enterocolitica* MRS40(pYV40) (S1), an ampicillin-sensitive derivative of E40(pYV40)(S2) was used for genetics and electron microscopy. An effector multmutant, called ΔHOPEMT, MRS40(pIML421)(S2) was used to prepare needles. The various pYV plasmid mutants and the expression plasmids are listed in Table S1. The oligonucleotides used for genetic constructions are given in Table S2.

Bacteria were routinely grown on Luria-Bertani agar plates and in liquid Luria-Bertani medium. For the induction of the *yop* regulon, *Y. enterocolitica* bacteria were inoculated to an OD₆₀₀ of 0.1 and cultivated in brain-heart infusion (BHI; Remel) supplemented with 4 mg/ml glycerol, 20 mM MgCl₂ and 20 mM sodium oxalate (BHI-Ox) for 2 h at 28 °C, then shifted to 37 °C and incubated for 4 h(S4). Expression of the different *yseP* genes cloned downstream from the pBAD promoter was induced by adding 0.2 % arabinose to the culture just before the shift at 37 °C, and again two hours later. Ampicillin was used at a concentration of 200 μg/ml to select for the expression plasmids.

Alleles to be inserted in the pYV plasmids were subcloned into the pKNG101 suicide vector and the allelic exchange was selected by plating diploid bacteria on sucrose(S5).

Proteins from the supernatant were precipitated overnight at 4°C with trichloroacetic acid 10% (w/v) final. Electrophoresis was carried out in 12 % or 15 % (w/v) polyacrylamide gels in the presence of SDS (SDS-PAGE). Proteins secreted by 3x10⁸ bacteria were loaded by lane. For the total bacterial cells, the proteins from 10⁷ bacteria were loaded by lane. After electrophoresis, proteins were stained with Coomassie brilliant blue (Pierce) or transferred by electroblotting to a nitrocellulose
membrane. Immunoblotting was carried out using rabbit polyclonal antibodies (anti-YscP(S6)), polyclonal anti-YscF antibodies raised against the synthetic YscF peptide (NFSGFTKGNDIALDAMAQTLK) (Centre d’Economie Rurale, Marloie, Belgium). Detection of immunoblots was performed with secondary antibodies conjugated to horse-radish peroxidase (1:2000; Dako) before development with supersignal chemiluminescent substrate (Pierce).

Visualization of the needle-like structures at the cell surface of the bacteria was done by electron microscopy as described by Hoiczyk and Blobel (1977). After 4 hours of induction at 37 °C, bacteria were harvested at 2,000 x g and resuspended gently in Tris-HCl, pH 7.5. Droplets were applied for 1 min to freshly glow-discharged, formvar-carbon coated grids, and negatively stained with 1% (wt/vol) uranylacetate. Bacteria were visualized in a Philips Morgagni 268D electron microscope at a nominal magnification of x 44,000 and an acceleration voltage of 80 kV. Sizes were measured with the “Soft Imaging System” software (Hamburg, Germany). The corresponding cells were analysed in parallel for the presence of YscF by immunoblot.

In order to purify needles, bacteria were cultivated for 2h at 28 °C in BHI-Ox or BHI-Ca²⁺, then shifted to 37 °C and incubated for 4h (S4). Bacteria were harvested by centrifugation (10 min at 5’700 x g) and washed once in 1/30 of the culture volume with 20 mM TrisHCl (pH 7.5). The washing supernatant was passed through a 0.45 µm mesh filter and centrifuged for 30 min at 17’500 x g. The pellet was resuspended in 1/60 of the initial culture volume of TrisHCl 20 mM (pH 7.5), CHAPS 0.1% (w/v) and centrifuged again for 30 min at 17’500 x g. The supernatant was collected and the needles were precipitated for one hour one ice with polyethylene glycol 6000 (10% w/v) and NaCl (100 mM). The needles were then collected by 30-
min centrifugation at 17'500 x g and resuspended in 1/300 of initial culture volume of 20 mM TrisHCl (pH 7.5).

Figure S1

Legend to fig S1
Proposed model for the control of the YscF-needle length by the YscP ruler.
Table S2: Oligonucleotides used in this study

<table>
<thead>
<tr>
<th>Oligo code</th>
<th>Oligonucleotide sequence</th>
<th>Underlined</th>
</tr>
</thead>
<tbody>
<tr>
<td>3072</td>
<td>gatcggccataataaatccgctgt</td>
<td>NcoI</td>
</tr>
<tr>
<td>3073</td>
<td>gatcgagttaacttccgtgatccagctccacccac</td>
<td>EcoRI</td>
</tr>
<tr>
<td>3066</td>
<td>ttcataatcggtttctagaaggg</td>
<td></td>
</tr>
<tr>
<td>3067</td>
<td>gcaggtggcactggagaa</td>
<td></td>
</tr>
<tr>
<td>3068</td>
<td>ttctgataatggatgacagt</td>
<td></td>
</tr>
<tr>
<td>3069</td>
<td>catcttagtgccaaatgt</td>
<td></td>
</tr>
<tr>
<td>3070</td>
<td>caacagcttgtgctaaaaae</td>
<td></td>
</tr>
<tr>
<td>3071</td>
<td>gaagacgcggtagactgtgta</td>
<td></td>
</tr>
<tr>
<td>3078</td>
<td>gtcagggcgtttgctactagagaaaccgggttactcttt</td>
<td>NcoI, XbaI</td>
</tr>
<tr>
<td>3079</td>
<td>gtcagggcgtttgccagacttccagaaggg</td>
<td>NcoI</td>
</tr>
<tr>
<td>3124</td>
<td>ttgggtagcagattc</td>
<td></td>
</tr>
<tr>
<td>3126</td>
<td>catgatatagggtattct</td>
<td></td>
</tr>
<tr>
<td>3187</td>
<td>gatcgccgtcatcttagagccgggctttct</td>
<td>NcoI, XbaI</td>
</tr>
<tr>
<td>3188</td>
<td>gatcgccgtcaactggagctgctgactgacctgcag</td>
<td>NcoI</td>
</tr>
<tr>
<td>3239</td>
<td>gctatgacgcagctcgcgggctcgcggat</td>
<td></td>
</tr>
<tr>
<td>3240</td>
<td>gaaagaacggctacctttca</td>
<td></td>
</tr>
<tr>
<td>3242</td>
<td>agacaggaattcactcte</td>
<td></td>
</tr>
<tr>
<td>3243</td>
<td>cgtcgccgagctcctcc</td>
<td></td>
</tr>
<tr>
<td>3244</td>
<td>ttctgatctacccgtag</td>
<td></td>
</tr>
<tr>
<td>3245</td>
<td>gacagcttgaagattta</td>
<td></td>
</tr>
<tr>
<td>3083</td>
<td>gtcagggcgtttgctactagaggtgcagccgaacaactgtgc</td>
<td>NcoI, XbaI</td>
</tr>
<tr>
<td>3084</td>
<td>gtcagggcgttaacagcggtctagtacgta</td>
<td>NcoI</td>
</tr>
</tbody>
</table>
Supplementary references


3 Results

3.2 Protective Anti-V Antibodies Inhibit Pseudomonas and Yersinia Translocon Assembly within Host Membranes


*These authors contributed equally to the work

Summary

Pathogenic *Yersinia* species and *P. aeruginosa* share a similar type III secretion system. The translocon consists of the proteins YopB/PopB, YopD/PopD and LcrV/PcrV; the latter is known to be a protective antigen. The translocators cause hemolysis of erythrocytes infected with wildtype *P. aeruginosa*. Wildtype *Y. enterocolitica* is only slightly hemolytic, but a multiknockout mutant deprived of all the effectors and of YopN (∆HOPEMN) is hemolytic. We showed that anti-PcrV and also antibodies directed against LcrV from *Y. pestis* protect erythrocytes from *P. aeruginosa* caused lysis, while anti-PopB and anti-PopD antibodies have no effect. Similarly the anti-LcrV antibodies inhibited the hemolytic activity of ∆HOPEMN *Y. enterocolitica*.

Wildtype *Yersinia* inserted the translocators YopB and YopD into erythrocyte membranes but no LcrV could be detected. A mutant in lcrV (∆HOPEMNV) inserted reduced amounts of YopB and YopD into erythrocyte membranes but could not assemble a functional pore. The assembly of the translocation pore, composed of the translocators YopB/YopD and PopB/PopD was disturbed in immunoprotected membranes mimicking the phenotypes of V knockout mutants. Thus, protective antibodies against the V antigens of *Yersinia* and *P. aeruginosa* act at the level of the formation of the translocation pore in membranes of infected host cells by blocking the function of the V antigen. The V antigen could act as an extrabacterial chaperone or assembly scaffold for the translocation pore.

Statement of my work

I contributed to this publication by performing all the experiments done with *Y. enterocolitica* i.e. the figures 3 and 4. I was involved in writing the manuscript.
Protective Anti-V Antibodies Inhibit *Pseudomonas* and *Yersinia* Translocon Assembly within Host Membranes

Julien Goure,1,a Petr Broz,1,a Olivier Attree,2 Guy R. Cornelis,3 and Ina Attree1

1Biochimie et Biophysique des Systèmes Intégrés, CEA-Grenoble, UMR5092 CNRS, Grenoble, and 2Centre de Recherches du Service de Santé des Armées, La Tronche, France; 3Biozentrum der Universität Basel, Switzerland

Pathogenic *Yersinia* species and *Pseudomonas aeruginosa* share a similar type III secretion/translocation system. The translocation system consists of 3 secreted proteins, YopB/PopB, YopD/PopD, and LcrV/PcrV; the latter is known to be a protective antigen. In an in vitro assay, the translocation system causes the lysis of erythrocytes infected with wild-type (wt) *P. aeruginosa*. wt *Y. enterocolitica* is not hemolytic, but a multiknockout mutant deprived of all the effectors and of YopN (AHOPEMN) is hemolytic. In the presence of antibodies against PcrV and *Y. pestis* LcrV, the hemolytic activity of *P. aeruginosa* was inhibited. Similarly, the hemolytic activity of AHOPEMN was inhibited in the presence of anti-LcrV antibodies. The assembly of the translocon, composed of PopB/D and YopB/D proteins, was disturbed in immunoprotected erythrocyte membranes, mimicking the phenotypes of V knockout mutants. Thus, protective antibodies against the V antigens of *Yersinia* species and *P. aeruginosa* act at the level of the formation of the translocon pore in membranes of infected host cells by blocking the function of LcrV/PcrV. The hemolysis assay could be adapted for high-throughput screening of anti-infectious compounds that specifically target the type III translocon.

Injectisomes are complex nanomachines that allow pathogenic or symbiotic bacteria to inject proteins across the membrane of eukaryotic host cells. They consist of a basal body that contains a type III secretion (T3S) apparatus and a stiff needle that can be extended by a flexible pilus or filament [1, 2]. Upon contact with a eukaryotic cell membrane, the injectisome secretes, presumably in a sequential manner, a set of proteins called “translocators” and “intracellular effectors” [3, 4]. The translocators are a group of, generally, 3 proteins that are absolutely required for the proper delivery of the effectors across the host cell membrane [3–12].

Pathogenic members of the genus *Yersinia*—for example, *Y. pestis* (the causative agent of plague) and the enteric pathogens *Y. enterocolitica* and *Y. pseudotuberculosis*—share a common injectisome called “Ysc” and a common set of translocators and effectors called “Yops.” The translocators are called “YopB,” “YopD,” and “LcrV.” The latter is a bona fide Yop; it has a different name because it was discovered as a soluble protective antigen linked to virulence (hence, it is named “V antigen”) >40 years ago [13, 14], long before the concept of T3S had been shaped [15]. Interestingly, the opportunistic pathogen *Pseudomonas aeruginosa*, which is evolutionarily remote from enterobacteriaceae, has a very similar injectisome called “Psc” and a set of similar translocators called “PopB,” “PopD,” and “PcrV” [16–18]. Both sets of translocators have been shown to form pores in erythrocytes (red blood cells [RBCs]) [5, 9], in eukaryotic cell membranes [19, 20], and in liposomes [21]. Formation of pores is readily detectable with wild-type (wt) *P. aeruginosa* but not with wt *Y. enterocolitica*. Only *Y. enterocolitica* mutants that are devoid of the effectors or of the control protein YopN form readily detectable pores [5, 11, 20]. An interpretation of this observation is that translocated Yop effectors obstruct the translocation chan-
nel [5, 20]. However, it has also been shown that the Rho-GAP activity of YopE prevents membrane damage in cells infected with wt bacteria [22]. When YopN is missing, secretion is contact independent and effectors are not efficiently translocated [11]. The structure of the translocation pore, the stage during which the translocation pore is inserted, and how it is connected to the needle of the injectisome are not clear yet. It is tempting to consider the translocation pore as an integral part of the injectisome, but, unlike the needle, it could be assembled only after contact with a target cell. It has been shown that PopB and PopD are able to oligomerize in vitro and that their interaction with lipids promotes the formation of ringlike structures with external and internal diameters of 80 and 40 Å, respectively [23]. Although PcrV is unable to interact with lipids either in vitro or in vivo [9, 23], it is required for proper assembly of the PopB/D translocon in membranes of infected erythrocytes [9].

Y. pestis LcrV possesses a highly protective antigenic character, and antibody therapy against bubonic and pneumonic plague has been shown to be effective when tested in animal models of disease [24–26]. Similarly, in animal models, active immunization with PcrV or passive immunization with anti-V antibodies provides a high level of protection against lethal P. aeruginosa infections [7, 27]. Furthermore, administration of anti-PcrV F(ab)′2 in a P. aeruginosa–provoked sepsis model [21] was triggered by sodium oxalate [11].

In the present study, we examined the action of anti-V antibodies on formation of the translocation pore in P. aeruginosa and Y. enterocolitica hemolysis assays. It has already been shown with P. aeruginosa that a high level of hemolysis can be obtained at a low MOI (MOI, 1) within 1 h of coincubation. Another advantage of this model is that RBCs are not a limiting factor, and their membranes can be isolated after infection and analyzed for translocon proteins without being contaminated with infecting bacteria [9, 31]. In the present study, we applied the RBC assay to Yersinia species by using poly-Yop effector mutants of Y. enterocolitica [20]. We demonstrate that the antibodies against the V antigens, through their direct interaction with V proteins, inhibit bacteria-induced hemolysis by acting at the level of type III translocon assembly in host cell membranes, for both pathogenic species.

**MATERIALS AND METHODS**

**Bacterial strains and growth conditions.** The bacterial strains used in the present study are listed in Table 1. The P. aeruginosa strain used was the cytotoxic cystic fibrosis isolate CHA [19, 32]. P. aeruginosa were grown either on Pseudomonas isolation agar (Difco) plates or in liquid Luria broth (LB) medium at 37°C with agitation. All the mutants of Y. enterocolitica used were derived from the strain E40, a strain from serotype O:9 [4, 11]. Y. enterocolitica strains were inoculated to an OD600 of 0.1 and cultivated in brain-heart infusion broth (ICN) for 3 h at 37°C. In vitro, secretion of Y. enterocolitica was triggered by sodium oxalate [11].

**Production and purification of antibodies.** The production and purification of the rabbit-derived anti-PcrV, anti-PopB, and anti-PopD polyclonal antibodies (PAb) has been described elsewhere [9, 23]. MAb166 [27] was provided by D. W. Frank (Medical College of Wisconsin). The LcrV coding sequence was obtained from genomic DNA of the Y. pestis strain EV76 (gift from E. Carniel, Pasteur Institute, Paris) by polymerase chain reaction (PCR) using the primers 5'-GATAAGACTTCTAACCAAAACCCAAT-3' and 5'-AAGGATCGTGGACTTACAATTACCTCGTGTCA-3'. The PCR product was digested with EcoRI and SalI and cloned into the expression plasmid pGEX-6P-2 (Amersham Biosciences). A soluble glutathione-S-transferase (GST)–LcrV fusion was produced in Escherichia coli and purified on GSTrap (Amersham Biosciences). The GST-LcrV protein fusion bound on the column was cleaved with PreScission Protease (Amersham), resulting in the elution of purified LcrV. Three CD1 mice were immunized with 100-μL intramuscular injections of 10 μg of purified LcrV in PBS con-

---

**Table 1. Bacterial strains.**

<table>
<thead>
<tr>
<th>Strains</th>
<th>Relevant genotype or phenotype</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>P. aeruginosa</em>, CHA</td>
<td>Mucoid, cytotoxic cystic fibrosis isolate</td>
<td>[32]</td>
</tr>
<tr>
<td>Y. enterocolitica</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E40 Wild-type strain with the plasmid pYV40</td>
<td>[39]</td>
<td></td>
</tr>
<tr>
<td>ΔHOPEMND pYV40</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔHOPEMNV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔHOPEMVQ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔHOPEMD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔN</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE.** *P. aeruginosa*, *Pseudomonas aeruginosa*; *Y. enterocolitica*, *Yersinia enterocolitica*. 
Hemolysis assays and immunoprotection experiments. Hemolysis assays were performed as described elsewhere [9]. Briefly, sheep RBCs (Eurobio) were washed 3 times in PBS (pH 7.4) (150 mmol/L NaCl) and resuspended in RPMI 1640 medium (Sigma) at 5 × 10^8 RBCs/mL at 4°C. Bacteria were grown in LB to an OD_{600} of 1.0, centrifuged, and resuspended in RPMI 1640 at 5 × 10^8 bacteria/mL. Hemolysis assays were initiated by mixing 100 μL of RBCs and 100 μL of bacteria in round-bottom 96-well plates, which were then centrifuged at 2000 g for 10 min and incubated for 1 h at 37°C. The release of hemoglobin was measured, and the percentage of hemolysis was calculated as described elsewhere [31]. Immunoprotection experiments were performed by incubating bacteria for 45 min

Figure 1. Immunoprotection of red blood cells (RBCs) against Pseudomonas aeruginosa–induced hemolysis. A, Lysis of RBCs by type III secretion of P. aeruginosa (MOI, 1) at 37°C, after 1 h in the presence of different antibodies added to the bacteria before coincubation. Anti-PcrV and anti-PopB polyclonal antibodies (PAb) were affinity purified from rabbit serum, anti-LcrV PAb was purified on protein A from mouse serum, and anti-PopD was total rabbit serum. MAb166 is a protective monoclonal antibody against PcrV [27]. B, Titration of protective antibodies by recombinant LcrV (rLcrV) or PcrV (rPcrV). The hemolysis assay was performed in the presence of immunoprotective anti-PcrV PAb added in quantities necessary to achieve 90%–100% protection. Purified rPcrV and rLcrV proteins were added to the assay, and hemolysis was measured after 1 h of incubation.
Assembly of the *Pseudomonas aeruginosa* PopB/D translocon in immunoprotected red blood cell (RBC) membranes. **A**, RBC membranes isolated on sucrose density gradients after performance of hemolysis assays in the presence of either protective anti-PcrV polyclonal antibodies (PAb) or anti-PopB PAb. **B**, RBC membranes isolated after hemolysis assay with the wild-type (*wt*) and the *pcrV* mutant (*ΔV*) [9]. The translocon content of PopB, PopD, and PcrV within membranes was analyzed by Western blotting.

Figure 2. Assembly of the *Pseudomonas aeruginosa* PopB/D translocon in immunoprotected red cell membranes. **A**, RBC membranes isolated on sucrose density gradients after performance of hemolysis assays in the presence of either protective anti-PcrV polyclonal antibodies (PAb) or anti-PopB PAb. **B**, RBC membranes isolated after hemolysis assay with the wild-type (*wt*) and the *pcrV* mutant (*ΔV*) [9]. The translocon content of PopB, PopD, and PcrV within membranes was analyzed by Western blotting.

with different concentrations of antibodies at room temperature, before the standard hemolytic assay. Negative controls included corresponding preimmune rabbit serum. In titration experiments, a constant concentration of 5 ng/μL PAb was added to bacteria, then increasing amounts of the recombinant PcrV or LcrV were incubated with the bacteria-PAb mixture for 45 min at room temperature.

**RBC membrane isolation.** RBCs were resuspended in Tris-saline (30 mmol/L Tris and 150 mmol/L NaCl [pH 7.5]) at 1 × 10^8^ cells/mL. Before the infection, 3 × 10^7^ bacteria were incubated with 180 μg of PAb in 700 μL of Tris-saline buffer for 45 min at room temperature. Then, hemolytic reactions were prepared in 50-mL conical tubes. The mixture of bacteria and antibodies was mixed with 300 μL of RBCs at 1 × 10^8^ cells/mL and 1 mL of a 2× protease inhibitor cocktail (Complete; Roche). Samples were centrifuged at 2000 g for 10 min at room temperature and incubated for 1 h at 37°C. Hemolysis was assessed spectrophotometrically, as described above. Then, 3 mL of distilled water at 4°C was added to each sample to lyse all RBCs, and these were vortexed and centrifuged again to remove bacteria. The RBC membranes were isolated by flotation on a sucrose density gradient, as described elsewhere [9]. The material at the 44%/25% sucrose interface was collected, diluted in Tris-saline, and concentrated by centrifugation in a TLA-100.3 rotor (Beckman) at 450,000 g for 20 min at 4°C. The pellets were resuspended in Laemmli sample buffer and analyzed by Western blotting.

**Immunoblotting analysis.** Immunoblotting analysis was performed with primary PAb against YopB (gift from Å. Forsberg, Umeå University), PopB, PopD, and PcrV [9]; monoclonal antibodies (MAbs) against YopD [20] and LcrV [11]; and a secondary antibody conjugated to horseradish peroxidase (Sigma). Membranes were developed by use of an enhanced chemiluminescence kit (Amersham Biosciences).

**RESULTS AND DISCUSSION**

Since PcrV has been found to be necessary for assembly of PopB/D pores in RBC membranes [9], we asked whether antibodies against PcrV would interfere with the PopB/D-dependent hemolysis induced by cytotoxic *P. aeruginosa* strain CHA. Affinity-purified PAb against translocator proteins PopB and PopD did not inhibit hemolysis. Concentrations of both antibodies up to 50 ng/μL had no protective effect. In contrast, affinity-purified anti-PcrV PAb [9] mixed with either bacteria or RBCs before infection inhibited hemolysis in a dose-dependent manner (figure 1A). Concentrations of antibodies as low as 0.25 ng/μL were able to reduce *P. aeruginosa*-induced lysis by 50%. Increasing the concentration of antibodies up to 10 ng/μL in the infection assay resulted in complete protection of RBCs from lysis. MAb166 is an anti-PcrV MAb that has been shown to protect mice from lethal *P. aeruginosa* infection [27]. In the hemolysis assay, MAb166 prevented hemolysis, but an 18-fold greater concentration of MAb166 than of PAb was required to obtain 50% inhibition. The higher neutralization activity of the PAb could be due to the binding of several PcrV epitopes or to a higher affinity of some antibody component, compared with MAb166. The former hypothesis is favored because, in a competition ELISA, a 100-fold excess of PAb did not hinder the binding of MAb166 to recombinant PcrV (rPcrV) (data not shown). This could have practical importance, because efficient neutralization of PcrV by MAbs would then require a combination of several MAbs, as seems to be the case for botulinum toxin type A [34].
LcrV from *Yersinia* species and PcrV from *P. aeruginosa* share 41% amino acid identity [16], and they most likely share the same function in the assembly of the translocon. We raised mouse PAbs against recombinant LcrV (rLcrV) from *Y. pestis*. Similar to anti-PcrV PAbs and MAb166, anti-LcrV PAbs inhibited *P. aeruginosa*-induced hemolysis (i.e., 50% inhibition was obtained with 10 ng/μL anti-LcrV PAbs). In summary, these data show that the PAbs against PcrV and LcrV, as well as the protective MAb166, hinder cytotoxic *P. aeruginosa* from lysing RBCs.

LcrV and PcrV are surface-exposed antigens ([29, 35] and I.A., unpublished data) and, therefore, are probably accessible to antibodies. To further confirm that the protection against hemolysis was due to the direct interaction between antibodies and the antigen during the infection process, we set up competition experiments in which the antibodies necessary to achieve 90%–100% protection were kept constant and increasing amounts of the recombinant antigen were added to the infection mixture. With rPcrV, as few as 3–4 molecules/10 molecules of antibodies were sufficient to restore 50% hemolysis, showing that the protection is due to direct PcrV/antibody interaction (figure 1B).

RBC lysis occurs by osmotic shock following the formation of PopB/D pores within erythrocyte membranes. Since PcrV is required for formation of functional Pop pores, we addressed the question of whether PopB/D inserts into membranes in the presence of anti-V antibodies. The hemolysis assay was scaled up, and antibodies were added at levels necessary to achieve 90%–100% protection. After 1 h of incubation, the RBCs were lysed by the addition of water, and the membranes were purified by sucrose density gradient, as described elsewhere [9]. The purified membranes were examined for the presence of Pop translocators by Western blotting. *P. aeruginosa*-infected RBC membranes contained both translocators, PopB and PopD, as reported elsewhere (figure 2) [9]. Notably, in the presence of anti-PcrV PAbs, PopD protein was absent from infected RBC membranes (figure 2), corroborating the phenotype of the PcrV knockout bacteria that were unable to assemble the functional translocon (figure 2) [9]. It should be noted that systematically less PopB could be detected in membranes purified from these immunoprotection experiments. Antibodies against PopB were not able to disturb PopB/D pores inserted into host membranes (figure 2), which is in agreement with the incapacity of these antibodies to immunoprotect infected RBCs. These results show that anti-PcrV antibodies either block the proper insertion of pore-forming proteins or destabilize them within membranes. That PopB was still found in immunoprotected membranes, although it was unable to form functional pores, suggests that protective antibodies do not prevent contact between the host cell and the bacterial injectisome.

Since the serum raised against the *Y. pestis* rLcrV prevented, to some degree, *P. aeruginosa* T3S–induced hemolysis, we applied the hemolysis test to several *Y. enterocolitica* strains. As was already reported by several authors [5, 20], the wt *Yersinia* strains had very low hemolytic activity, even when the bacteria–host cell contact was forced with centrifugation. Indeed, no detectable hemolysis could be observed at 1 h after infection (figure 3A). Neyt et al. [20] and Marenne et al. [11] reported that, in contrast to the wt strain, the mutant strain ΔHOPEMN, which lacks T3S effectors (YopH, -O, -P, -E, and -M) as well as the control protein YopN [36], provokes macrophage cell lysis through the formation of pores presumably constituted
by the translocators YopB and YopD. Notably, in the standard RBC assay, ΔHOPEMN bacteria lysed ~30% of the erythrocytes within 1 h of coincubation (MOI, 1), a value lower than that observed with cytotoxic P. aeruginosa but still very significant (figure 3A). ΔHOPEMN-induced hemolysis was dependent on the presence of LcrV, since the mutant ΔHOPEMNV showed only a basal level of hemolysis. In addition, LcrV was not directly hemolytic to RBCs, since the mutants ΔHOPEMN and ΔHOPEMND, which secrete the same amounts of LcrV as wt bacteria, were not hemolytic. This result is in agreement with data showing that P. aeruginosa strains that secrete PcrV are nonhemolytic [9]. LcrV mutants are known to produce less YopB and YopD, compared with wt bacteria [37–39], and this effect can be attenuated by also mutating yopQ (figure 3C) [11]. We thus also tested a ΔHOPEMNVQ mutant in the hemolysis assay, and it was also found to be nonhemolytic (figure 3A), showing that the lack of hemolysis observed with ΔHOPEMNV was not due to insufficient secretion of YopB and YopD but was directly due to the absence of LcrV (figure 3C).

Since PcrV is required for correct formation of PopB/D pores, we addressed the function of LcrV in Y. enterocolitica. RBC membrane fractions were examined for the presence of the translocators after infection with the same strains of Y. enterocolitica (figure 3D). Only YopD was readily detectable in membranes of RBCs infected with wt bacteria. In contrast, YopB and YopD were readily detectable in membranes of RBCs infected with ΔHOPEMN and ΔN bacteria. This difference reflects the fact that wt bacteria produce and secrete less Yops on contact with RBCs than do yopN mutant bacteria, which are deregulated for Yop secretion (figure 3B and 3C) [36]. This shows that centrifugation-achieved contact with RBCs does not trigger optimal Yop secretion of wt bacteria. Both YopB and YopD were detected in membranes of RBCs infected with ΔHOPEMNVQ, but the amount of both translocators, especially YopB, was reduced, compared with that in ΔHOPEMN or ΔN bacteria. This may simply reflect the fact that ΔHOPEMNVQ bacteria secrete less YopB/D than do ΔHOPEMN bacteria, but it should be noted that they secrete at least as much YopB as do wt bacteria (figure 3C). Nevertheless, although both YopB and YopD were detected in the membrane, no pore was formed. This suggests that, although LcrV is necessary for the proper assembly of the YopB/D pore in the host cell membrane, it is not necessary for the insertion of the translocators within host membranes.

Anti-LcrV antibodies and anti-PcrV antibodies were then tested for their capacity to protect erythrocytes from hemolysis by ΔHOPEMN. As can be seen in figure 4A, anti-LcrV PAbs were capable of protecting RBCs. The specific anti-LcrV serum was as immunoprotective as were the PcrV PAbs in the P. aeruginosa/RBC assay. However anti-PcrV PAbs had no protective effect on ΔHOPEMN-induced hemolysis, suggesting that, although some epitopes are shared by LcrV and PcrV, other neutralization epitopes are unique to LcrV.

Next, we addressed the question of whether YopB/D pores are formed in the presence of anti-LcrV antibodies. ΔHOPEMN bacteria were preincubated for 30 min with antibodies at levels necessary to achieve 90%–100% protection. Immunoprotected membranes were purified and examined for the presence of the translocators by Western blotting. The amount of YopB was severely reduced in the presence of protective antibodies. It should be noted that less YopD could be detected in immunoprotected membranes (figure 4B). This suggests that anti-LcrV antibodies, similar to anti-PcrV antibodies, prevent the assembly of the functional translocation pore.

PcrV/LcrV protective antigens would thus act as extracellular chaperones or scaffolds in the sense that they would bind
unfolded PopB/YopB and PopD/YopD emerging from the bacteria and ensure their correct folding and assembly into a functional pore. This hypothesis, which is supported by the fact that the T3S apparatus exports unfolded proteins [40], is compatible with the known localization of LcrV at the bacterial surface [29, 35]. It implies that the V antigen interacts, at least transiently, with the B and D antigens, which is in agreement with the observation of Sarker et al. [39]. However, it does not imply that the V antigen remains bound to the assembled pore and, thus, is not contradictory to results showing the absence of direct interactions between PcrV and Pop proteins folded in vitro [9, 23]. Finally, although it is inconsistent with the idea that the purified LcrV forms channels on its own, the chaperone or scaffold hypothesis is compatible with the observation that LcrV determines the size of the pore [10, 18].

In conclusion, we have demonstrated that the protective antibodies against the V antigens (PcrV and LcrV) of P. aeruginosa and Yersinia species act by preventing the assembly of a functional type III translocon in host cell membranes. In addition, our work has shown that the hemolysis assay is well suited for study of the function of the type III translocon and could be adapted for screening of anti-infectious molecules that specifically target bacterial toxin translocons.

Acknowledgments

We thank Prof. Dara W. Frank for providing MAb166, Dr. Åke Forsberg for providing anti-YopB antibody, Dr. Elisabeth Carniel for providing Yersinia pestis EV76 genomic DNA, Sylvie Elsen for helpful discussions, and Valerie Gros for excellent technical assistance.

References

22. Viboud GI, Bliska JB. A bacterial type III secretion system inhibits actin polymerization to prevent pore formation in host cell membranes. EMBO J 2001; 20:5373–82.
Inhibition of Type III Translocon Assembly


3.3 The V-antigen of Yersinia Forms a Distinct Structure at the Tip of Injectisome Needles


Science 310: 674-676 (2005)

*These authors contributed equally to the work
Summary

The V-antigen of *Yersinia* and *P. aeruginosa* are required for the correct assembly of a functional TTS translocation pore in the target cell membrane. Further, antibodies against the V-antigen prevented the formation of the translocation pore and inhibited effector translocation. Thus the V-antigens were proposed to act as an extrabacterial chaperone or assembly platform for the formation of the translocation pore. The obvious location for such a protein would be at the tip of the injectisome needle, where the secreted proteins are supposed to emerge.

Transmission electron micrographs of wildtype *Y. enterocolitica* indicated that the needles protruding from the bacterial surface end with a well-defined structure. STEM analysis of purified needles revealed that this so-called "tip complex" comprises a head, a neck and a base. The tip complex is the same in secreting as well as in non-secreting conditions. To determine the components of the needle fraction we analyzed purified needles. The two translocators LcrV and YopD, as well as YscF the needle subunit were found. Crosslinking of purified needles suggested that YscF and LcrV interact, thus LcrV might be a structural component of the needle.

The tip complex was absent on needles from bacteria deprived of LcrV (ΔHOPEMNVQ) and could be brought back by complementing the mutation in trans. Control needles (mutants in *yopN, yopQ* or *yopBD*) exhibited a wildtype tip complex. Thus the formation of the tip involved LcrV, but not YopQ, YopN or YopBD.

Immunogold labeling of wildtype needles with anti-LcrV antibodies demonstrated a strong binding to the tip complex. Antibodies against YopB and YopD did not label the tip complex and anti-YscF antibodies bound to the needle itself. Together these results clearly proved that LcrV forms the observed tip complex.

*P. aeruginosa* and *A. salmonicida* possess an injectisome closely related to that of *Yersinia*. Their respective LcrV orthologs, PcrV (32.3 kDa) and AcrV (40.2 kDa) are different in size to LcrV (37.6 kDa). We demonstrated that PcrV as well as AcrV could functionally complement an *lcrV* deletion in *Y. enterocolitica*. The needles exhibited distinct tip complexes similar to wildtype needles that were smaller in the case of PcrV and larger with AcrV.

Altogether these results shown that the injectisome needle is topped with a distinct structure called the “tip complex” that is formed by the major protective antigen of *Yersinia*, LcrV.
Statement of my work

I contributed to this work by providing TEM images of attached needles (Fig. S1), by generating the anti-LcrV antibodies, by affinity-purifying all the antibodies used in this study and by performing the hemolysis experiments necessary for this study. I also did the crosslinking of purified needles to show interaction between LcrV and YscF. I cloned the LcrV orthologs, PcrV and AcrV and checked their functional complementation. I also contributed in the writing the manuscript.
The V-Antigen of *Yersinia* Forms a Distinct Structure at the Tip of Injectisome Needles

Catherine A. Mueller,†1* Petr Broz,†1* Shirley A. Müller,1,2 Philippe Ringler,1,2 Françoise Erne-Brand,1,2 Isabel Sorg,1 Marina Kuhn,1 Andreas Engel,1,2 Guy R. Cornelis1†

Many pathogenic bacteria use injectisomes to deliver effector proteins into host cells through type III secretion. Injectisomes consist of a basal body embedded in the bacterial membranes and a needle. In *Yersinia*, translocation of effectors requires the YopB and YopD proteins, which form a pore in the target cell membrane, and the LcrV protein, which assists the assembly of the pore. Here we report that LcrV forms a distinct structure at the tip of the needle, the tip complex. This unique localization of LcrV may explain its crucial role in the translocation process and its efficacy as the main protective antigen against plague.

Type III secretion (T3S) is commonly used by Gram-negative pathogenic bacteria to introduce effector proteins into target host cells (1). *Yersinia pestis* and *Y. enterocolitica*, causing bubonic plague and gastroenteritis respectively, share the same T3S system consisting of the Ysc (Yop secretion) injectisome or the Yop secretion injectisome, respectively, share the same T3S system consisting of a basal body and an outer membrane pore, to confer greater sensitivity to virstatin. This complex consists of the YscF and YscN effector proteins.

References and Notes

3. Materials and methods are available as supporting material on Science Online.

*1Biozentrum der Universität Basel and 2Maurice E. Müller Institute, Klingelbergstrasse 50-70, CH-4056, Basel, Switzerland.*

†These authors contributed equally to this work.

†To whom correspondence should be addressed. E-mail: guy.cornelis@unibas.ch
complex, and we observed many examples of two needles joined tip to tip by a single antibody (Fig. 2). No antibodies to LcrV attached to needles purified from the lcrV mutant strain (ΔHOPEMNVOQ). Furthermore, antibodies directed against YopB or YopD did not bind to wild-type needles (17). In contrast, affinity-purified polyclonal antibodies against YscF bound to the needle end opposite the tip complex (Fig. S5). Together, these results clearly indicate that LcrV forms the observed tip complex.

*Pseudomonas aeruginosa* and *Aeromonas salmonicida* possess an injectisome closely related to that of *Yersinia*. Their respective LcrV orthologs, PcrV (32.3 kD) and AcrV (40.2 kD), are different in size to LcrV (37.2 kD). The pcrV+ and acrV+ genes were used to complement the lcrV deletion in *Y. enterocolitica* E40 (ΔHOPEMNVOQ). The recombinant bacteria could assemble translocation pores. Their needles contained proteins with the size of PcrV and AcrV (Fig. S6) and exhibited distinct tip complexes (Fig. 3). The head and neck domains of the tip complex formed by PcrV (Fig. 3A, center) were similar to those formed by LcrV, but the base was narrower (Fig. S7). The tip complex formed by AcrV was larger (Fig. 3A, right, and Fig. S7), more variable in shape, and more fragile, being absent or altered for many needles. This is reflected by the lower resolution of the AcrV average. In all three cases, a central channel seemed to permeate both the needle and the tip complex (Fig. 3B and fig. S7).

That the needle has a defined tip structure at its distal end, comprising LcrV, is in agreement with previous reports showing that LcrV is surface-exposed (3, 4) and essential for the assembly of a functional translocation pore (6). LcrV may act as an assembly platform for the EspA filament of enteropathogenic *Escherichia coli*, which forms a physical bridge between the needle and the host cell (19). The EspA homolog, SeeB of *Salmonella* SPI-2, forms an undefined sheathlike structure on the distal end of the T3S needle (20).

The localization of LcrV at the tip of the needle and its role in the assembly of the pore may explain the protective action of antibodies to LcrV. Possibly, the antibodies interfere with the function of the tip complex, impairing the translocation process.

**References and Notes**

Bats Are Natural Reservoirs of SARS-Like Coronaviruses

Wendong Li,1,2 Zhengli Shi,2a Meng Yu,3 Wuzu Ren,2 Craig Smith,4 Jonathan H. Epstein,5 Hanzhong Wang,2 Gary Cramer,3 Zhihong Hu,2 Huajun Zhang,2 Jianhong Zhang,2 Jennifer McCarn,3 Hume Field,4 Peter Daszak,5 Bryan T. Eaton,3 Shuyi Zhang,1,6* Lin-Fa Wang3*

Severe acute respiratory syndrome (SARS) emerged in 2002 to 2003 in southern China. The origin of its etiological agent, the SARS coronavirus (SARS-CoV), remains elusive. Here we report that species of bats are a natural host of coronaviruses closely related to those responsible for the SARS outbreak. These viruses, termed SARS-like coronaviruses (SL-CoVs), display greater genetic variation than SARS-CoV isolated from humans or from civets. The human and civet isolates of SARS-CoV nest phylogenetically within the spectrum of SL-CoVs, indicating that the virus responsible for the SARS outbreak was a member of this coronavirus group.

Severe acute respiratory syndrome (SARS) was caused by a newly emerged coronavirus, now known as SARS coronavirus (SARS-CoV) (1, 2). In spite of the early success of etiological studies and molecular characterization of this virus (3, 4), efforts to identify the origin of SARS-CoV have been less successful. Without knowledge of the reservoir host distribution and transmission routes of SARS-CoV, it will be difficult to prevent and control future outbreaks of SARS.

Studies conducted previously on animals sampled from live animal markets in Guangdong, China, indicated that masked palm civets (Paradoxurus hermaphroditus) and two other species had been infected by SARS-CoV (5). This led to a large-scale culling of civets to prevent further SARS outbreaks. However, subsequent studies have revealed no widespread infection in wild or farmed civets (6, 7). Experimental infection of civets with two different human isolates of SARS-CoV resulted in overt clinical symptoms, rendering them unlikely to be the natural reservoir hosts (8). These data suggest that although P. larvata may have been the source of the human infection that precipitated the SARS outbreak, infection in this and other common species in animal markets was more likely a reflection of an "artificial" market cycle in naive species than an indication of the natural reservoir of the virus.

Bats are reservoir hosts of several zoonotic viruses, including the Hendra and Nipah viruses, which have recently emerged in Australia and East Asia, respectively (9–11). Bats may be persistently infected with many viruses but rarely display clinical symptoms (12). These characteristics and the increasing presence of bats and bat products in food and traditional medicine markets in southern China and elsewhere in Asia (13) led us to survey bats in the search for the natural reservoir of SARS-CoV.

In this study, conducted from March to December of 2004, we sampled 408 bats representing nine species, six genera, and three families from four locations in China (Guangdong, Guangxi, Hubei, and Tianjin) after trapping them in their native habitat (Table 1). Blood, fecal, and throat swabs were collected; serum samples and cDNA from fecal or throat samples were independently analyzed, double-blind, with different methods in our laboratories in Wuhan and Geelong (14).

Among six genera of bat species surveyed (Rousettus, Cynopterus, Myottis, Rhinolophus, Nyctalus, and Miniopterus), three communal, cave-dwelling species from the genus Rhinolophus (horseshoe bats) in the family Rhinolophidae demonstrated a high SARS-CoV antibody prevalence: 13 out of 46 bats (28%) in R. pearsoni from Guangxi, 2 out of 6 bats (33%) in R. presilius from Guangxi, and 5 out of 7 bats (71%) in R. macrocotis from Hubei. The high seroprevalence and wide distribution of seropositive bats is expected for a wildlife reservoir host for a pathogen (15).

The serological findings were corroborated by polymerase chain reaction (PCR) analyses with primer pairs derived from the nucleocapsid (N) and polymerase (P) genes (table S1). Five fecal samples tested positive, all of them from the genus Rhinolophus: three in R. pearsoni from Guangxi and one each in R. macrocotis and R. ferrumequinum, respectively, from Hubei. No virus was isolated from an inoculation of Vero E6 cells with fecal swabs of PCR-positive samples.

A complete genome sequence was determined directly from PCR products from one of the fecal samples (sample Rp3) that contained relatively high levels of genetic material. The genome organization of this virus (Fig. 1), tentatively named SARS-like coronavirus isolate Rp3 (SL-CoV Rp3), was essentially identical to that of SARS-CoV, with the exception of three regions (Fig. 1, shaded boxes). The overall nucleotide sequence identity between SL-CoV Rp3 and SARS-CoV Tor2 was 92% and increased to ~94% when the three variable regions were excluded. The variable regions are located at the 5′ end of the S gene (equivalent to the S1 coding region of coronavirus S protein) and the region immediately upstream of the N gene. These regions have been identified as “high mutation” regions among different SARS-CoVs (5, 16, 17). The region upstream of the N gene is known to be prone to deletions of various sizes (5, 16, 17).

Predicted protein products from each gene or putative open reading frame (ORF) of SL-CoV Rp3 and SARS-CoV Tor2 were com-
Supporting Online Material for

The V-Antigen of Yersinia Forms a Distinct Structure at the Tip of Injectisome Needles

Catherine A. Mueller, Petr Broz, Shirley A. Müller, Philippe Ringler, Françoise Erne-Brand, Isabel Sorg, Marina Kuhn, Andreas Engel, Guy R. Cornelis†

†To whom correspondence should be addressed. E-mail: guy.cornelis@unibas.ch

Published 28 October 2005, Science 310, 674 (2005)
DOI: 10.1126/science.1118476

This PDF file includes:

Materials and Methods
Figs. S1 to S8
Tables S1 and S2
References and Notes
Supporting Online Material

Materials and Methods

This study was carried out with Y. enterocolitica E40 (1) carrying several mutations on the virulence pYV plasmid, listed in Table S1. The oligonucleotides used for the genetic constructions are listed in Table S2.

To delete the complete yopB and yopD genes, flanking regions of the yopB (pYVe227 (accession NC_002120) bp 17702-17196, primers 3854/3862) and the yopD (pYVe227 bp 15076-14861, primers 3863/3861) genes (2) were cloned by overlapping PCR into pBluescript KS+II with SalI and XbaI restriction sites. The resulting plasmid was called pISO82 (Table S1). The SalI-XbaI fragment of pISO82 containing the flanking regions of the yopB and yopD genes was cloned into the same sites of the suicide vector pKNG101 (Table S1), resulting in the mutator plasmid pISO83 (Table S1). The yopB and yopD genes on the Y. enterocolitica MRS40 pYV plasmid were deleted by allelic exchange with pISO83 as described previously (3). The resulting Y. enterocolitica mutant pYV plasmid was called pISO4005 (Table S1).

The lcrV mutation was complemented by plasmid pMN12 containing lcrV+ downstream of the yopE promoter (3).

The pcrV and acrV (4) sequences were amplified by PCR on genomic DNA from Pseudomonas aeruginosa PAO1 (accession NC_002516, primers 3808/3809) and Aeromonas salmonicida JF2267 (accession AJ516009, primers 3810/3811). The PCR products were digested with Ncol/EcoRI and AflIII/EcoRI and cloned into the Ncol/EcoRI sites of the expression vector pBAD/MycHisA giving plasmids pPB24 and pPB25 (Table S1).

Bacteria were routinely grown on Luria-Bertani agar plates and in liquid Luria-Bertani medium. Ampicillin was used at a concentration of 200 µg/ml to select for the expression plasmids. For the induction of the yop regulon (secretion permissive conditions) Y. enterocolitica bacteria were inoculated to an OD₆₀₀ of 0.1 and cultivated in brain-heart infusion (BHI; Remel) supplemented with a carbon source, 20 mM MgCl₂ and 20 mM sodium oxalate (BHI-Ox) for 2 hours at room temperature, then shifted to 37 °C and incubated for 4 hours (5). To keep the yop regulon in a non-induced state (secretion non-permissive conditions) bacteria were inoculated to an OD₆₀₀ of 0.1 and cultivated in BHI supplemented with a carbon source, 20 mM MgCl₂ and 5 mM CaCl₂ (BHI-Ca²⁺) for 2 hours at room temperature, then shifted to 37 °C and incubated for 4 hours.

Expression of the different genes cloned downstream of the pBAD promoter was induced by adding 0.2 % arabinose to the culture just before the shift to 37 °C, and again 2 hours later. The carbon source was glycerol (4 mg/ml) when expressing genes from the pBAD promoter, and glucose (4 mg/ml) in the other cases. The supernatant of every culture used for needle purification was analysed for secreted Yop proteins.

Secreted proteins of all the strains were analyzed by Coomassie stained SDS-PAGE, to verify that YopB and YopD were well secreted (data not shown). Secreted proteins were precipitated for 1 hour at 4 °C with trichloroacetic acid 10 % (w/v) final
and separated by SDS-PAGE. In each case, proteins secreted by \(3 \times 10^8\) bacteria were loaded per lane. After electrophoresis, proteins were stained with Coomassie brilliant blue (Pierce) or transferred to nitrocellulose membranes. Immunoblotting was carried out using rabbit polyclonal antibodies directed against YscF (MIPA 80) and LcrV (MIPA 220). Detection was performed with secondary antibodies conjugated to horseradish peroxidase (1:2000; Dako) before development with supersignal chemiluminescent substrate (Pierce).

To prepare the anti-LcrV antibodies (MIPA 220), lcrV DNA was amplified from pYV40 DNA (primers 3283/3290). The PCR product was digested with NdeI and BamHI, and cloned into the expression vector pET28a (Novagen) giving plasmid pPB10 (Table S1). A soluble His-LcrV protein was produced in \(E.\ coli\) BL21 (DE3) pLysS and purified on chelating sepharose beads (Amersham Biosciences). A rabbit was immunized by 4 injections with a total of 1 mg of His-LcrV in 20 mM phosphate buffer (CER, Marloie, Belgium). The serum was affinity-purified on His-LcrV immobilized on nitrocellulose membranes. The serum was then concentrated on a ProteinG-column (MabTrap Amersham Biosciences). The Bradford assay (BioRad) was used to determine the concentration of purified antibodies.

To produce polyclonal anti-YscF antibodies (MIPA 223), yscF DNA was amplified from pYV40 DNA (primers 3759/3760). The PCR product was digested with BamHI and XhoI, and cloned into the expression vector pGEX4T3 (Amersham Biosciences) giving plasmid plSO66 (table S1). YscF was produced as a glutathione S-transferase fusion protein encoded by plasmid plSO66. Expression of the protein was induced in \(E.\ coli\) TOP10 by addition of isopropyl-\(\beta\)-D-thiogalactopyranoside (0.2 mM final concentration), as soon as the culture reached an \(OD_{600}\) of 0.6. Four hours after induction, bacteria were collected, lysed by sonication in lysis buffer (PBS, 1% Triton-X100, 5mM dithiotreitol, 1 mM phenylmethylsulfonylfluoride and protease inhibitor cocktail complete Mini (Roche)), and purified by affinity chromatography with glutathione-Sepharose beads (Amersham Biosciences). The beads were washed five times with PBS at 4 °C. YscF was eluted from the beads by thrombin cleavage (thrombin protease 50 units/ml in PBS) for 1 hour at room temperature. The thrombin was then removed by incubation with benzamidine-Sepharose beads. A rabbit was immunized by 4 injections with a total of 1 mg of YscF (CER, Marloie, Belgium). The serum was purified on a Protein G-column (MabTrap Amersham Biosciences). The Bradford assay (BioRad) was used to determine the concentration of purified antibodies.

Hemolytic assays were carried out as described by Goure et al. (6).

To purify needles, \textit{Yersinia} bacteria were cultivated in non-permissive or permissive conditions for secretion (3, 5) using the following protocols:

- **Non-permissive conditions (BHI-Ca\(^{2+}\))**: Less injectisomes are built under non-permissive conditions, due to a known feedback regulatory effect (5, 7). Bacteria from 3 litres of culture were harvested by centrifugation (20 min at 4000 x g) and resuspended in 20 mM TrisHCl, pH 7.5 (1/30 of the initial culture volume). The bacteria were sheared by passing the suspension through an 18G needle using a syringe. They were then pelleted by centrifugation (10 min at 8300 x g). The supernatant was collected and passed through a 0.45 µm mesh filter (cellulose acetate membrane). The filtrate was concentrated 10 fold
using an Amicon Stirred Ultraconcentration Cell # 8200 (YM30 membrane (Ultradex YM = Regenerated Cellulose Acetate, 30K), 5 bar pressure). The supernatant was further concentrated using a Millipore Ultrafree-15 Centrifugal filter device Biomax-10K and centrifuged for 30 min at 20000 x g. The pellet, containing needles, was resuspended in 20 mM TrisHCl, pH 7.5 (1/48000 of the initial culture volume) and analyzed by SDS-PAGE, immunoblotting and electron microscopy.

Permissive conditions (BHI-Ox): Bacteria from 300 ml of culture were harvested by centrifugation (10 min at 5700 x g) and washed once with 20 mM TrisHCl, pH 7.5 (1/30 of the initial culture volume). The washing supernatant was passed through a 0.45 μm mesh filter (cellulose acetate membrane) and centrifuged for 30 min at 20000 x g. The resulting pellet was resuspended in 20 mM TrisHCl, pH 7.5 (1/3000 of the initial culture volume) and analyzed by SDS-PAGE, immunoblotting and electron microscopy.

For the cross-linking experiments, purified needles were diluted 25 x in 20 mM TrisHCl, pH 7.5 and put on ice. Glutaraldehyde (Sigma) was added to a final concentration of 0.4 % (v/v). The cross-linking reaction was allowed to proceed for 15 minutes and was then quenched by the addition of 1 M TrisHCl, pH 8 (1/10 of the reaction volume). The cross-linked products were analyzed by SDS-PAGE and Western blotting.

Visualization of the needle-like structures on the cell surface of bacteria was done by electron microscopy as described by Hoiczyk and Blobel (8). After 4 hours of induction at 37 °C, bacteria were harvested at 2000 x g and carefully resuspended in 20 mM TrisHCl, pH 7.5. Droplets were adsorbed to freshly glow-discharged, formvar-carbon coated grids, and negatively stained with 2 % (w/v) uranyl acetate. Bacteria were visualized in a Philips Morgagni 268D electron microscope at an acceleration voltage of 80 kV.

For scanning transmission electron microscopy (STEM), the purified needles were diluted with buffer (20 mM TrisHCl, pH 7.5) as required, adsorbed to thin carbon film, washed on 4 droplets of quartz double-distilled water and stained with 2 % (w/v) sodium phosphotungstate. Digital dark-field images were recorded using a Vacuum Generators STEM HB5 interfaced to a modular computer system (Tietz Video and Image Processing Systems GmbH, D-8035 Gauting). The microscope was operated at 100 kV and a nominal magnification of 500000 x, using doses that ranged between 9000 and 13000 electrons/nm². The contrast was reversed to show protein in bright shades in the figures.

To calculate the averages of the tip complexes, subframes were manually selected from the STEM dark-field images recorded at a nominal magnification of 500000 x and angularly and translationally aligned to an arbitrary reference using the SEMPER program package (9). A first average calculated from 52-95 aligned subframes was two-fold symmetrized along the cylinder axis and used to calculate a refined average. Those subframes that had a cross-correlation value > 0.65 were included in the final average; 65 of the 95 initially selected for the wt, 36 of 52 for the PcrV ortholog, and 35 of 58 for the AcrV ortholog. A two-fold symmetry was then applied. The resolution was determined from the Fourier ring correlation function of the independent averages calculated from the odd and even numbered subframes applying the 0.5 criterion.
For the immuno-electron microscopy experiments, 5 µl aliquots of the purified needles suspended in 20 mM TrisHCl, pH 7.5 were incubated for 45 min with 2.5 µl of antibody solution at room temperature, and diluted up to 20 x with buffer immediately before grid preparation. In each case, both the initial antibody concentration employed and the dilution made before adsorption were adjusted to obtain optimum imaging conditions (sufficient needles and a low background of free antibodies) even though a large excess of antibodies was used for the reaction. The following, affinity purified, rabbit polyclonal antibodies were used: anti-LcrV (0.268 mg/ml, MIPA 220), anti-YopD (0.04 mg/ml, MIPA 24), anti-YopB (0.7 mg/ml, MIPA 38) and anti-YscF (1.4 mg/ml, MIPA 223).
**Figures**

**Figure S1**

*Fig. S1* Transmission electron micrograph of *Y. enterocolitica* E40 strain ΔHOPEMT negatively stained with 2 % uranyl acetate. Needles protrude from the cell surface and have a distinct structure at their tip (arrow). Scale bar: 40 nm.
**Fig. S2** Galleries showing the tip complexes of needles detailed in Fig. 1. Scale bars: 10 nm. (A) Tip complex of wt needles formed under secretion-permissive (S+) and non-permissive (S-) conditions. (B) Tip complex of needles formed by the lcrV mutant (ΔV needles) and the lcrV mutant complemented with lcrV+ (ΔV+LcrV needles).
Figure S3

Fig. S3 (A) Silver stained SDS-PAGE (top) and Western blots (bottom) of the needles purified from different *Y. enterocolitica* strains. The black arrowheads indicate the bands corresponding to LcrV (37.2 kDa), YopD (33.2 kDa) and YscF (9.5 kDa). The flagellin contamination is marked by a white arrowhead. (B) Cross-linking with glutaraldehyde. Purified needles were incubated with 0.4 % (v/v) glutaraldehyde for 15 minutes and analyzed by SDS-PAGE and Western blotting with anti-LcrV and anti-YscF antibodies: NC, not cross-linked; X, cross-linked. The arrowheads indicate cross-linked products of LcrV. The lowest of these bands corresponds to a complex of about 45 kDa i.e., one LcrV and one YscF. Cross-linking of the needle subunit YscF lead to a ladder-like pattern as expected.
**Figure S4**

Images and compiled galleries showing the tip complexes of needles isolated from *yopN (ΔN), yopQ (ΔQ), yopBD (ΔBD)* mutants. Scale bars: 10 nm.
Fig. S5 Anti-YscF antibody labeling of wt needles imaged by dark-field STEM. Clusters of antibodies bind to the needle ends that do not have a tip complex, sometimes also linking two needles together. The sides of the needles were not labelled. Presumably the helical packing of YscF in the needle effectively buries all reactive epitopes. Scale bar: 20 nm.
Fig. S6 LcrV-orthologs from *P. aeruginosa* and *A. salmonicida* transcomplement the lcrV mutant of *Y. enterocolitica* (A) Coomassie stained SDS-PAGE of proteins secreted by *Y. enterocolitica* ΔHOPEMNVQ (ΔV), ΔHOPEMNVQ complemented with LcrV (ΔV+LcrV), ΔHOPEMNVQ complemented with PcrV from *P. aeruginosa* (ΔV+PcrV) and ΔHOPEMNVQ complemented with AcrV from *A. salmonicida* (ΔV+AcrV). (B) Lytic activity on red blood cells after 2 hours of contact with *Y. enterocolitica* ΔHOPEMN (LcrV), ΔHOPEMNVQ+PcrV (ΔV+PcrV) and ΔHOPEMNVQ+AcrV (ΔV+AcrV). (C) Silver stained SDS-PAGE (top) and Western blotting (bottom) of the purified needles from *Y. enterocolitica* ΔHOPEMN transcomplemented with the LcrV-orthologs from *P. aeruginosa* (PcrV; 32.2 kDa) and *A. salmonicida* (AcrV; 40.2 kDa). AcrV and flagellin are of similar molecular weight.
Fig. S7 Profiles perpendicular to the needle axis calculated from the averages of PcrV (A) and AcrV (B) tip structures. The locations of the profiles are the same as for the wt tip structure shown in Fig. 3. A central channel is indicated by the dip in the profile evident in all except the neck profile from the AcrV complex. The magnitude of the central dip is related to the resolution of the average and to the ratio of inner to outer radius of the cylindrical structure (16). Scale bar: 5nm in (A) and (B).
Fig. S8 Hypothetical model of the function of the LcrV tip complex. (A) No contact to host cell: LcrV forms the complex at the tip of the needle. This implies that LcrV is exported before contact with a target cell (or before secretion is triggered by Ca\(^{2+}\)-chelation) and hence that LcrV has a special status in the export hierarchy. However, it is not yet known whether LcrV is present at the tip while the needle grows or whether it is installed at the tip when the needle has reached its final length. Although localized at the tip of the needle, LcrV does not act as a polymerizing cap, like the hook- and filament-caps of the flagellum (17), because the needle subunits assemble normally in its absence (Fig 1B). YopN is not present at the tip of the needle as shown in Fig S4 and by work of others (18) (B) Contact with host cell membrane: The tip complex assists the assembly of the translocation pore, serving as an assembly platform.
## Tables

<table>
<thead>
<tr>
<th>Plasmid</th>
<th>Current designation</th>
<th>Relevant characteristics</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>pYV plasmids</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pYV40</td>
<td>wt</td>
<td>pYV plasmid of <em>Y. enterocolitica</em> E40</td>
<td>(10)</td>
</tr>
<tr>
<td>pIML421</td>
<td>ΔHOPEMT</td>
<td>pYV40 yopE₂₅, yopH₃₅, yopO₆₅-₅₅₈, yopP₂₃, yopM₂₃, yopT₁₃₅</td>
<td>(11)</td>
</tr>
<tr>
<td>pMN4003</td>
<td>ΔHOPEMNVQ</td>
<td>pYV40 yopE₂₅, yopH₃₅, yopO₆₅-₅₅₈, yopP₂₃, yopM₂₃, yopN₆₅-₅₅₈, lcrV₆₆-₄₁₀, yopQ₁₇</td>
<td>(3)</td>
</tr>
<tr>
<td>pIM417</td>
<td>ΔHOPEMN</td>
<td>pYV40 yopE₂₅, yopH₃₅, yopO₆₅-₅₅₈, yopP₂₃, yopM₂₃, yopN₆₅-₅₅₈</td>
<td>(12)</td>
</tr>
<tr>
<td>pIM41</td>
<td>ΔN</td>
<td>pYV40 yopN₆₅-₅₅₈</td>
<td>(13)</td>
</tr>
<tr>
<td>pABL402</td>
<td>ΔQ</td>
<td>pYV40 yopQ₁₇</td>
<td>(14)</td>
</tr>
<tr>
<td>pISO4005</td>
<td>ΔBD</td>
<td>pYV40 yopB yopD</td>
<td>This work</td>
</tr>
</tbody>
</table>

**Clones and vectors**

<table>
<thead>
<tr>
<th>Clones and vectors</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>pBAD/Myc-HisA</td>
<td></td>
<td>Invitrogen</td>
<td></td>
</tr>
<tr>
<td>pET28a</td>
<td></td>
<td>Novagen</td>
<td></td>
</tr>
<tr>
<td>pGEX4T3</td>
<td></td>
<td>Amersham</td>
<td></td>
</tr>
<tr>
<td>pISO66</td>
<td></td>
<td>pGEX4T3 yscF⁺</td>
<td></td>
</tr>
<tr>
<td>pISO82</td>
<td></td>
<td>pBluescriptKS+ llpYVe227bp17702-17196/bp15076-14861</td>
<td>This work</td>
</tr>
<tr>
<td>pISO83</td>
<td></td>
<td>pKNG101pyVe227bp17702-17196/bp15076-14861</td>
<td>This work</td>
</tr>
<tr>
<td>pKNG101</td>
<td></td>
<td>Suicide vector, orIr₀₉K, secBR⁺, oriT₀₂₉K-strAB</td>
<td>(15)</td>
</tr>
<tr>
<td>pMN12</td>
<td></td>
<td>pBBR1MCS-2 yopLcrV⁺</td>
<td>(3)</td>
</tr>
<tr>
<td>pPB10</td>
<td></td>
<td>pET28a-lcrV⁺</td>
<td>This work</td>
</tr>
<tr>
<td>pPB24</td>
<td></td>
<td>pBAD/Myc-HisA-pherV⁺</td>
<td>This work</td>
</tr>
<tr>
<td>pPB25</td>
<td></td>
<td>pBAD/Myc-HisA-acyrV⁺</td>
<td>This work</td>
</tr>
</tbody>
</table>

**Table S1** Plasmids used in this study.
<table>
<thead>
<tr>
<th>Codes</th>
<th>Oligonucleotides</th>
<th>Underlined sites</th>
</tr>
</thead>
<tbody>
<tr>
<td>3808</td>
<td>ATCATGCCATGGCAGAATCGAGAACCTAAATGGCC</td>
<td>NcoI</td>
</tr>
<tr>
<td>3809</td>
<td>CCGGGCGAATTCTGATCGCGGCTGAGAATGTCC</td>
<td>EcoRI</td>
</tr>
<tr>
<td>3810</td>
<td>TGCCCACTATGCAAGCAACATTGCGACTACAAC</td>
<td>AflIII</td>
</tr>
<tr>
<td>3811</td>
<td>CCGGGCGAATTCTGAGATCGCCAAAGAATGGTC</td>
<td>EcoRI</td>
</tr>
<tr>
<td>3283</td>
<td>GATCCGATCCTTACCTCAGTCATCTAG</td>
<td>BamHI</td>
</tr>
<tr>
<td>3290</td>
<td>GGGAAATCCATAGATGAGCCTACGAA</td>
<td>NdeI</td>
</tr>
<tr>
<td>3759</td>
<td>GATCGGATCCAGTGAATTCTTCTGAGTTTAC</td>
<td>BamHI</td>
</tr>
<tr>
<td>3760</td>
<td>GATCCCTCGAGTATGGGAACTCTGTAGGATG</td>
<td>XhoI</td>
</tr>
<tr>
<td>3854</td>
<td>ATCATGCTGACATGCAAACAGAGACGACAGAC</td>
<td>Sall</td>
</tr>
<tr>
<td>3861</td>
<td>ATCATGTCTAGACAGGTCTTAGCTACTACATG</td>
<td>XbaI</td>
</tr>
<tr>
<td>3862</td>
<td>TTAACATCAAGGTTCATAATGTCATGAGTTATC AACGCACTCATG</td>
<td></td>
</tr>
<tr>
<td>3863</td>
<td>CATGAGTGCGTGTGATAACCATGACCATTATGACCT TGGTTAGTTAA</td>
<td></td>
</tr>
</tbody>
</table>

**Table S2** Oligonucleotides used in this study.
References

3 Results

3.4 Unpublished results
3.4.1 The orientation of the LcrV molecule in the tip complex

(STEM analysis was done in collaboration with Philippe Ringler, Françoise Erne-Brand, Shirley A. Müller and Andreas Engel)
(The modeling of the LcrV tip complex was done by Ansgar Philippsen)

Introduction

The crystal structure of the V-antigen from *Y. pestis* shows that this protein is dumbbell shaped (Fig. 17, Derewenda *et al.*, 2004). It consists of two globular domains connected by two long alpha helices. Modeling of the LcrV molecule into the structure of the tip complex, suggested that the globular domains would form the head and the base of the tip complex (A. Philippsen, unpublished data). However, the molecule can be orientated in two ways, either with the N-terminal domain forming the base or the other way round forming the head of the tip complex. To determine which model was true, we decided to investigate the orientation of LcrV in the tip complex. We started two different approaches to answer this question.

![Fig. 17. Structure of LcrV from *Y. pestis* (Derewenda *et al.*, 2004).](image)

The first approach was to find a permissive site in LcrV to insert a tag. This would allow to immunolabel tip complexes with antibodies binding to one specific epitope. So far only polyclonal anti-LcrV antibodies that bound to different epitopes in LcrV were used. As the crystal structure of the molecule is known, the immunolabelling would allow to determine how the molecule is oriented.

The second approach takes advantage of the size differences between LcrV (37.6 kDa) and its orthologs, PcrV (32.3 kDa) from *Pseudomonas aeruginosa* and AcrV (40.2 kDa) from *Aeromonas salmonicida*. These two bacteria are endowed with a T3S system closely related to the T3S system of *Yersinia* spp. The PcrV and AcrV proteins are able to complement a mutation in the *lcrV* gene of *Yersinia* and form smaller and larger tip complexes respectively. Alignment of the three proteins reveals that the size differences are restricted to the two
globular domains of the proteins (residues 1-145 and 183-278), while the two long helices, α7 and α12, that connect them are conserved (Fig. 18A, B). For example, AcrV differs from LcrV only by two big insertions in the second globular domain that make the whole protein over 3 kDa larger. In order to determine the orientation of the LcrV molecule in the tip complex we decided to take advantage of the visible size differences between tip complexes formed by LcrV, PcrV and AcrV, by engineering hybrids between these three proteins. The hybrids would be considerably smaller or larger than wildtype LcrV in one of the globular domains. Therefore they should form tip complexes with slight changes in the head or the base parts, which can then be observed by STEM. This would tell us which domains of the molecule form which parts of the tip complex.

<table>
<thead>
<tr>
<th>PcrV</th>
<th>LcrV</th>
<th>AcrV</th>
</tr>
</thead>
<tbody>
<tr>
<td>150</td>
<td>150</td>
<td>150</td>
</tr>
<tr>
<td>160</td>
<td>160</td>
<td>160</td>
</tr>
<tr>
<td>170</td>
<td>170</td>
<td>170</td>
</tr>
<tr>
<td>180</td>
<td>180</td>
<td>180</td>
</tr>
<tr>
<td>190</td>
<td>190</td>
<td>190</td>
</tr>
<tr>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>210</td>
<td>210</td>
<td>210</td>
</tr>
<tr>
<td>220</td>
<td>220</td>
<td>220</td>
</tr>
<tr>
<td>230</td>
<td>230</td>
<td>230</td>
</tr>
<tr>
<td>240</td>
<td>240</td>
<td>240</td>
</tr>
<tr>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>260</td>
<td>260</td>
<td>260</td>
</tr>
</tbody>
</table>

-1985.2 Da
-3216.7 Da
+3763.4 Da
-1455.5 Da

Fig. 18. (A) Alignment of PcrV from P. aeruginosa, LcrV from Y. enterocolitica and AcrV from A. salmonicida using Multalin (www.expasy.ch). The two helices, α7 and α12, connecting the globular domains are marked in gray. (B) Schematic representations of the structures of the three proteins PcrV (green), LcrV (blue) and AcrV (red). The size differences in the globular domains in comparison to LcrV are indicated.
Results and Discussion

Insertion of a 6xHis tag into LcrV

We generated the vector pPB22 (Appendix A) carrying lcrV with a his-tag in the aminoterminus. To test whether the N-terminally His-tagged LcrV complements a mutation in the lcrV gene, plasmid pPB22 was transformed into Y. enterocolitica ΔHOPEMNV bacteria. Secretion was induced in vitro and the culture supernatant was analyzed. His-LcrV was secreted suggesting that the His-tag in the N-terminus of the protein did not interfere with its secretion (data not shown). This result was surprising because it is known for the effector proteins that already small changes in the N-terminus lead to a loss of secretion.

To verify functional complementation, Y. enterocolitica ΔHOPEMNV complemented with pPB22 was tested in a red blood cell hemolysis assay. The His-tagged protein was capable of complementing the mutation (data not shown), indicating that the His-tag does not interfere with the formation of the tip complex and its function.

An important prerequisite for the immunolabelling is to determine if the tag is accessible to antibodies. This was tested in an antibody protection assay with antibodies directed against the His-tag. The antibodies protected the erythrocytes only slightly from lysis by Y. enterocolitica ΔHOPEMNV + pPB22 (Fig. 19). This result suggested that the His-tag is probably partially buried in the structure and not accessible to antibodies.

![Fig. 19. Hemolysis caused by Y. enterocolitica ΔHOPEM (A) and ΔHOPEMNV complemented with pPB22 (B) in the presence of anti-His antibodies. The bacteria were pre-incubated with the antibodies for 20 minutes at 37°C and the red blood cells were infected for 1 h at 37°C.](image)

Insertion of a FLAG-tag into LcrV

We constructed two plasmids, pPB46 and pPB47, capable of expressing FLAG-tagged LcrV. The FLAG tag was inserted in a loop between strands β4 and β5 (Fig. 20). This loop varies between different species and strains of Yersinia and is exposed at the surface, according to the crystal structure. The difference between the two constructs is that in pPB46
the tag is inserted between aa 227 and 228 and in pPB47 the tag replaces aa 226 to 233 of LcrV. Both constructs were transformed into *Y. enterocolitica ΔHOPEMNV* and secretion was checked *in vitro*. Both constructs were secreted, suggesting that the FLAG-tag did not interfere with secretion (data not shown). To verify functional complementation, we tested *Y. enterocolitica ΔHOPEMNV* harboring plasmids pPB46 or pPB47 in a hemolysis assay. Both constructs were able to complement the mutation in the *lcrV* gene, even though not to the same level as the wildtype protein (Fig. 21).

**Fig. 20.** Structure of LcrV of *Y. pestis* as published by Derewenda et al. 2004 and graphical representation of the loop between strands β4 and β5. The length and aminoacid composition of this loop varies between *Y. pestis*, and the two *Y. enterocolitica* strains KNG22703 and E40. The FLAG tag was either inserted in this loop (pPB46) or replaces a part of the loop (pPB47).

**Fig. 21.** Hemolysis caused by *Y. enterocolitica ΔHOPEMNV* complemented with plasmids pPB46 and pPB47. Three clones were analyzed for each plasmid.
To determine the accessibility of the FLAG tag, we checked if anti-FLAG antibodies were able to protect red blood cells from hemolysis by ΔHOPEMNV bacteria expressing the FLAG-tagged LcrV proteins (Fig. 22). Strong inhibition of hemolysis was observed for the ΔHOPEMNV bacteria carrying pPB46 (Fig. 22C). Already 0.1 µg of antibodies per well was enough to reduce hemolysis by 80%, but only high concentrations lead to complete protection. The FLAG antibodies were therefore more efficient in blocking hemolysis than anti-LcrV antibodies at low concentrations (Fig. 22D). In contrast the ΔHOPEMNV bacteria carrying plasmid pPB47 or pPB42 (wt LcrV as a control, Fig. 22A, B), were still able to cause more than 70% of hemolysis even at highest antibody concentrations. These results demonstrated that the FLAG tag inserted between aa 227 and 228, in the case of pPB46, is exposed at the surface of the protein and accessible to antibodies. In contrast to this a FLAG tag that replaces the aa 226 to 233 (pPB47), seems to be buried in the structure and not accessible. The very efficient inhibition of hemolysis observed for pPB46 makes it an ideal candidate for immunolabelling. Instead of using whole anti-FLAG antibodies, anti-FLAG Fabs could be used. Fabs are smaller and would allow a much more accurate localization of the tag.

Fig. 22. Hemolysis caused by *Y. enterocolitica* ΔHOPEMNV complemented with pPB42 (wt LcrV, A), pPB47 (B) or pPB46 (C) in the presence of anti-FLAG antibodies. (D) Hemolysis caused by *Y. enterocolitica* ΔHOPEMN in the presence of anti-LcrV antibodies. The bacteria were pre-incubated with the antibodies for 20 minutes at 37°C and the red blood cells were infected for 1 h at 37°C.
Generation of Hybrids between LcrV, PcrV and AcrV

In total we generated 16 different hybrids (Appendix A) between LcrV, PcrV and AcrV but we restricted the analysis to four constructs: pPB30, 31, 34 and 35. These plasmids would allow expression of different hybrid proteins (H5, H6, H8 and H10, Fig. 23), which would have large size differences in certain domains, in comparison to wildtype LcrV. The expression of the hybrid proteins was first tested in *E. coli*. All four hybrids were expressed and had the expected size (data not shown). To check if the hybrid proteins were expressed and secreted by *Yersinia*, the plasmids were transformed into *Y. enterocolitica ΔHOPEMNV* bacteria. Secretion was triggered by Ca\(^{2+}\) chelation and the culture supernatant was analyzed. All hybrid proteins were secreted into the culture supernatant in comparable amounts (Fig. 24A).

![Fig. 23. Schematic representation of the four Hybrid proteins (H5, H6, H9 and H10) and the corresponding wildtype proteins. Expression plasmids, hybrid compositions and sizes are indicated.](image)

<table>
<thead>
<tr>
<th>aa:</th>
<th>LcrV</th>
<th>PcrV</th>
<th>AcrV</th>
<th>size (kDa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pPB42</td>
<td>LcrV</td>
<td>1-324</td>
<td></td>
<td>37.6</td>
</tr>
<tr>
<td>pPB24</td>
<td>PcrV</td>
<td>1-294</td>
<td></td>
<td>32.2</td>
</tr>
<tr>
<td>pPB25</td>
<td>AcrV</td>
<td>1-361</td>
<td></td>
<td>40.2</td>
</tr>
<tr>
<td>pPB30</td>
<td>H5</td>
<td>1-145</td>
<td>124-294</td>
<td>35.6</td>
</tr>
<tr>
<td>pPB31</td>
<td>H6</td>
<td>146-324</td>
<td>1-123</td>
<td>34.3</td>
</tr>
<tr>
<td>pPB34</td>
<td>H9</td>
<td>1-145</td>
<td></td>
<td>41.6</td>
</tr>
<tr>
<td>pPB35</td>
<td>H10</td>
<td>146-324</td>
<td>1-143</td>
<td>36.2</td>
</tr>
</tbody>
</table>

The ability of the hybrid proteins to form functional tip complexes was tested by measuring pore formation in a hemolysis assay (Fig. 24B). In parallel we tested ΔHOPEMNV bacteria complemented with wildtype LcrV, PcrV or LcrV proteins to compare the levels of hemolysis. The results indicated that even though all hybrid proteins were secreted, not all could complement the *lcrV* mutation with the same efficacy. We observed that whenever the N-terminus was from LcrV, the hybrids caused approximately the same level of hemolysis as wildtype LcrV. On the other hand when the N-terminus was from PcrV the hemolysis was reduced to low levels as observed for wildtype PcrV. Similar results were obtained with hybrids composed of AcrV and LcrV. We concluded that the N-terminus of the hybrid proteins determined the efficacy of the hemolysis. This effect could be direct, i.e. the N-terminal domain itself interacts with the pore components YopB and YopD or it could be indirect, i.e. the N-terminus is required for the stability of the whole tip complex and thus is affecting its pore forming ability. To answer this question the interaction sites between the LcrV-tip complex and the translocators need to be defined.
Fig. 24. (A) Coomassie stained SDS-PAGE and western blot analysis of proteins secreted by *Y. enterocolitica* ΔHOPEMNV complemented with hybrids H5, H6, H9 and H10. The secreted hybrids proteins are indicated by red arrowheads. Two clones were analyzed for hybrid H9. (B) Lytic activity on red blood cells after 2 h of contact with *Y. enterocolitica* ΔHOPEMNV complemented with wildtype LcrV, PcrV, AcrV or the hybrid proteins H5, H6, H9 and H10.
In order to determine the orientation of the LcrV molecules forming the tip complex, we compared the size of hybrid tip complexes to the size of tip complexes formed by the LcrV, PcrV and AcrV wildtype proteins. Needles were prepared and purified as described before and subjected to analysis by STEM. Averages of all hybrid tip complexes could be produced (Fig. 25). As published before, tip complexes formed by LcrV consist of three distinct parts: the head, the neck and the base. Tip complexes formed by PcrV have a smaller base, while both the neck and the head are still comparable to the LcrV tip complex. Tip complexes formed by the LcrV-PcrV hybrid protein had the characteristic shape, consisting of a head, a neck and a base similar to wildtype LcrV tip complexes. However, in this hybrid protein the first globular domain of PcrV was replaced by the corresponding domain of LcrV, which is over 3.2 kDa bigger. This replacement lead to a significant increase of the base part in comparison to PcrV tip complexes, whilst the rest of the tip complex seemed unchanged. This suggested that the N-terminal globular domain forms the base. According to this the second globular domain forms the head of the tip complex. The results obtained with the PcrV-LcrV hybrid protein confirmed this hypothesis. Here the N-terminal globular domain of LcrV was exchanged by the smaller domain of PcrV (~3.2 kDa). As expected we observed that tip complexes made by this hybrid had a smaller base, resembling tip complexes formed by PcrV.

Tip complexes formed by AcrV were larger and more diverse in shape. The base had a different shape, the neck was less pronounced and the head appeared broader than in the LcrV tip complex. In the LcrV-AcrV hybrid the second globular domain, which, according to our hypothesis, would form the head of the tip complex is almost 4 kDa larger than in LcrV. Consistent with this, the tip complexes formed by this protein had a “normal” base, but the head was larger and different in shape. The last hybrid, AcrV-LcrV, had the smallest size difference to the LcrV wildtype protein. The N-terminal globular domain of LcrV was replaced by the corresponding domain of AcrV, leading to a reduction in size of 1.5 kDa. Thus we expected to see a change in the base part of the tip complex. No reduction of the base could be observed, but the base had indeed a different shape resembling the base of the AcrV tip complex.

The results presented above allow us to present a simple model of the tip complex formed by LcrV (Fig. 26). In this model the molecule would be oriented with the N- and C-terminus to the needle, the first globular domain forming the base of the tip complex, the second globular domain forming the head of the tip complex. The two long alpha helices (α7 and α12) connect the two globular domains and face inward.
Fig. 25. Tip complexes formed by *Y. enterocolitica* ΔHOPEMNV complemented with the four hybrid proteins. (A) Projection averages of tip complexes formed by wildtype PcrV and LcrV (top) and LcrV-PcrV (H5), PcrV-LcrV (H6) hybrids (bottom). Schematic representations of all proteins are drawn next to the corresponding tip complexes. (B) Projection averages of tip complexes formed by wildtype AcrV and LcrV (top) and LcrV-AcrV (H9), AcrV-LcrV (H10) hybrids (bottom). Schematic representations of all proteins are drawn next to the corresponding tip complexes.
Fig. 26. Atomic modeling of the LcrV tip complex on top of the injectisome needle (cylinder). A side-view and a top view are shown.
Materials and Methods

Cloning

The lcrV sequence was amplified by PCR on pYV40 DNA using primers 3503 and 3504. The PCR products were digested with NdeI and KpnI and cloned into the NdeI and KpnI sites of the vector pLJM3 giving plasmid pPB22 (Appendix A). This plasmid encoded a N-terminally his-tagged lcrV gene under the yopE promoter, allowing the expression of His-LcrV in *Y. enterocolitica*. The FLAG motive was introduced into the lcrV gene using overlapping PCR. The first two PCR reactions were performed using the primer pairs 4230/3807 and 4231/3806 for pPB46 or primer pairs 4232/3807 and 4233/3807 for pPB47. Plasmid pMN12 was used as DNA template. The second, overlapping PCR was performed on the PCR products obtained from the first two PCR reactions using primers 3806 and 3807 for both constructs. The PCR products were digested with Ncol and EcoRI and introduced into the Ncol/EcoRI sites of the expression vector pBADmycHisA (Invitrogen), giving plasmid pPB46 or pPB47. Hybrids between lcrV, pcrV or acrV were generated using overlapping PCR. Individual parts of every hybrid were amplified from the corresponding DNA sequences by PCR with the primer pairs as indicated (Table 2). The PCR products were mixed and served as template for the overlapping PCR which was performed with the appropriate primers (Table 2). The PCR product was digested with Ncol/EcoRI or AflIII/EcoRI and cloned into the Ncol/EcoRI sites of the expression vector pBADmycHisA (Invitrogen) giving plasmids pPB30, pPB31, pPB34 and pPB35.

<table>
<thead>
<tr>
<th>Construct</th>
<th>First round of PCR</th>
<th>Overlapping PCR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Primers 1</td>
<td>Template 1</td>
</tr>
<tr>
<td>pPB30</td>
<td>H5</td>
<td>3934/3806</td>
</tr>
<tr>
<td>pPB31</td>
<td>H6</td>
<td>3937/3957</td>
</tr>
<tr>
<td>pPB34</td>
<td>H9</td>
<td>3942/3806</td>
</tr>
<tr>
<td>pPB35</td>
<td>H10</td>
<td>3945/3810</td>
</tr>
</tbody>
</table>

Table 2. Primers used to generate Hybrid H5, H6, H9 and H10. MIPA numbers are indicated.

Expression test in *E. coli*

To check expression of proteins from the pBAD vector, plasmids were transformed into *E. coli* TOP10 bacteria. Overnight cultures were inoculated to an OD$_{600}$ of 0.1 in fresh LB medium containing appropriate antibiotics and grown at 37°C. Expression was induced for 4 h by the addition of 0.2 % arabinose as soon as the cultures reached an OD$_{600}$ of 0.6. The bacteria were collected by centrifugation and analyzed by SDS-PAGE followed by Coomassie staining or western blotting.

Expression and secretion test in *Y. enterocolitica*

*In vitro* secretion was performed as described before by (Mueller, Broz *et al.*, 2005).

Functional complementation test

Hemolysis assays were performed as described before by (Goure, Broz *et al.*, 2005).

STEM analysis of Hybrid tip complexes

Needles purification and STEM analysis was done as described before by (Mueller, Broz *et al.*, 2005).
3.4.2 Production of antibodies directed against PcrV and AcrV

Introduction

To complete the list of tools necessary for the analysis of the tip complex, antibodies against PcrV from *Pseudomonas aeruginosa* and AcrV from *Aeromonas salmonicida* were generated. These antibodies allow the detection of the proteins in western blots, helping the analysis of the hybrids between LcrV/PcrV and LcrV/AcrV. In addition it would be possible to label hybrid tip complexes with anti-LcrV, anti-PcrV or anti-AcrV antibodies, examine them by electron microscopy and thereby determine which parts of these tip complexes are formed by which proteins.

Results and Discussion

In order to produce antibodies directed against PcrV and AcrV, the *pcrV* and *acrV* sequences were amplified by PCR on genomic DNA from *Pseudomonas aeruginosa* PAO1 and *Aeromonas salmonicida* JF2267 using the primer pairs MIPA 3808/4250 and MIPA 3810/4251 respectively. The PCR products were digested with NcoI/EcoRI or AflIII/EcoRI and cloned in frame with a C-terminal 6xHis tag into the Ncol/EcoRI sites of the expression vector pBADmycHisA giving plasmids pPB44 and pPB45 (Appendix A).

Plasmids pPB44 and pPB45 were transformed into *E. coli* TOP10. Protein expression was induced by the addition of 0.2 % arabinose for 4 h at 37°C. Soluble PcrV-His and AcrV-His proteins were purified on chelating sepharose beads (Amersham Biosciences). Further purification was achieved by size exclusion chromatography on a Superdex 200 preparative column. Rabbits were immunized by 4 injections with a total of 1 mg of either PcrV-His or AcrV-His in 20 mM Phosphate-Buffer, 500 mM NaCl.
3.4.3 Determination of the Stoichiometry of needle components
(Mass per length measurements were done by Viola Huschauer and Shirley A. Müller, purified YscF was provided by Isabel Sorg)

Introduction

To generate an accurate atomic model of the tip complex it is not only necessary to know the orientation of LcrV, but also how many molecules of LcrV form the tip complex. Therefore we decided to quantify the amount of LcrV and YscF protein in purified needles and calculate the ratio of LcrV:YscF per needle. Together with the known length of the needles and the known mass-per-length value of purified needles it should be possible to estimate the number of LcrV molecules per needle tip complex.

Results and Discussion

Dilutions of known amounts of purified YscF and His-LcrV were compared to the YscF and LcrV content in purified needle fractions (Fig. 27). Thus the molar ratio of purified wt needles was estimated to be around 1 LcrV to 33 +/- 7 YscF. The mass-per-length value of purified needles was determined to be 21.6 +/- 1.7 kDa/nm, which means 2.3 +/- 0.2 YscF molecules/nm (Viola Huschauer and Shirley Müller, unpublished data). Assuming that the Y. enterocolitica needle has a mean length of 55-60 nm, one needle would consist of approximately 127-138 YscF monomers. Thus we can speculate that three to six molecules of LcrV form a needle tip.

Fig. 27. Quantification of the LcrV and YscF content in purified needle fractions. The amount of purified YscF and His-LcrV is indicated in ng of protein. Black arrows indicate where the protein contents of purified needles (NP) match known amounts of purified YscF and LcrV. The quantification was carried out in three independent experiments, giving a molar ratio of 32.3 +/- 7.3 molecules of YscF per molecule of LcrV.
Materials and Methods

Protein purification
The LcrV gene was amplified by PCR from the pYV plasmid DNA of the *Y. enterocolitica* strain MRS40, using the primers MIPA 3283 and 3290. The PCR product was digested with NdeI and BamHI, and cloned into the expression vector pET28a (Novagen). A soluble His-LcrV protein was produced in *E. coli* BL21 (DE3) pLysS and purified on chelating sepharose beads (Amersham Biosciences). YscF was produced as a glutathione S-transferase fusion protein encoded by plasmid pISO66. Expression of the protein was induced by adding 0.2 mM isopropyl-β-D-thiogalactopyranoside (final concentration) at an optical density of 0.6. Four hours after induction, cells were collected, lysed by sonication in lysis buffer (PBS, 1% Triton-X100, 1 mM phenylmethylsulfonylfluoride, 5mM dithiotreitol, protease inhibitor cocktail complete Mini (Roche)), and purified by affinity chromatography with glutathione-Sepharose (Amersham Pharmacia Biotech). Loaded beads were washed five times with PBS at 4°C. YscF was eluted from the beads by thrombin cleavage (thrombin protease 50 units/ml in PBS) for 1 h at room temperature. Thrombin was removed by incubation with benzamidine-Sepharose beads.

Quantification
Purified needles as well as different amounts of purified His-LcrV and YscF were separated by SDS-PAGE, transferred to nitrocellulose membranes and subjected to western blot analysis with anti-LcrV and anti-YscF antibodies. The intensities of the LcrV and YscF protein bands were analyzed by scanning the films (EPSON PERFECTION 4870 PHOTO, at 300 dpi) and subsequent quantification of the pixel intensities using ImageJ 1.33u (http://rsb.info.nih.gov/ij/). The number of molecules of LcrV and YscF in the needle fraction was determined by comparing the intensities of signals in the needle fraction with signals of purified His-LcrV and YscF standards.
3.4.4 Estimation of the size of pores made by LcrV and its orthologs

Introduction

Recent data, published by Goure, Broz et al. and Mueller, Broz et al. suggested that the tip complex formed by LcrV would act as an assembly platform for the translocation. It was shown that PcrV/AcrV can complement a Y. enterocolitica lcrV mutation and form different sized tip complexes. One could therefore hypothesize that such tip complexes would form smaller or bigger pores. This would explain an interesting observation published in 2001. The authors had complemented a lcrV mutation with pcrV from P. aeruginosa and observed that the pore size, measured by osmoprotection, had apparently decreased (Holmström et al., 2001).

We decided to use osmoprotection to estimate the size of pores formed by tip complexes made of LcrV, PcrV or AcrV. The principle of osmoprotection is to do a hemolysis assay in the presence of carbohydrates of increasing osmotic diameter. As long the carbohydrates are small enough to pass through the translocation pore, they distribute equally in the red blood cells and the medium and they cannot counteract the osmotic pressure due to hemoglobin in the red blood cells, which leads to hemolysis. Carbohydrates that are bigger than the translocation pore, cannot enter the red blood cells, stay in the medium and counteract the osmotic pressure in the red blood cell, thus preventing hemolysis. This allows to estimate the pore size if the diameter of the carbohydrates is known.

Results and Discussion

Y. enterocolitica ΔHOPEMNV bacteria complemented by LcrV (pPB42), PcrV (pPB24) or AcrV (pPB25) were tested in a hemolysis assay. Different sized carbohydrates ranging from 0.92 to 3.8 nm in diameter were added to the medium (Table 3). We observed that PEG 3200 (Ø 3.2 nm) protected erythrocytes from hemolysis by pores formed by LcrV or AcrV tip complexes (Fig. 28). Carbohydrates smaller than PEG 3000 did not protect the erythrocytes, suggesting that the diameter of the pores formed by LcrV or AcrV tip complexes was between 2.4 and 3.2 nm. The levels of hemolysis caused by Y. enterocolitica ΔHOPEMNV complemented with PcrV (pPB24) were too low to allow any reliable conclusions on the size of the pore (data not shown).

Material and Methods

Hemolysis was done as described as before (Goure, Broz et al., 2005).
Table 3. Name and osmotic diameter of the carbohydrates used in this study. Osmotic diameters as reported by Hakansson et al., 1996; Holmstrom, et al. 2001; Dacheux et al., 2001; Blocker et al., 1999.

<table>
<thead>
<tr>
<th>Name</th>
<th>Osmotic diameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>0.92 nm</td>
</tr>
<tr>
<td>Raffinose</td>
<td>1.14 nm</td>
</tr>
<tr>
<td>PEG 400</td>
<td>1.36 nm</td>
</tr>
<tr>
<td>PEG 600</td>
<td>1.6 nm</td>
</tr>
<tr>
<td>PEG 1000</td>
<td>2 nm</td>
</tr>
<tr>
<td>PEG 1500</td>
<td>2.1 nm</td>
</tr>
<tr>
<td>Dextrin 15</td>
<td>2.2 nm</td>
</tr>
<tr>
<td>PEG 2000</td>
<td>2.4 nm</td>
</tr>
<tr>
<td>PEG 3000</td>
<td>3.2 nm</td>
</tr>
<tr>
<td>PEG 4000</td>
<td>3.8 nm</td>
</tr>
</tbody>
</table>

Fig. 28. Hemolysis of *Y. enterocolitica* ΔHOPEMV complemented with (A) pPB42 (LcrV) or (B) pPB25 (AcrV) in the presence of carbohydrates of increasing diameter.
3.4.5 The translocators YopB and YopD interact with liposomes \textit{in vitro} (Freeze Fracture Electron microscopy was done by Mohamed Chami)

\textbf{Introduction}

The visualization and analysis of the translocation pore and its component remains one of the burning questions in the field of type III Secretion. So far no convincing images of the pore could be presented. Some very promising data were published by Schoehn et al. in 2003 (Schoehn \textit{et al.}, 2003). The authors expressed and purified the translocators PopB and PopD of \textit{P. aeruginosa} together with their chaperone PcrH. They discovered that upon a shift to acidic pH the chaperone gets partially detached from the translocators, which had been unknown so far. Further they showed that the translocators are able to bind to liposomes at acidic pH. Electron microscopy analysis revealed ring-like structures on and next to the liposomes, suggesting that the translocators oligomerize and form pore-like structures upon contact to membranes. Unfortunately these pictures were far from being convincing and represented a major drawback of the publication. Nevertheless, we decided to use the same strategy to investigate the \textit{Y. enterocolitica} translocators YopB and YopD.

\textbf{Results and Discussion}

\textit{SycD allows soluble expression of PopB and PopD in E. coli}

The two hydrophobic translocators of \textit{Y. enterocolitica}, YopB and YopD contain two and one transmembrane domain respectively. It has been reported before that both require an intrabacterial chaperone to be expressed and soluble (Neyt and Cornelis, 1999b; Schoehn \textit{et al.}, 2003). We constructed plasmid pPB14, capable of co-expressing both translocators together with their chaperone SycD, which was cloned with a N-terminal His tag (Appendix A). Soluble chaperone-translocator complexes could be produced in \textit{E. coli} and were purified on chelating sepharose beads (Fig. 29). The N-terminal His-tag in SycD did not disturb the chaperone/translocator complex formation.
Fig. 29. Purification of soluble complexes between His-SycD/YopB and His-SycD/YopD. Lanes 1-8 show purification fractions after elution from chelating sepharose beads with 300 mM Imidazole. YopB and YopD elute mostly in fractions 2 and 3 together with the chaperone SycD. Low levels of the chaperone can still be detected in the following fractions.
YopB and YopD do not interact with membranes when bound to their chaperone

To test if the translocators are able to interact with membranes, we mixed purified complexes His-SycD/YopB and His-SycD/YopD with artificial liposomes (15% Cholesterol, 25% DOPS and 60% DOPC) at pH 7.4 and separated soluble from membrane bound proteins by floatation in an Opti-Prep gradient (45%-5%). After the centrifugation, control liposomes were visible as a turbid band at the top of the gradient. Liposomes that had been incubated with protein migrated to the same fractions as the control liposomes. Analysis of the gradient revealed that the proteins could only be detected in the lowest fractions of the gradient, indicating that no interaction with the liposomes had occurred (Fig. 30).

Fig. 30. Interaction of the translocators with liposomes in the presence of the chaperone. (A) Graph indicating the localization of the liposomes after floatation in the OptiPrep gradient (white arrowhead). (B) Fractions (1-25) of the OptiPrep gradient were collected and analyzed by SDS-PAGE followed by Silver staining. The proteins were found in the lowest fractions of the gradient (black arrowheads). Lane 2 shows total cell lysate.

YopB and YopD interact with membranes upon release from the chaperone

As mentioned before, Schoehn et al. have shown that a change to acidic pH leads to the release of the chaperone PcrH from the translocators PopB/PopD. In this form the translocators can interact with artificial membranes. We decided to use the same approach to study the interaction of YopB and YopD with membranes. Purified complexes His-SycD/YopB and His-SycD/YopD were mixed with liposomes (15% Cholesterol, 25% DOPS and 60% DOPC) and the solution was dialysed against sodium acetate pH 5.0. In this way we would allow the translocators to immediately interact with membranes upon the release from the chaperone.

Visible aggregation and precipitation of the liposomes was observed after the dialysis in the protein/liposome mix, while the control liposome solution remained turbid. The dialysed samples were subjected to gradient floatation to separate the soluble proteins from the liposomes and the membrane bound protein. Again, control liposomes migrated to the top of
the gradient while liposomes that had been incubated with proteins were now found in the middle part of the gradient. This suggested that the overall density of these liposomes had changed due to the interaction with the proteins. The translocators YopB and YopD, as well as traces of the chaperone SycD, could be found in the same fractions as the liposomes (Fig. 31). Minor amounts of all three proteins could still be found at the bottom of the gradient. This result indicated that upon pH-triggered release of the YopB and YopD from the chaperone, the translocators were able to interact with artificial membranes. No conclusion could be made concerning the nature of this interaction i.e. whether the proteins were inserted into the membranes or just adhered peripherically to the liposomes. Notably, small amounts of the chaperone SycD were also found in the liposome-containing fractions at acidic pH. This may be due to non-specific association of the chaperone to the liposomes or the membrane bound translocators.

Fig. 31. Interaction of the translocators with liposomes after the release from the chaperone by pH-shift. (A) Graph indicating the localization of the liposomes after floatation in the OptiPrep gradient (white arrowhead). (B) Fractions of the OptiPrep gradient (1-25) were collected and analyzed by SDS-PAGE followed by Silver staining. The proteins migrate in the same fractions as the liposomes (black arrowheads). Lane 2 shows total cell lysate.

The role of the lipid composition

Several recent publications suggest that lipid rafts may play an important role during the infection with some bacterial pathogens endowed with a type III Secretion System (Hayward et al., 2005; Schoehn et al., 2003; van der Goot et al., 2004). For P. aeruginosa, Schoehn et al. reported that the lipid composition of liposomes was important for the in vitro interaction with the translocators PopB/PopD. They showed that phosphatidylserine (DOPS) is needed for the association of the translocators with the liposomes, while cholesterol seems to be necessary for the lysis of the liposomes by PopB/PopD. We decided to study the effect of the lipid composition in our in vitro assay as well. We have not observed any lysis of liposomes upon interaction with YopB/YopD in our experiments, possibly because the lipid composition of the liposomes used was not adequate. We generated new liposomes with different lipid...
compositions (L1-L5, Table 4). Proteoliposomes were prepared by dialysis and isolated by floatation. Independently of the lipid composition we observed liposome aggregation after the pH shift. Control liposomes of all compositions (L1-L5) migrated to the top of the gradient after the floatation. Surprisingly L3 and L4 liposomes had also migrated to the top of the gradient, while L1, L2 and L5 liposomes were located in the middle of the gradient (Fig. 32). SDS-PAGE and silver staining revealed that in all cases the proteins were associated with liposomes (Fig. 32, data not shown). The different migration properties of L3 and L4 (no DOPS) liposomes suggested that the proteins interacted differently with liposomes in the presence/absence of DOPS. In contrast to data published for P. aeruginosa, the presence/absence of cholesterol in the liposomes membranes did not have any effect.

<table>
<thead>
<tr>
<th></th>
<th>DOPC</th>
<th>DOPS</th>
<th>DOPE</th>
<th>Cholesterol</th>
<th>Sphingomyelin</th>
</tr>
</thead>
<tbody>
<tr>
<td>L1</td>
<td>60%</td>
<td>25%</td>
<td>15%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L2</td>
<td>25%</td>
<td>25%</td>
<td>15%</td>
<td>25%</td>
<td>25%</td>
</tr>
<tr>
<td>L3</td>
<td>60%</td>
<td>25%</td>
<td>15%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L4</td>
<td>60%</td>
<td>40%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L5</td>
<td>60%</td>
<td>40%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4. Lipid composition of the different liposomes L1-L5 (w/w).

Fig. 32. Interaction with liposomes of different compositions. (A) Graph indicating the localization of all control liposomes (L1-L5) after floatation in the OptiPrep gradient (black arrowhead). (B) Interaction of the translocators with liposomes (L1-L5) after the release from the chaperone by pH-shift. The graphs indicate the localization of the proteoliposomes (L1-L5, Black arrowheads) and the proteins (star). The localization of the protein was determined by SDS-PAGE analysis (data not shown).
Analysis of liposomes by TEM

Schoehn et al. had prepared proteoliposomes as described above and analyzed them by transmission electron microscopy. They observed that PopB alone, PopD alone and an equimolar mix of both were able to form ring-like structures on and next to the liposomes. These rings had an external diameter of 8 nm and an internal diameter of 4 nm.

We analyzed by TEM proteoliposomes incubated with YopB and YopD. We could not observe any ring-like structures in our samples (data not shown). This was not surprising as membrane proteins are hard to observe by TEM when they are inserted in a membrane.

Analysis of proteoliposomes by freeze-fracture EM

Freeze fracture electron microscopy is a technique used to study insertion of proteins into membranes. The sample is applied on the grid and shot into liquid propane. The rapid cooling prevents formation of crystalline ice and results in amorphous ice. The frozen sample is split with a blade and the surface is coated with heavy metal (etched). Thus a replica is made. After the sample has been digested away, the replica is examined by EM. We took advantage of this technique to study proteoliposomes with different lipid compositions (L1, L2 and L4) that had been prepared as described before (Fig. 33). Control liposomes were well distributed in the sample. They had a diameter ranging from 50-500 nm. In contrast to this the proteoliposomes were aggregated and the size of the liposomes seemed to have decreased. Two distinct populations of proteins could be observed on L1 and L2 liposomes: inserted and membrane surface associated. The inserted proteins had a diameter of 8-10 nm suggesting that they were oligomers; as monomers would be too small to be detected by freeze fracture EM. However, the population did not appear to be homogenous, slightly smaller and bigger complexes could be observed. It was not possible to determine if these particles were pores due to the low resolution of freeze fracture EM. The second population of protein complexes was covering the surface of the liposomes. They may represent pre-insertion forms of the complexes. These might be responsible for the liposome aggregates, as they seemed to tether the liposomes together.

In contrast to this the proteins in the L4 liposome sample formed bigger protein aggregates that could be observed distributed between the liposomes. Such kind of aggregates can be generally observed when precipitated proteins are analyzed by freeze-fracture EM. Occasionally inserted complexes could be found as well, although in very low amounts.

These data suggested that the negatively charged phospholipid DOPS promoted the association of the translocators YopB/YopD with membranes and was required for the insertion of proteins complexes into the liposome membranes. When DOPS was missing, the proteins could not interact with the membranes and tended to aggregate. The insertion of the complexes into the liposome membranes could alter the density of the liposomes, which
would explain the difference in the migration pattern of the different liposomes in the gradient, observed before.

**Fig. 33.** Freeze-fracture EM analysis of proteoliposomes. (A) Control liposomes. (B-D) L1 Proteoliposomes. (E) L2 Proteoliposomes. (F) L4 Proteoliposomes. Black arrows indicate membrane-inserted complexes; white arrows indicate membrane-associated protein. Protein aggregates are indicated. Scale bars: 500 nm. Electron micrographs were provided by M. Chami and A. Engel.
Materials and Methods

Construction of the expression vector

A section of the *Y. enterocolitica* translocator operon, containing the genes *sycDyopByopD*, was amplified by PCR on the pYV40 DNA with primers MIPA 3277 and MIPA 3282. The PCR product was digested with BamHI and NdeI and cloned into the BamHI and NdeI sites of the expression vector pET28a (Novagen) giving plasmid pPB14 (*Appendix A*), which allowed co-expression YopB and YopD together with N-terminally 6xHis tagged SycD.

Protein expression and purification

The plasmid was transformed into *E. coli* BL21 (DE3) pLysS. The bacteria were grown in Luria-Bertani medium. Protein expression was induced by the addition of 1 mM IPTG for 4 h at 37°C. Cells were harvested by centrifugation and lysed by 3 passes in the French pressure cell in binding buffer (20 mM Phosphate, 500 mM NaCl). The supernatant was cleared by centrifugation and the proteins were purified using chelating sepharose beads.

Liposome preparation

Liposomes containing five distinct ratios of lipids were produced: L1-L5. A film of dried lipids was prepared under Argon flow. The film was solubilized by resuspension in binding buffer (20 mM Phosphate, 500 mM NaCl) containing 3 % Octylglucoside and the detergent was dialysed out to allow formation of the liposomes.

Preparation of proteoliposomes

400 µg of proteins were mixed with 250 µl of liposomes. This mix was dialyzed against sodium acetate pH 5.0 for 6 h at room temperature. The solution was adjusted to 45% OptiPrep and transferred to an ultracentrifugation tube. A stepwise gradient from 35-5% OptiPrep was layered on top and centrifuged for 16 h at 150 000 g at 4°C. fractions of 0.5 ml were collected from the top of the gradient. Aliquots were analysed by SDS-PAGE and Silver staining.

Electron microscopy

Droplets were applied for 1 min to freshly glow-discharged, formvar-carbon coated grids, and negatively stained with 2% (w/v) uranyl acetate. The samples were visualized in a Philips Morgagni 268D electron microscope at an acceleration voltage of 80 kV.

Freeze fracture electron microscopy

Was done as described by (Chami *et al.*, 2005).
3.4.6 Purification of the TTS translocation pore using tagged translocators

Introduction

The purification and visualization of the translocation pore remains so far one of the unsolved questions in the field of type III Secretion. Previous attempts focused on the purification of the hydrophobic translocators, which presumably form the translocation pore, and the reconstitution of the pore into artificial membranes in vitro. The disadvantage of such an approach is, that, even if it succeeds, it is not possible to prove that the pores formed in vitro are exactly the same as the translocation pores formed in vivo by the bacteria. To avoid this disadvantage, we decided to purify the translocation pore out of membranes of erythrocytes that were infected with Y. enterocolitica, using a tag on one of the translocators. Using this kind of approach we could be sure that the purified pores represent the functional and native translocation pore. The first step of this approach is to insert a tag either in YopB or in YopD. It is crucial that the tagged protein is still functional and thus fully able to complement a mutation in the corresponding gene.

Results and Discussion

Expression of YopB or YopD in E. coli

We constructed vectors pPB1-6, capable of expressing YopB/YopD without a tag or with a His-tag in the amino- or carboxyterminus. Protein expression from these vectors was first tested in E. coli TOP10. No overexpression of the recombinant proteins could be detected on Coomassie stained SDS-PAGE (Fig. 34A). Western blot analysis revealed that even though all proteins were expressed, the levels remained very low (Fig. 34A). To clarify if the protein expression had a detrimental effect on the bacteria, the growth was monitored for 500 minutes after the induction. Constructs expressing YopB lead to a stop in growth or even to lysis of the E. coli (Fig. 34B). This suggested that YopB had a strong toxic effect on the bacteria. Expression of YopD had a less drastic effect, but still lead to decreased growth (Fig. 34C). No toxic effect is observed when they are expressed together with their chaperone SycD, which presumably prevents the interaction with membranes (chapter 3.4.5).

Complementation of yopB/yopD mutants with tagged-translocators

In order to test if constructs pPB1-6 can complement a deletion of the yopB/yopD genes, the plasmids were transformed into Y. enterocolitica ΔHOEMNB or ΔHOEMND bacteria and analyzed in a red blood cell hemolysis assay (Fig. 35). C-terminally tagged
translocators (pPB1 and pPB4) caused only low levels of hemolysis. This suggested that the C-terminal tag interfered with pore formation. The N-terminally tagged translocators (pPB2 and pPB5), were able complement the respective mutation as well as the untagged proteins (pPB3 and pPB6). This observation was surprising, because it is known for the effector Yops that changes in the aminoterminus abolish the secretion. It suggests that the secretion signal of YopB and YopD might be different or localized in another place.

Isolation of membranes containing tagged pores

In order to purify pores we need enough starting material i.e. membranes containing translocation pores. To test the yield of tagged translocators, we performed a “large scale” hemolysis experiment. In contrast to a hemolysis experiment done with 5x10^7 RBCs the “large scale” hemolysis is done with 3x10^9 RBCs. Two strains were analyzed in parallel: Y. enterocolitica ΔHOPEMN and Y. enterocolitica ΔHOPEMND complemented with pPB5 (Fig. 36). The complemented mutant caused a bit less hemolysis than the ΔHOPEMN strain. Membranes of the RBCs were isolated after the infection and the amounts of the translocators YopB and YopD in the membranes were compared. The complemented mutant inserted considerable amounts of translocators into the red blood cell membranes, only slightly less than the ΔHOPEMN strain (Fig. 36), correlating with the levels of hemolysis. Unfortunately, even though protease inhibitors were added, native YopD as well as His-YopD tended to be degraded (Fig. 36, black arrowheads). This degradation might interfere with the purification therefore it is necessary to find a way to avoid it. Nevertheless, if proper upscaling is achieved, this assay should provide enough starting material to start the purification of the native pore via the His-tag in YopD. As an alternative the same attempt can be done using His-tagged YopB.
**Fig. 34.** Expression analysis of plasmids pPB1-6 in *E. coli* TOP10 bacteria. (A) Coomassie stained SDS-PAGE and western blots of total cell pellets of *E. coli* TOP10 bacteria harboring plasmids pPB1-6 after 4 h of induction with 0.2 % arabinose at 37°C. (B, C) Growth curves of *E. coli* TOP10 bacteria harboring plasmids pPB1-6. Bacteria were grown at 37°C and samples were collected up to 500 minutes after induction.
Fig. 35. Hemolysis of *Y. enterocolitica* strains ΔHOPEMN, ΔHOPEMNB, ΔHOPEMND and ΔHOPEMNB/ΔHOPEMND complemented with pPB1-3/pPB4-6 respectively.

Fig. 36. Isolation of red blood cell membranes after infection with *Y. enterocolitica* ΔHOPEMN or ΔHOPEMND complemented with pPB5. (A) Hemolysis levels caused by the two strains. (B) Western blots of isolated red blood cell membranes probed with anti-YopB and anti-YopD antibodies. Proteins are indicated (white arrowheads); YopB: 41.9 kDa, YopD: 33.7 kDa and His-YopD: 34.5 kDa. Notably, YopD migrates at a higher apparent molecular weight in SDS-PAGE and degradation of YopD can be observed (black arrowhead).
Material and methods

Construction of vectors

The *yopB* or *yopD* genes were amplified by PCR on pYV40 DNA. The PCR products were digested with Ncol/PstI or Xhol/PstI and cloned into the Ncol/PstI or Xhol/PstI sites of the expression vector pBADmycHisA (Invitrogen) giving plasmid pPB1-6. These plasmids allowed expression of YopB or YopD with a C-terminal 6xHis-tag, a N-terminally 6xHis-tag or no tag.

Expression in *E. coli*

The plasmids were transformed into *E. coli* TOP 10 and expression was induced by the addition of 0.2 % Arabinose at 37°C for 4 h. The bacteria were collected and the proteins were separated by SDS-PAGE. To produce the growth-curves, the growth was monitored from 0 to 500 min after induction by measuring the OD$_{600}$.

Complementation of *yopB/yopD* mutants with tagged-translocators

The plasmids pPB1-3 were transformed into *Y. enterocolitica* ∆HOPEMNB, plasmids pPB4-6 into *Y. enterocolitica* ∆HOPEMND.

To check the functional complementation of the mutations by the different constructs, a red blood cell hemolysis assay was performed as described before (Goure, Broz et al., 2005).

“Large scale” Hemolysis

Isolation of red blood cells membranes after infection was done as described before (Goure, Broz et al., 2005).
4 Discussion
4 Discussion

What are the different roles of the three translocators within the translocon?

Our analysis of the *Y. enterocolitica* type III secretion translocon allows for the first time to understand the function of the three translocators because it shows that the translocon consists of two distinct parts, the tip complex and the actual translocation pore.

The two hydrophobic translocators, YopB and YopD in *Y. enterocolitica*, presumably form the pore in the target cell membrane. Many studies have shown that these proteins interact with membranes and even insert into membranes. *In vitro* in contact with liposomes, they were shown to form oligomeric, pore-like structures, which can even function as channels (Faudry *et al.*, 2006). Pore-formation *in vivo* requires the presence of the tip complex, a structure present at the tip of the injectisome needle, the putative exit point of secreted proteins (Mueller, Broz *et al.*, 2005). This structure is formed by the third translocator (LcrV in *Y. enterocolitica*). We speculate that it assists the hydrophobic translocators to fold correctly and assemble into a functional pore upon secretion (Goure, Broz *et al.*, 2005). We assume that the pore stays connected to the needle via the tip complex. Thus the secretion and the translocation processes are coupled and the bacteria can inject effectors in one step into the target cell.

How does LcrV help in the pore assembly?

*Yersiniae* deprived of LcrV are no longer hemolytic. Analysis of erythrocytes membranes indicated that *lcrV* mutant bacteria still insert YopB and YopD into the target cell membranes but cannot form a functional pore (Goure, Broz *et al.*, 2005). This suggests that tip complex somehow assists the assembly of the translocation pore.

Due to the size of the needle channel, the secreted proteins have to travel through the needle in a partial unfolded state. The tip complex could help the translocators that emerge at the tip of the needle to fold in a correct way, acting as some sort of extracellular chaperone. Consistent with this, our data show that *lcrV* mutants missing the tip complex insert considerably less translocators into erythrocyte membranes than wildtype bacteria. This suggests that the tip complex could not only ensure proper folding but also the insertion of the translocators into the membrane. In contrast to this, we also demonstrated that *in vitro* YopB and YopD insert into membranes even in the absence of the tip complex. This may be
explained by the fact that *in vitro* the concentration of the proteins is much higher and could force the equilibrium towards insertion.

Another possibility would be that the tip complex could also stabilize or retain the translocators in the membrane, keeping the local concentration of translocators high enough to allow interaction between them and formation of the translocation pore. In the absence of the tip complex the translocators are still inserted but they would easily diffuse or would not be retained in the membrane.

We also speculate that the tip complex provides interaction sites acting as some sort of scaffold for pore assembly. Only on this scaffold a functional pore can be formed and via the tip complex the pore stays connected to the needle. This idea is supported by the fact that the three translocators were reported to interact with each other, suggesting that there is no further mediator between the tip complex and the pore. This theory is contradicted by the observation that *in vitro* purified translocators can also form functional channels (Faudry et al., 2006). But these *in vitro* experiments were done with unnaturally high protein concentrations and do only partially reflect what happens in nature.

**Is the tip complex a conserved feature of all TTSSs?**

Based on our results we suggest that the tip complex might be a general feature found in every type III secretion system. It can assumed that tip complexes similar to the LcrV tip complex of *Yersinia* can be found on injectisome needles from *P. aeruginosa* and *A. salmonicida* because PcrV and AcrV form a tip complex in a *Yersinia lcrV* mutant background (Mueller, Broz et al., 2005). In addition purified needles from *P. aeruginosa* have also a tip complex at one end (C. Gebus and C.A. Mueller, unpublished results).

EspA, the hydrophilic translocator from EPEC could be considered a functional homolog of LcrV. Though EspA is smaller (20.5 kDa) than LcrV (37.6 kDa) and the two proteins do not share significant sequence similarity, EspA has been shown to form a comparable structure, a helical filament at the tip of the injectisome needle. This suggests that in this case the tip complex has evolved to polymerize to a long filament than a short ring.

Recently a sheath-like structure was found to cover the distal end of the injectisome needles from the *S. Typhimurium* SPI-2 TTSS. The protein SseB, which shares homology to EspA from EPEC, is part of this structure. It is not clear yet if this sheet is not just an artifact, because in contrast to the EspA filament of EPEC, there is no need to elongate the SPI-2 needle with a sheet. The needle is already long enough to reach the target cell membrane, when the bacteria were taken up into phagosomes. One possible explanation could be that the sheet protects the needle from the acidic pH in the phagosome, which could destabilize it.
No filament or tip complex has been observed for the needle complexes of *S. flexneri* and *S. Typhimurium* SPI-1, even though they are the best analyzed NCs of all type III secretion systems. It is still possible that the tip complex was either not detected or it was detached and lost during the purification. Only recently it could be shown that IpaD localizes to the distal end of the *S. flexneri* needles (Espina et al., 2006). As IpaD has basically the same function as LcrV, we can speculate that IpaD as well as its homologs SipD from *S. Typhimurium* and BipD from *Burkholderia pseudomallei* would form a similar tip complex. But only STEM analysis of purified needles will show if there is a tip complex and how it looks like.

Taken together, it seems that in every type III secretion system the needle is topped with a distinct structure, be it a tip complex or a filament, which is formed by the hydrophilic translocator.

**Is the tip complex the connector between the pore and the translocation pore? Is there a need for a connecting structure?**

The concept of type III secretion requires that the translocation pore remains connected to the needle once it is assembled. Indeed no leakage of effectors into the culture medium can be observed during infection (Mota et al., 2005a). Based on our results we assume that the tip complex serves as a connector between the needle and the translocation pore, but so far this was not shown directly. However it is known that LcrV interacts with YopB and YopD, suggesting that there is no other protein in between. Such a protein would be necessary for the translocation, but by now all proteins encoded on the pYV plasmid were mutated and no new translocators were identified.

The situation seems to be clearer for EPEC. Here the bacteria are separated from the enterocytes by the thick glycokalyx layer and the needle is too short to bridge this distance. The EspA filament elongates the needle and allows the bacterium to reach the target cell membrane. Therefore it must serve as a connector between the needle and the translocation pore that is inserted in the target cell membrane. In addition a channel that could serve as a hollow conduit for the effector proteins to the target cell membrane spans the filament. Interestingly, STEM images of *Yersinia* wildtype needles also show that a channel spans all the way through the needle and the tip complex.

The need for a connecting structure seems quite obvious for EPEC, but for *Yersinia* the situation is different because the needle itself is long enough to span the space between the bacterium and the target cell. So, why is the needle not directly connected to the translocation pore? An explanation could be that the tip complex may act as an adaptor between the helical needle and the presumably ring-like translocation pore. Indeed the recently published
modeling of a tip complex on top of a type III secretion needle, suggests that LcrV would continue the helix of the needle (Deane et al., 2006).

**Are other proteins a part of the tip complex?**

Silver stained SDS-PAGE analysis of purified needles revealed several other major bands beside LcrV, YscF and flagellin. One band was identified as YopD, but we showed that that it is not part of the tip complex. Several minor bands remain to be identified, therefore we cannot completely exclude that some other proteins could be minor components of the needle and the tip complex. Intriguingly, the needles from lcrV mutant bacteria are not blunt ended but distinctly pointed. This suggests that a pyramid-like structure could be hidden underneath the tip complex. Several secreted Ysc proteins could be possible candidates for this structure. This structure could even serve as a polymerization cap for needle assembly. A capping protein has been identified for the flagellar filament, but could not be found so far for the needle The pointed end of the needles might also just be the end of the helix viewed from the side, appearing higher at one side and therefore pointed. This would be in agreement with the modeling presented by (Deane et al., 2006). In addition when STEM images of isolated needle are closely observed the base of the tip complex appears higher at one side (Mueller, Broz et al., 2005). This difference is not visible in the final averages of the tip complex where the base looks even. But due to the averaging such differences disappear and the base seems to be even. This would suggest that LcrV just continues the helix of the needle. In agreement with this we were able to crosslink LcrV and YscF, suggesting a direct interaction.

**Correlation between pore formation “in vitro” and “in vivo”**

The analysis and visualization of the translocation pore is one of the major unsolved questions in the field of type III secretion. So far the only promising approaches were done in vitro with purified translocator proteins (Schoehn et al., 2003, P. Broz unpublished data). The main drawback of such approaches is that there is no way to validate that the “in vitro pore” is the same as the pore formed in vivo. Nevertheless these in vitro experiments provided interesting results and insights.

To purify the translocators of Yersinia or Pseudomonas, they have to be expressed together with their native chaperone, that prevents the premature interaction of the translocators and the degradation. When placed at acidic pH, the translocators are partially released from the chaperone and form homo- or heteromeric oligomers. These oligomers are able to bind membranes and also to insert into membranes. They have the appearance of
ring-like structures with an outer diameter of around 8-10 nm and an inner diameter of 4 nm. Furthermore these rings may indeed act as channels as they have been shown to lead to release of fluorescent dyes from liposomes.

All these observations may be related to events occurring in vivo during an infection. The secretion machinery removes the chaperone and the translocators are exported. The translocators oligomerize upon secretion and insert into the target cell membrane. In vitro they form ring-like structure even before they insert into membranes (Schoehn et al., 2003). Our freeze-fracture analysis also suggests that the oligomeric form exists already before the membranes insertion. But in vivo this seems rather unlikely because the needle tip is in close contact to the membrane. The tip complex formed by the third translocator somehow facilitates the oligomerization and pore formation in vivo. By acting as a scaffold it also imposes a fixed stoichiometry. Faudry et al. (Faudry et al., 2006) speculate that the pH change used in vitro to trigger interaction with membranes might mimic the action of the tip complex in vivo. Analyzing the hemolytic abilities of lcrV mutant bacteria at acidic pH should validate this explanation.

Another drawback of the “in vitro pores”, formed by PopB and PopD, is that they seem to be a mixture of pore-like structures with different sizes, 3.4-6.1 nm in diameter (Faudry et al., 2006). In contrast to this pores formed by P. aeruginosa in vivo have a size of 2.8-3.5 nm. Our freeze fracture analysis of proteoliposomes formed by incubation with YopB and YopD, reveals transmembrane particles of varying sizes (P. Broz unpublished data). This suggests that even though the hydrophobic translocators have some intrinsic pore-forming properties that allow them to form pores at high concentration like in these in vitro assays, the tip complex is necessary to catalyze this reaction in vivo so that the right translocation pore is formed.

What is the status of the translocators in the type III secretion hierarchy?

The localization and the function of the three translocators implicates that they need to have their own status in the secretion hierarchy. The type III secretion hierarchy has never been experimentally established. But it is known that knock out mutations in early substrates that build the outer part of the injectisome, like YscF and YscP, abolish the secretion later substrates. It is assumed that the secreted substrates can be classified into three major classes. First, the early substrates that are essential for the assembly of the secretion apparatus itself. Upon contact with a target cell they should be followed by the hypothetical middle substrates, the translocators. And finally, when the translocation pore is assembled the late substrates, the effector proteins, can be secreted. How the three classes are
distinguished is unknown, but it is possible that they have different secretion signals. Indeed the three translocators seem to have a different secretion signal than the effectors (Fields et al., 1999). We observed that N-terminal tags do not affect the secretion of the translocators, while changes in the N-terminus interfere with the secretion of the effectors.

But there must be some differences between LcrV and the hydrophobic translocators as well. We demonstrated that the LcrV tip complex is already assembled on the needle in non-secreting conditions, before secretion is triggered, and that YopB and YopD are not part of the tip complex. Therefore LcrV must be secreted right after the needle component YscF but before the actual translocation pore components.

How the secretion hierarchy is established is unknown, but it is intriguing that the three translocators are somehow involved in the regulation of type III secretion: LcrV interacts with LcrG, thus controlling effector proteins secretion. SycD the chaperone of both YopB and YopD is also critically involved in the regulation of yop gene expression. It is possible that these interactions ensure the secretion of the three translocators at the right time.

Is the tip complex involved in the trigger mechanism?

It has been proposed that type III secretion is triggered by the contact between the needle tip and the target cell (Mota et al., 2005a). It is tempting to hypothesize that the tip complex might be involved in the trigger mechanism. As bacteria do not form pores, the secreted proteins should end up in the culture supernatant. On the contrary, it was shown that lcrV mutant do not secrete proteins into the culture supernatant, suggesting that the secretion can’t be triggered (DeBord et al., 2001). Recently it was reported that contact with liposomes can trigger the secretion by S. flexneri (van der Goot et al., 2004) and IpaD, an ortholog of LcrV, is localized at the tip of the needle in S. flexneri (Espina et al., 2006). Therefore it could be therefore possible that the tip complex could sense the presence of membranes and transmit this signal via an unknown mechanism to the machinery, triggering the secretion of the translocators and effectors. Deane et al. speculate that the tip complex would sense contact and transmit the signal via intersubunit contacts of the needle to the bacterium (Deane et al., 2006). So far no convincing data could be presented that would support such a model.

The contact between the needle tip and the host membrane alone is not sufficient to trigger effector secretion; another prerequisite is the ability of the bacterium to form the translocation pore. Bacteria deprived of YopB do not secrete effectors into the medium even though they are in contact with eukaryotic cells (L.J. Mota unpublished data). This suggests that the formation of the pore by the tip complex i.e. the opening of a continuous channel between the bacterium and the eukaryotic cytosol leads to the secretion of the effectors and no special signal is required. This scenario would imply that the pore-forming translocators are
localized in the needle or the injectisome, ready to be secreted as soon as the tip reaches a membrane.

Requirements on membrane side?

As mentioned in the introduction, it has been shown for Shigella, Salmonella and EPEC that the lipid composition of the membrane is very important. These three pathogens require the presence of cholesterol in the host cell membrane to translocate effectors via the type III secretion system (Hayward et al., 2005). As the translocators insert directly into host cell membrane it was speculated that the formation of the translocation pore could depend on the presence of certain lipids in the host cell membrane. In addition the authors show that purified Salmonella SipB and Shigella IpaB are cholesterol-binding proteins and that cholesterol is the main binding determinant of purified SipB/IpaB to host cells (Hayward et al., 2005). As cholesterol is a component of lipid rafts it suggests that these pathogens can only assemble the translocation pore in the special lipid environment of lipid rafts.

We were interested if the family of Ysc-type TTSSs (Yersinia, Pseudomonas) also requires cholesterol for translocation. Our in vitro experiments with purified translocators indicated that phosphatidylserine (PS) is necessary for the binding of YopB and YopD to liposomes and also for the insertion of the proteins into membranes. Other lipids like cholesterol and sphingomyelin were not necessary. In addition unpublished data from J. Mota show that when macrophages are depleted from cholesterol, by incubating them with methylcyclodextrin, the infection is not affected.

Data published on P. aeruginosa (Faudry et al., 2006; Schoehn et al., 2003) also show that the translocators require negatively charged phospholipids (PS) to bind membranes and insert into membranes. Initially Schoehn et al. reported that PS is necessary for the binding to membranes but that cholesterol is required for lysis (insertion of the translocators) of liposomes. But it seems that the authors had observed aggregation of liposomes and misinterpreted this observation as liposomes lysis. Later the same group had to revise their result, as they could not observe liposome lysis any more. Another interesting observation is that purified IpaB from S. flexneri leads to the release of Calcein from liposomes that contain negatively charged lipids, but not from liposomes containing positively charged lipids (De Geyter et al., 2000). This suggests that the formation of the type III secretion translocon, in all systems, requires negatively charged phospholipids in the target cell membrane.

Altogether it seems that the requirements on the membrane depend on the type of TTSS system that the bacteria have acquired. Ysc-type TTSS are independent of lipid rafts, while they are crucial for others. This may also reflect the different infection strategies of these
pathogens. Some pathogens, like Yersinia and P. aeruginosa, are extracellular. To avoid phagocytosis by macrophages, they need to act in seconds and inject effector proteins into the macrophage. On the other hand, Shigella, Salmonella and EPEC invade epithelial cells. They can take their time to find the right spot (lipid raft) to successfully enter their target cells.
Action of protective antibodies

For decades LcrV has been known to be the major protective antigen against plague infections. Later the same activity was reported for antibodies directed against the V antigens of \textit{P. aeruginosa} and \textit{A. salmonicida}. Only recently it could be shown that antibodies against IpaD, a functional homolog of LcrV, from \textit{S. flexneri} also prevent hemolysis. Antibodies against EspA are found in human maternal milk and were proposed to provide protection against EHEC (Noguera-Obenza \textit{et al.}, 2003).

Our results show that the V-antigens are forming an exposed structure at the tip of the injectisome needle and that antibodies bind specific to this tip complex. It is this binding that affects the action of the tip complex and interferes with the formation of a translocation pore. Further we could show that if LcrV contains a FLAG tag, anti-FLAG antibodies can also interfere with the function of the tip complex. This suggests that it is not a specific motif of LcrV that has to be bound by the antibodies, but that the sheer physical presence of the relatively large antibodies impairs pore formation.

Interestingly we did not observe any protective action with antibodies directed against YscF, the needle subunit. This is in apparent contradiction to reports found in literature that show that vaccination of animals with YscF provides significant protective immune response to plague infections. This contradiction may be explained by the observation that our YscF antibody recognizes only the lower end of the needle. During the assembly and function of the needle this part is never exposed, except when the needles are broken off. One could imagine that antibodies directed against other epitopes of YscF could possibly interfere with the assembly of the needle or the tip complex, which would explain the protective action observed \textit{in vivo}.

Therapeutic target?

Our work shows that the tip complex is vital for the success of the whole TTS apparatus. At the same time it is the weakest point of the whole system because of its exposed localization. Only antibodies directed against the tip complex can efficiently disturb the system. Therefore the tip complex is probably the best-suited target for new infectives, as these would not even have to pass through the bacterial membranes to block the function of the TTSS. In addition our work has shown that the hemolysis assay is well suited for the study of the function of the translocon and could be adapted for screening of new anti-infectives that specifically target the TTS system system. Further analysis of the tip complex and the crystal structure of LcrV may be used to specifically design molecules that could interfere with the function of the tip complex.
5 Outlooks
5 Outlooks

To finally understand the translocation process, we will need to understand the function of the tip complex and the translocation pore in detail and also how these structures are connected to the injectisome needle. Therefore it is necessary to determine the interaction sites between the different parts of the translocon and to investigate the structure of the translocation pore. It is also crucial to establish the chronological order of events during the assembly and the function of the injectisome. Here are some questions directly arousing from the present study and which would be relevant to address:

- How is the tip complex connected to the translocation pore and the needle? Which domains of LcrV interact with YscF (the needle)? Which domains interact with YopB and YopD (the translocation pore)?

- How many molecules of LcrV form the tip complex (Stoichiometry)?

- Are there other proteins involved? Small, secreted Ysc proteins? What is the pyramid underneath the tip complex?

- What is the composition and structure of the translocation pore? How does the membrane topology of YopB and YopD look like?

- Is the tip complex involved in the trigger mechanism? How is the formation of the pore involved in the trigger mechanism?

- What is the hierarchy of secretion and how is it established? Are the translocators secreted? How are the chaperones involved? What are the export signals of LcrV, YopB and YopD?

- Is LcrG the chaperone of LcrV?

- How are the coiled-coil domains of LcrV involved in polymerization?
## A List of constructs

<table>
<thead>
<tr>
<th>MIPA number</th>
<th>name</th>
<th>description</th>
<th>vector</th>
<th>resistance</th>
</tr>
</thead>
<tbody>
<tr>
<td>3921</td>
<td>pPB 1</td>
<td>yopB-his</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3922</td>
<td>pPB 2</td>
<td>his-yopB</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3923</td>
<td>pPB 3</td>
<td>yopB</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3924</td>
<td>pPB 4</td>
<td>yopD-his</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3925</td>
<td>pPB 5</td>
<td>his-yopD</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3926</td>
<td>pPB 6</td>
<td>yopD</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3927</td>
<td>pPB 7</td>
<td>lcrVsycDyopByopD</td>
<td>pET28a</td>
<td>Kan</td>
</tr>
<tr>
<td>3932</td>
<td>pPB 15</td>
<td>his-sycDyopB-his</td>
<td>pET28a</td>
<td>Kan</td>
</tr>
<tr>
<td>3933</td>
<td>pPB 16</td>
<td>his-sycDyopB-his</td>
<td>pET28a</td>
<td>Kan</td>
</tr>
<tr>
<td>3934</td>
<td>pPB 17</td>
<td>his-sycDyopB</td>
<td>pET28a</td>
<td>Kan</td>
</tr>
<tr>
<td>3941</td>
<td>pPB 24</td>
<td>pcrV of *P. aeruginosa PAO1</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3942</td>
<td>pPB 25</td>
<td>acrV of *A. salmonicida JF2287</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3930</td>
<td>pPB 28</td>
<td>H3 (PcrV aa1-105, LcrV aa125-329)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3931</td>
<td>pPB 29</td>
<td>H4 (PcrV aa1-174, LcrV aa196-329)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3932</td>
<td>pPB 30</td>
<td>H5 (LcrV aa1-145, PcrV aa124-294)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3933</td>
<td>pPB 31</td>
<td>H6 (PcrV aa1-123, LcrV aa146-329)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3934</td>
<td>pPB 32</td>
<td>H7 (LcrV aa1-181, PcrV aa160-294)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3935</td>
<td>pPB 33</td>
<td>H8 (PcrV aa1-159, LcrV aa182-329)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3936</td>
<td>pPB 34</td>
<td>H9 (LcrV aa1-145, AcrV aa146-361)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3937</td>
<td>pPB 35</td>
<td>H10 (AcrV aa1-143, LcrV aa146-329)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3938</td>
<td>pPB 36</td>
<td>H11 (LcrV aa1-181, AcrV aa180-361)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3939</td>
<td>pPB 37</td>
<td>H12 (AcrV aa1-179, LcrV aa182-329)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3940</td>
<td>pPB 38</td>
<td>H13 (LcrV aa1-181, PcrV aa160-233, LcrV aa268-329)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3941</td>
<td>pPB 39</td>
<td>H14 (PcrV aa1-159, LcrV aa182-267, PcrV aa234-294)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3942</td>
<td>pPB 40</td>
<td>H15 (LcrV aa1-181, AcrV aa180-300, LcrV aa301-361)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3943</td>
<td>pPB 41</td>
<td>H16 (AcrV aa1-179, LcrV aa182-267, AcrV aa301-361)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3944</td>
<td>pPB 42</td>
<td>lcrV</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3945</td>
<td>pPB 43</td>
<td>lcrV del aa218-243</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3946</td>
<td>pPB 44</td>
<td>pcrV-his</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3947</td>
<td>pPB 45</td>
<td>acrV-his</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3948</td>
<td>pPB 46</td>
<td>LcrV with FLAG tag between aa227-228</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3949</td>
<td>pPB 47</td>
<td>LcrV with FLAG tag replacing aa226-233</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>3950</td>
<td>pPB 48</td>
<td>His-LcrV aa1-156 (his-G1)</td>
<td>pBAD</td>
<td>Amp</td>
</tr>
<tr>
<td>Sequence</td>
<td>Vector</td>
<td>Description</td>
<td>Selection Marker</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>--------</td>
<td>-------------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td>3951</td>
<td>pPB</td>
<td>His-LcrV aa1-192 (his-G1A1)</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3952</td>
<td>pPB</td>
<td>His-LcrV aa1-289 (his-G1A1G2)</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3953</td>
<td>pPB</td>
<td>His-LcrV aa1-329 (his-G1A1G2A2)</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3954</td>
<td>pPB</td>
<td>His-LcrV aa193-289 (his-G2)</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3955</td>
<td>pPB</td>
<td>His-LcrV aa193-329 (his-G2A2)</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3956</td>
<td>pPB</td>
<td>His-LcrV aa157-329 (his-A1G2A2)</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3957</td>
<td>pPB</td>
<td>His-LcrV aa290-329 (his-A2)</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3958</td>
<td>pPB</td>
<td>His-LcrV aa157-192 (his-A1)</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3959</td>
<td>pPB</td>
<td>His-LcrV aa157-289 (his-A1G2)</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3960</td>
<td>pPB</td>
<td>his-lcrV</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3961</td>
<td>pPB</td>
<td>his-pcrV</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3962</td>
<td>pPB</td>
<td>his-acrV</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3963</td>
<td>pPB</td>
<td>His-H5</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3964</td>
<td>pPB</td>
<td>His-H6</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3965</td>
<td>pPB</td>
<td>His-H9</td>
<td>pBAD Amp</td>
<td></td>
</tr>
<tr>
<td>3966</td>
<td>pPB</td>
<td>His-H10</td>
<td>pBAD Amp</td>
<td></td>
</tr>
</tbody>
</table>
B References


C Acknowledgments

Prof. Dr. Guy Cornelis thank you for your continuous support and your enthusiasm about my project. I am grateful for your trust in my abilities and your advice whenever the project was in a difficult phase. You had always time to discuss and to share your broad knowledge with me.

Catherine Müller thank you for the excellent and successful collaboration that we had. I had a lot of fun working and discussing with you, developing new “working hypotheses” for the tip complex. I hope we will continue like this and finish another great story.

Dr. Luis Jaime Mota and Dr. Isabel Sorg thank you both for discussions, the time you took to help me with my project and all the practical help with experiments in the lab.

Marina Kuhn thank you for your friendship and all the support you gave me during my diploma and the PhD.

I would also like to thank all the past and present members of the lab for the nice atmosphere, all the laughs and the help you provided: Marlise Amstutz, Emilie Clément, Dr. Geertrui Denecker, Andreas Diepold, Dr. Gottfried Eisner, Dr. Mario Feldmann, Chantal Fiechter, Franziska Fischer, Viola Huschauer, Dr. Laure Journet, Michel Letzelter, Silke Lützelschwab, Yvonne Lussi, Manuela Mally, Kerstin Maylandt, Salome Meyer, Cécile Pfaff, Dr. Nadine Schracke, Dr. Hwain Shin, Jaqueline Stalder, Dr. Paul Troisfontaines and Steffi Wagner.

Prof. Dr. Andreas Engel thank you for your support and your interest in type III secretion systems. I appreciate all the time you took to discuss with us and provide input for the project.

Dr. Shirley Müller, Dr. Philippe Ringler and Françoise Erne-Brand thank you for the wonderful microscopy work you did. It was a pleasure to work with you and I hope you are still motivated to see some more “needles” in the future.

Dr. Myriam Duckely and Kitaru Suda thank you for the knowledge you shared about membrane proteins and for the time you took to help me with my experiments.

Thanks to all the present and former members of the 4th floor for the nice and professional atmosphere.

Markus Dürrenberger, Vesna Oliveri and Ursula Sauder thank you for providing the ZMB facilities.

Dr. Ina Attree and Dr. Julien Gouré thank you for the great collaboration we had and the knowledge and motivation you shared with me. I had a lot of fun in Grenoble and learned all the secrets of “hemolysis”.

Last but not least, I would like to thank my family and especially my girlfriend Daniela for their support during my PhD and for all their encouragement. Without your help I would have not made it.
Curriculum vitae

**BROZ Petr**
Rixheimerstrasse 16, 4055 Basel
076 477 43 49
petr.broz@stud.unibas.ch
Swiss
30.12.1977 in Prague / CZ

### Personal information
- **Surname/ First name**: BROZ Petr
- **Address**: Rixheimerstrasse 16, 4055 Basel
- **Telephone**: 076 477 43 49
- **E-mail**: petr.broz@stud.unibas.ch
- **Nationality**: Swiss
- **Date and place of birth**: 30.12.1977 in Prague / CZ

### Occupational field
- **Molecular Microbiologist**

### Education and work experience

<table>
<thead>
<tr>
<th>Dates</th>
<th>Title of qualification awarded</th>
<th>Principal subjects</th>
<th>Name and address of employer</th>
<th>Supervisor</th>
<th>Subject</th>
</tr>
</thead>
</table>
| December 2002 to now | **PhD, mark 5.5 magna cum laude**                                   | Molecular Microbiology/ Microbial Pathogenesis          | Department of Microbiology, Biozentrum, University of Basel, 50-70 Klingelbergstrasse, 4056 Basel, Switzerland | Prof. Dr. Guy Cornelis | *Functional and structural characterization of the Yersinia enterocolitica type III secretion translocon*

<table>
<thead>
<tr>
<th>Dates</th>
<th>Title of qualification awarded</th>
<th>Name and type of organisation providing education and training</th>
<th>Minor Subject</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>September 1997 to October 2002</td>
<td><strong>Diplom für Biologie II, mark: 5.5</strong></td>
<td>University of Basel, Switzerland</td>
<td>Molecular Microbiology/ Microbial Pathogenesis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1993 to 1996</td>
<td><strong>Certificate of Matura type B (latin)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Technical skills
- **Molecular Biology**: Cloning, DNA purification and analysis, Allelic exchange in bacteria
- **Biochemistry**: Protein expression and purification, HPLC, Protein analysis (SDS-PAGE, Western blot, Co-Immunoprecipitation, Overlay, pull-down techniques), Lipid vesicle preparation, Gradient centrifugation
- **Cell biology**: Cell culture, transfection, cell infection assays, Immunofluorescence
- **Other**: Electron microscopy, Immunogold labelling, TLC of lipids
Teaching experience

<table>
<thead>
<tr>
<th>Dates</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2003 to Juli 2004</td>
<td>Supervision of trainee</td>
</tr>
<tr>
<td>2002-2006 (one week per year)</td>
<td>Teaching assistantship in practical courses at the Biozentrum der Universität Basel</td>
</tr>
<tr>
<td>October 2003 to March 2004</td>
<td>Tutoring of first semester biology students (certificate)</td>
</tr>
</tbody>
</table>

Publications


Posters


Talks


Language skills

<table>
<thead>
<tr>
<th>Language</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>German</td>
<td>Native speaker</td>
</tr>
<tr>
<td>English</td>
<td>Fluent</td>
</tr>
<tr>
<td>French</td>
<td>Good knowledge</td>
</tr>
<tr>
<td>Czech</td>
<td>Mother tongue, fluent</td>
</tr>
</tbody>
</table>

Additional experience

<table>
<thead>
<tr>
<th>Dates</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 2000 to June 2000</td>
<td>Offiziersschule der Schweizerischen Armee in Dailly / VS</td>
</tr>
<tr>
<td>Juli 2000 to September 2000</td>
<td>Praktischer Dienst bei Fest RS 259 in Mels / SG</td>
</tr>
</tbody>
</table>

Interests

sports (Karate, hiking)  
travelling, foreign cultures  
books, cinema
References

**Professor Guy R. Cornelis**  
Biozentrum, University of Basel  
Klingelbergstrasse 50/70  
4056 Basel  
Switzerland  
guy.cornelis@unibas.ch

**Dr. Luis Jaime Mota**  
Centre for Molecular Microbiology and Infection, Division of Investigative Sciences  
Flowers Building, South Kensington Campus  
Imperial College London, London SW7 2AZ  
England  
j.mota@imperial.ac.uk

**Dr. Laure Journet**  
ESBS UMR 7175  
Récepteurs et Protéines Membranaires  
Bd Sebastien Brand  
BP 10413  
67412 Illkirch CEDEX  
France  
journet@esbs.u-strasbg.fr